PharmGKB ID	Variant	Literature	Genes	Association	Significance	P-Value	# of Cases	# of Controls	Biogeographical Groups	Phenotype Categories	Pediatric	More Details	Drugs
1184349845	CYP2C19*1; CYP2C19*17	PMCID:PMC4104276	CYP2C19	CYP2C19 *17 is not associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	no	= 0.046	1632		European	Toxicity	false		clopidogrel
982028939	rs4986893	PMID:19106084	CYP2C19	Allele A is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	yes	= 0.01	1147		Multiple groups	Toxicity	false	Death from cardiovascular causes, myocardial infarction, or stroke. Significance measured as per carrying at least one CYP2C19 reduced-function allele. CYP2C19 Genotyping Results in Clopidogrel Allocated Subjects: Intermediate metabolizer (N=357) -*1A/*2A, *1A/*3, *1A/*4, *1A/*8; Poor metabolizer (N=38) *2A/*2A, *2A/*3, *2A/*4, *2A/*5A, *2A/*8. The *2 allele (rs4244285) accounted for 95% of the subjects who were classified as carriers of a reduced-function allele. Carriers of a *2 allele (rs4244285) had a higher rate of the primary efficacy outcome (HR: 1.42; 95% CI, 0.98 to 2.05; P=0.04) and of stent thrombosis (HR: 3.33; 95% CI, 1.28 to 8.62; P=0.004) than did noncarriers.	clopidogrel
1184349841	rs1045642	PMCID:PMC4104276	ABCB1	Allele A is not associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.	no	= 0.046	1632		European	Toxicity	false		clopidogrel
1444701722	CYP2C19*1; CYP2C19*2	PMID:25828136	CYP2C19	CYP2C19 *2 is associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	< 0.05	85		Unknown	Efficacy	false	Patients were treated with standard clopidogrel regimen. Platelet reactivity (PR) was measured on multiple occasions following PCI (days 1, 2, 3, 7, 30; months 2, 3, 6, 9, 12).	clopidogrel
982028928	rs4244285	PMID:19106084	CYP2C19	Allele A is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	yes	= 0.02	1477		Multiple groups	Toxicity	false	Significance measured as per carrying at least one CYP2C19 reduced-function allele. CYP2C19 Genotyping Results in Clopidogrel Allocated Subjects: Intermediate metabolizer (N=357) -*1A/*2A, *1A/*3, *1A/*4, *1A/*8; Poor metabolizer (N=38) *2A/*2A, *2A/*3, *2A/*4, *2A/*5A, *2A/*8. The *2 allele (rs4244285) accounted for 95% of the subjects who were classified as carriers of a reduced-function allele. Carriers of a *2 allele (rs4244285) had a higher rate of the primary efficacy outcome (HR: 1.42; 95% CI, 0.98 to 2.05; P=0.04) and of stent thrombosis (HR: 3.33; 95% CI, 1.28 to 8.62; P=0.004) than did noncarriers.	clopidogrel
982033024	rs6785930	PMID:19106083	P2RY12	Allele A is not associated with risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.	no	= 0.36	2208		Unknown	Toxicity	false		clopidogrel
1184349853	CYP2C19*1; CYP2C19*2	PMID:23895809	CYP2C19	CYP2C19 *2 is associated with increased platelet reactivity by P2Y12 reaction units when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to CYP2C19 *1/*1.	yes	< 0.001	289		Multiple groups	Other	false	African American race (P = .007) and CYP2C19*2 allele status (P = .0003) have significant independent effects on the PRU value without any interaction between the two. On multivariate analysis, AA race (odds ratio [OR] 2.03, 95% CI 1.08-3.81), carrier of CYP2C19*2 allele (OR 2.07, 95% CI 1.22-3.53), and age (OR 1.03, 95% CI 1.01-1.06) were independent correlates for PRU ¿208. All patients received a 600-mg loading dose of clopidogrel 6 hours before platelet reactivity testing or a 75-mg maintenance dose for 5 days before testing. All patients received aspirin 325 mg 6 to 24 hours before testing. After the procedure, aspirin was prescribed indefinitely; and clopidogrel was prescribed for a minimum of 1 month in patients receiving bare metal stents for elective PCI, and for 12 months in patients receiving DES and in all patients with acute coronary syndrome.	clopidogrel
1448261213	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:26556524	CYP2C19	CYP2C19 *1/*1 + *1/*2 + *1/*3 is associated with response to clopidogrel and prasugrel in people with Myocardial Infarction.	not stated	= 0.007	50		East Asian	Efficacy	false	Switching patients with the *1/*2, *1/*3 or *1/*1 genotypes from prasugrel to clopidogrel resulted in a significant increase in the percentage of patients in the therapeutic range.	clopidogrel; prasugrel
769146312	rs12248560	PMID:20979470	CYP2C19	Allele T is associated with decreased cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome.	yes	= 0.02	2549	2510	Multiple groups, European or Latin American ancestry	Toxicity	false	Gain-of-function allele carriers (i.e., *1/*17, *17/*17, *2/*17, or *3/*17) had a more pronounced reduction in cardiovascular events (first primary composite efficacy outcome) with clopidogrel treatment as compared with placebo than did noncarriers.	clopidogrel
1184349829	CYP2C19*1; CYP2C19*13	PMCID:PMC4104276	CYP2C19	CYP2C19 *13 is not associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	no	= 0.046	1632		European	Toxicity	false		clopidogrel
1444697614	rs7667298	PMID:25738571	KDR	Genotype CC is associated with decreased likelihood of Angina Pectoris when treated with clopidogrel in people with Coronary Disease as compared to genotypes CT + TT.	yes	< 0.05	275		East Asian	Toxicity	false	CC carriers had a lower occurrence of target lesion revascularization and angina pectoris in contrast to the TT + CT carriers (all P<0.05).	clopidogrel
1444701710	CYP2C19*1; CYP2C19*2	PMID:25828136	CYP2C19	CYP2C19 *2 is not associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	no		43		Unknown	Efficacy	false	Patients were  treated with up to two additional 600 mg loading doses and 75–300 mg clopidogrel maintenance dose. Platelet reactivity (PR) was measured on multiple occasions following PCI (days 1, 2, 3, 7, 30; months 2, 3, 6, 9, 12) with dose adjustment for this group of patients (interventional group) at each measurement to achieve optimal PR (19-46U). Patients in the interventional group maintained better PR during 12 month follow-up and had a better outcome.	clopidogrel
1448261184	CYP2C19*2; CYP2C19*3; CYP2C19*17	PMCID:PMC4590670	CYP2C19	CYP2C19 *2 + *3 + *17 are associated with dose of clopidogrel.	not stated					Dosage	false	This study provided a table of dose adjustments for clopidogrel, based on CYP2C19 genotype and interacting drugs metabolized by CYP2C19. It was based on a clopidogrel dose of 75 mg.	clopidogrel
1451974300	rs2230414	PMCID:PMC9801627	RASGRP2	Allele T is not associated with increased resistance to clopidogrel in people with Coronary Disease as compared to allele G.	no	= 0.478	143	86	East Asian	Efficacy	false	alleles complemented.	clopidogrel
1184349837	rs776746	PMCID:PMC4104276	CYP3A5	Allele C is not associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to allele T.	no	= 0.046	1632		European	Toxicity	false		clopidogrel
769146308	rs4244285	PMID:20979470	CYP2C19	Allele A is not associated with cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	not stated	= 0.84	2549	2510	Multiple groups, European or Latin American ancestry	Toxicity	false	"The effect of clopidogrel as compared with placebo in reducing the first (and second) primary composite efficacy outcome (rate of cardiovascular events) was similar between heterozygous or homozygous carriers of loss-of-function alleles and noncarriers.
Patients were genotyped for  CYP2C19*2 and *3 loss-of-function allele tag SNPs."	clopidogrel
982028948	rs28399504	PMID:19106084	CYP2C19	Allele G is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele A.	yes	= 0.01	1147		Multiple groups	Toxicity	false	Death from cardiovascular causes, myocardial infarction, or stroke. Significance measured as per carrying at least one CYP2C19 reduced-function allele. CYP2C19 Genotyping Results in Clopidogrel Allocated Subjects: Intermediate metabolizer (N=357) -*1A/*2A, *1A/*3, *1A/*4, *1A/*8; Poor metabolizer (N=38) *2A/*2A, *2A/*3, *2A/*4, *2A/*5A, *2A/*8. The *2 allele (rs4244285) accounted for 95% of the subjects who were classified as carriers of a reduced-function allele. Carriers of a *2 allele (rs4244285) had a higher rate of the primary efficacy outcome (HR: 1.42; 95% CI, 0.98 to 2.05; P=0.04) and of stent thrombosis (HR: 3.33; 95% CI, 1.28 to 8.62; P=0.004) than did noncarriers.	clopidogrel
982033044	rs12248560	PMID:19463375	CYP2C19	Genotype CC is associated with greater platelet inhibition 2 h after a 600-mg dose when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes CT + TT.	yes	= 0.026	60		Unknown	Efficacy	false		clopidogrel
1444697601	rs2305948	PMID:25738571	KDR	Genotype TT is associated with increased risk of Angina Pectoris and Myocardial Infarction when treated with clopidogrel in people with Coronary Disease as compared to genotypes CC + CT.	yes	< 0.05	275		East Asian	Toxicity	false	The angina pectoris, recurrent MI, and combined end point events were significantly higher in the TT carriers than in the CC+CT carriers(all P<0.05).	clopidogrel
1444701698	CYP2C19*1; CYP2C19*2	PMID:25832119	CYP2C19	CYP2C19 *2 is associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1.	yes	< 0.001	765		Unknown	Efficacy	false	"Patients were undergoing elective coronary stent placement after pretreatment
with 600 mg of clopidogrel and aspirin (100 mg per day for at least five days or loading dose of 400 mg). After PCI, all patients received aspirin (100 mg per day) lifelong, and clopidogrel (75 mg per day) for 30 days after placement of baremetal stents or for six months after placement of at least one drug eluting
stent. The variables with the highest relative contribution to the variability of on-clopidogrel platelet reactivity were intrinsic platelet reactivity with 8 % followed by CYP2C19*2 polymorphism carrier status with 5 %, and BMI with 2 %."	clopidogrel
982033064	rs1057910	PMID:19463375	CYP2C9	Allele C is associated with decreased platelet inhibition 7h after a clopidogrel 600-mg loading dose when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.	yes	= 0.045	60		Unknown	Efficacy	false	The CYP2C9 genotype did not significantly influence the platelet response, except that CYP2C9*1*3 carriers had reduced platelet inhibition compared with platelet inhibition in CYP2C9*1*1 carriers at 7 h with the 600-mg clopidogrel dose (9%, 8% to 11% and 31%, 0% to 96%, respectively, p = 0.045).	clopidogrel
1450415697	rs3093135	PMID:31124413	CYP4F2	Genotype TT is associated with increased likelihood of Myocardial Infarction and Recurrence when treated with clopidogrel or ticagrelor in people with Coronary Artery Disease as compared to genotypes AA + AT.	yes	= 0.0049	462	166	Unknown	Efficacy	false	Association reported for TT (minor allele), although this gene is on minor chromosomal strand did not complement results because appear to be measured on plus strand based on comparison of minor allele frequencies in dbSNP.	clopidogrel; ticagrelor
1448115828	CYP2C19*1; CYP2C19*17	PMID:26526111	CYP2C19	CYP2C19 *17 is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2C19 *1.	no	= 0.479	209		European	Efficacy	false	All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting.	clopidogrel
1184470707	CYP2C19*1; CYP2C19*10	PMCID:PMC4090277	CYP2C19	CYP2C19 *10 is associated with decreased catalytic activity of CYP2C19 when assayed with clopidogrel in E. coli DH5alpha as compared to CYP2C19 *1.	yes	< 0.05	2		Unknown	Metabolism/PK	false	"This was also true for 2-oxo-clopidogrel.  For *10, rs6413438 was assayed.  CYP2C19.1B was used as the comparison and is described as ""wild-type""."	clopidogrel
1184349881	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24608794	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 are associated with increased risk of clopidogrel resistance when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 *1/*1.	yes	< 0.05	145		East Asian	Toxicity	false	"Defined  high platelet reactivity index. Patients underwent PCI. CYP2C19*2 (681G>A) and CYP2C19*3 (636G>A) were detected.  loading dose of
clopidogrel at 300 mg/day and a maintenance dose
of 75 mg/day for 1 week. Blood samples for platelet
function testing were drawn before and 2 h after loading
with clopidogrel 7 days after the intake of the first
maintenance dose. Carriers of two CYP2C19 loss-of-function alleles, BMI, and the presence of type 2 diabetes were three independent risk factors for clopidogrel resistance."	clopidogrel
1448115838	CYP2C9*1; CYP2C9*3	PMID:26526111	CYP2C9	CYP2C9 *3 is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2C9 *1.	no	= 0.464	209		European	Efficacy	false	All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting.	clopidogrel
1448115817	CYP2C9*1; CYP2C9*2	PMID:26526111	CYP2C9	CYP2C9 *2 is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2C9 *1.	no	= 0.882	209		European	Efficacy	false	All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting.	clopidogrel
1448101486	CYP2C19*1; CYP2C19*2	PMID:26071277	CYP2C19	CYP2C19 *2 is associated with decreased metabolism of clopidogrel in men with Coronary Artery Disease as compared to CYP2C19 *1.	not stated	< 0.008	106		Unknown	Metabolism/PK	false		clopidogrel
982029005	rs4244285	PMID:19934793	CYP2C19	Genotypes AA + AG are associated with increased likelihood of to be classified as clopidogrel poor responders when treated with clopidogrel in people with Cardiovascular Diseases as compared to genotype GG.	yes	< 0.001	297		Unknown	Efficacy	false	Patients undergoing elective coronary stenting.	clopidogrel
982033103	rs4244285	PMID:20492469	CYP2C19	Genotypes AA + AG are associated with increased platelet aggregation values when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	< 0.001	986		European	Efficacy	false		clopidogrel
1448613393	rs6809699	PMCID:PMC5411211	P2RY12	Genotypes AA + AC is associated with increased resistance to clopidogrel as compared to genotype CC.	yes	= 0.001	498		East Asian	Efficacy	false	in Chinese patients with acute coronary syndrome undergoing PCI. This variant is also called P2RY12 G52T.	clopidogrel
982028994	rs4244285	PMID:19934793	CYP2C19	Genotypes AA + AG are associated with decreased response to clopidogrel in people with Cardiovascular Diseases as compared to genotype GG.	yes	< 0.001	297		Unknown	Efficacy	false	Patients undergoing elective coronary stenting.	clopidogrel
1450415672	rs3093135	PMID:31124413	CYP4F2	Allele T is associated with increased likelihood of Epistaxis, Gastrointestinal Hemorrhage, Hematoma, Hematuria and Thrombosis when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele A.	yes	= 0.022	442		Unknown	Efficacy	false	Association reported for T (minor allele), although this gene is on minor chromosomal strand did not complement results because appear to be measured on plus strand based on comparison of minor allele frequencies in dbSNP.	aspirin; clopidogrel
1043764859	rs4244285	PMID:21163112	CYP2C19	Genotypes AA + AG are associated with increased risk of poor-response to clopidogrel when treated with clopidogrel in patients undergoing percutaneous coronary intervention (PCI) as compared to genotype GG.	yes	= 0.002	722		East Asian	Efficacy	false		clopidogrel
982033093	rs1799853	PMID:19463375	CYP2C9	Allele T is not associated with differences in platelet inhibition 7h after a clopidogrel 600-mg loading dose when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	no		60		Unknown	Efficacy	false		clopidogrel
1448613384	rs6809699	PMCID:PMC5411211	P2RY12	Genotypes AA + AC is associated with increased risk of adverse events when treated with clopidogrel as compared to genotype CC.	yes	= 0.010	498		East Asian	Toxicity	false	in Chinese patients with acute coronary syndrome undergoing PCI.  The A allele carriers had a significantly higher risk of total cardiovascular events as compared to non-carriers. This variant is also called P2RY12 G52T.	clopidogrel
982029017	rs1057910	PMID:19934793	CYP2C9	Genotypes AC + CC are associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Cardiovascular Diseases as compared to genotype AA.	yes	= 0.029	80		Unknown	Efficacy	false	This association was seen in participants with the CYP2C19*1/*1 genotype. Patients received a 300 mg clopidogrel loading dose (1-5 days before the intervention, followed by 75 mg/day). Platelet function was assessed by light transmittance aggregometry.	clopidogrel
769164682	rs662	PMID:21170047	PON1	Genotype TT is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	not stated	< 0.001	1982		Unknown	Toxicity	false	The TT genotype is also associated with lower PON1 plasma activity, lower plasma concentrations of active metabolite and lower platelet inhibition.	clopidogrel
982033119	rs12248560	PMID:20492469	CYP2C19	Genotypes CT + TT are associated with decreased platelet aggregation values when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	yes	= 0.01	986		European	Efficacy	false		clopidogrel
1448613376	rs6785930	PMCID:PMC5411211	P2RY12	Genotypes AA + AG is associated with increased resistance to clopidogrel as compared to genotype GG.	yes	= 0.002	498		East Asian	Efficacy	false	in Chinese patients with acute coronary syndrome undergoing PCI. This variant is also called P2RY12 C34T.	clopidogrel
982022890	CYP2C19*1; CYP2C19*17	PMID:22704413	CYP2C19	CYP2C19 *17 is associated with increased risk of bleeding when treated with clopidogrel as compared to CYP2C19 *1.	yes	< 0.05	520		East Asian	Toxicity	false	in Chinese patients with blood stasis syndrome undergoing percutaneous coronary intervention (PCI).	clopidogrel
982022883	CYP2C19*17	PMID:22704413	CYP2C19	CYP2C19 *17 is associated with enhanced response to clopidogrel (as measured by inhibition of ADP-induced platelet aggregation) when treated with clopidogrel as compared to CYP2C19 *1.	yes	< 0.05	520		East Asian	Efficacy	false	in Chinese patients with blood stasis syndrome undergoing percutaneous coronary intervention (PCI).	clopidogrel
982029028	rs1057910	PMID:19934793	CYP2C9	Genotypes AC + CC are associated with increased risk of clopidogrel poor response when treated with clopidogrel in people with Cardiovascular Diseases as compared to genotype AA.	yes	= 0.016	80		Unknown	Efficacy	false	This association was seen in participants with the CYP2C19*1/*1 genotype. Patients received a 300 mg clopidogrel loading dose (1-5 days before the intervention, followed by 75 mg/day). Platelet function was assessed by light transmittance aggregometry.	clopidogrel
982047486	CYP2C19*17	PMID:22955794	CYP2C19	CYP2C19 *17 is not associated with increased response to clopidogrel in people with Myocardial Ischemia as compared to CYP2C19 *1.	no	= 0.4	145		Central/South Asian	Efficacy	false	Patients classified as poor or intermediate metabolizers (having zero or one functional allele) had significantly higher residual platelet activity and lower antiplatelet response to clopidogrel than patients classified as extensive or ultrarapid metabolizers (having 2 functional or increased function alleles). While patients carrying the gain-of-function allele (*17) were observed to have lower residual platelet activity when compared to patients without this allele, the association was not significant.	clopidogrel
982047473	CYP2C19*2	PMID:22955794	CYP2C19	CYP2C19 *2 is associated with decreased response to clopidogrel in people with Myocardial Ischemia as compared to CYP2C19 *1.	yes	= 0.04	145		Central/South Asian	Efficacy	false	Patients classified as poor or intermediate metabolizers (having zero or one functional allele) had significantly higher residual platelet activity and lower antiplatelet response to clopidogrel than patients classified as extensive or ultrarapid metabolizers (having 2 functional or increased function alleles). Due to the distribution of alleles, poor and intermediate metabolizers were further defined as all patients carrying the *2 allele. The number of patients with the *3 allele was too small to be able to assess its effects on clopidogrel treatment.	clopidogrel
1451865844	rs12041331	PMID:35880550	PEAR1	Genotypes AA + AG is associated with decreased platelet aggregation when treated with aspirin and clopidogrel as compared to genotype GG.	yes	= 0.025	171		East Asian	Efficacy	false	in patients receiving dual anti-platelet therapy after PCI. Authors do not give rs number in methods or figures or any other indicator of locus genotyped but include an rs number in the discussion in reference to another study. Have assumed this is the locus tested in this paper and annotated to that locus.	aspirin; clopidogrel
1184349719	CYP2C19*1; CYP2C19*17	PMCID:PMC4104276	CYP2C19	CYP2C19 *17 is associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	yes	<  0.0001	430		African American/Afro-Caribbean	Toxicity	false	"33.3% 1-year mortality for CYP2C19*17/*17 homozygotes vs. 9.8% for CYP2C19*17/*1 heterozygotes vs. 4.9% for *1/*1 homozygotes; log-rank p= 1E-05 in Kaplan-Meier analysis. The authors state that the interaction between CYP2C19*17 SNP and clopidogrel treatment for mortality in African American TRIUMPH patients discharged on clopidogrel was significant (p= 0.091). CYP2C19 metabolizer status was significantly associated with mortality in African
Americans (log-rank p= 0.0371). PM had the highest survival (100% 1-year
survival) follow by individuals with IM or EM phenotype (97% and 94% 1-year survival). Individuals with ultra rapid metabolizer phenotype had the lowest 1-year survival (88% 1-year survival)."	clopidogrel
1448632016	rs6785930	PMID:28329746	P2RY12	Allele A is not associated with platelet reactivity when treated with clopidogrel as compared to allele G.	no	= 0.08	408		European	Efficacy	false	in Caucasian patients with stable coronary artery disease (CAD) after Percutaneous Coronary Intervention.	clopidogrel
1451974147	rs3785873	PMCID:PMC9801627	ITGB3	Allele A is not associated with increased resistance to clopidogrel in people with Coronary Disease as compared to allele G.	no	= 0.090	145	85	East Asian	Efficacy	false		clopidogrel
1448115929	rs1045642	PMID:26526111	ABCB1	Genotype AA is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to genotypes AG + GG.	no	= 0.909	209		European	Efficacy	false	All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting. Alleles given as C and T.	clopidogrel
1444695697	CYP2C19*1; CYP2C19*5; CYP2C19*6; CYP2C19*8; CYP2C19*9; CYP2C19*16; CYP2C19*22; CYP2C19*24	PMID:25001882	CYP2C19	CYP2C19 *5 + *6 + *8 + *9 + *16 + *22 + *24 are associated with decreased catalytic activity of CYP2C19 when assayed with clopidogrel or mephenytoin in COS-7 cells as compared to CYP2C19 *1.	no					Metabolism/PK	false	The kinetic parameters (Km, Vmax and CLint values for clopidogrel 2-oxidation or S-mephenytoin 4'-hydroxylation) for the following variants (CYP2C19.5, CYP2C19.6, CYP2C19.8, CYP2C19.9, CYP2C19.16, CYP2C19.22 and CYP2C19.24) could not be determined because these proteins were inactive at low substrate concentrations.  In a summary the following was listed for the activity: *5-no activity; *6-no activity; *8-22% of wild-type activity; *9-12% of wild-type activity; *16-11% of wild-type activity; *22-8% of wild-type activity; *24-no activity.	clopidogrel; mephenytoin
1184349702	CYP2C19*1; CYP2C19*2	PMCID:PMC4104276	CYP2C19	CYP2C19 *2 is associated with increased risk of all-cause mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	not stated	= 0.046	1632		European	Toxicity	false	5.4% 1-year mortality for CYP2C19*2 allele carriers vs. 3% for *1/*1 homozygotes; log-rank p= 0.0216 in Kaplan-Meier analysis. The authors state that the interaction between CYP2C19*2 SNP and clopidogrel treatment for mortality in Caucasian TRIUMPH patients discharged on clopidogrel was not significant (p= 0.860). No significant difference in mortality was found by analyzing CYP2C19 metabolizer status among Caucasians discharged on clopidogrel after acute myocardial in TRIUMPH (log-rank p=0.1726).	clopidogrel
1451089644	rs6809699	PMCID:PMC4980919	MED12L; P2RY12	Genotype AC is associated with decreased platelet aggregation when exposed to clopidogrel in healthy individuals as compared to genotype CC.	yes	= 0.03			Central/South Asian	Efficacy	false	for the H1/H2 haplotype (n=9) having higher aggregation ie. reduced DPMA and IPA compared to individuals with H1/H1 (n=77). Haplotype H1 is major allele for rs10935838G>A, rs2046934A>G, rs5853517 -/T, and rs6809699 C>A. No difference was found in the genotypes of responders and non-responders. Healthy individuals were given a single 300 mg dose and analysis was conducted at 4 hours.	clopidogrel
769164619	rs4244285	PMID:21262992	CYP2C19	Allele A is not associated with increased risk of cardiovascular events when treated with clopidogrel and Proton pump inhibitors in people with Myocardial Infarction as compared to allele G.	not stated		1579		Multiple groups	Toxicity	false	"Patients are treated co treated with clopidogrel and proton pump inhibitors. However, a numerically higher rate of in-hospital ischemic
events was observed in proton pump inhibitors-treated patients in the presence of two reduced function alleles. The article reports the finding for CYP2C19 loss-of-function alleles but does not list specific variants."	clopidogrel; Proton pump inhibitors
1184349711	CYP2C19*1; CYP2C19*2	PMCID:PMC4104276	CYP2C19	CYP2C19 *2 is not associated with increased risk of all-cause mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	no	=  0.26	430		African American/Afro-Caribbean	Toxicity	false	CYP2C19*2 (rs4244285) variant was found to be out of Hardy-Weinberg equilibrium (HWE) in African Americans (p=0.02).	clopidogrel
1451089637	rs5853517	PMCID:PMC4980919	MED12L; P2RY12	Genotype T/del is associated with decreased platelet aggregation when exposed to clopidogrel in healthy individuals as compared to genotype del/del.	yes	= 0.03			Central/South Asian	Efficacy	false	for the H1/H2 haplotype (n=9) having higher aggregation ie. reduced DPMA and IPA compared to individuals with H1/H1 (n=77). Haplotype H1 is major allele for rs10935838G>A, rs2046934A>G, rs5853517 -/T, and rs6809699 C>A. No difference was found in the genotypes of responders and non-responders. Healthy individuals were given a single 300 mg dose and analysis was conducted at 4 hours.	clopidogrel
1448115914	CYP1A2*1F	PMID:26526111	CYP1A2	CYP1A2 *1F is not associated with response to clopidogrel in people with Carotid Artery Diseases.	no	= 0.977	209		European	Efficacy	false	All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting.	clopidogrel
1451974167	rs58847127	PMCID:PMC9801627	ITGB3	Allele C is not associated with increased resistance to clopidogrel in people with Coronary Disease as compared to allele G.	no	= 0.291	145	85	East Asian	Efficacy	false		clopidogrel
1451089632	rs2046934	PMCID:PMC4980919	MED12L; P2RY12	Genotype AG is associated with decreased platelet aggregation when exposed to clopidogrel in healthy individuals as compared to genotype AA.	yes	= 0.03			Central/South Asian	Efficacy	false	for the H1/H2 haplotype (n=9) having higher aggregation ie. reduced DPMA and IPA compared to individuals with H1/H1 (n=77). Haplotype H1 is major allele for rs10935838G>A, rs2046934A>G, rs5853517 -/T, and rs6809699 C>A. No difference was found in the genotypes of responders and non-responders. Healthy individuals were given a single 300 mg dose and analysis was conducted at 4 hours.	clopidogrel
1448124144	rs2046934	PMCID:PMC4752331	P2RY12	Allele A is associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to allele G.	yes	= 0.041	39	229	East Asian	Efficacy	false	in patients with extracranial or intracranial stenting.	clopidogrel
1184349747	CYP2C19*1; CYP2C19*2	PMCID:PMC4104276	CYP2C19	CYP2C19 *2 is associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	not stated	= 0.0661	1632		European	Toxicity	false	Association with trend toward a increased recurrent myocardial Infarction	clopidogrel
1448603378	CYP2C19*1; CYP2C19*17	PMCID:PMC5331771	CYP2C19	CYP2C19 *17 is associated with decreased platelet reactivity when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.004	336		East Asian	Efficacy	false	CYP2C19*2 is associated with lower on-treatment platelet reactivity in Han Chinese patients treated with percutaneous coronary intervention as compared to CYP2C19*1/*1.	aspirin; clopidogrel
981500454	CYP2C19*1; CYP2C19*2	PMID:22464343	CYP2C19	CYP2C19 *2 is associated with increased risk of major adverse cardiovascular events and stent thrombosis when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	not stated	= 0.0092	23	23	Multiple groups, mostly white	Toxicity	false	This study showed that CYP2C19*2 carriers identified via point-of-care genetic testing after percutaneous coronary intervention (PCI) treated with prasugrel had  significantly reduced high on-treatment platelet reactivity as compared with those given standard treatment (p=0·0092). High on-treatment platelet reactivity is a marker associated with increased adverse cardiovascular events.	clopidogrel
1183704618	CYP2C19*1; CYP2C19*2	PMID:23517020	CYP2C19	CYP2C19 *1/*2 is associated with increased ADP-induced platelet aggregation (PA) when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.004	155		East Asian	Efficacy	false	in Korean patients undergoing percutaneous coronary intervention.	clopidogrel
769258865	rs662	PMID:21527445	PON1	Allele T is not associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	not stated	= 0.22	127	1439	Unknown	Toxicity	false	The T allele is also not associated with platelet response to clopidogrel. The study did not measure plasma levels of the active metabolite of clopidogrel and not assessed PON1 enzyme activity.	clopidogrel
1451089620	rs10935838	PMCID:PMC4980919	MED12L; P2RY12	Genotype AG is associated with decreased platelet aggregation when exposed to clopidogrel in healthy individuals as compared to genotype GG.	yes	= 0.03			Central/South Asian	Efficacy	false	for the H1/H2 haplotype (n=9) having higher aggregation ie. reduced DPMA and IPA compared to individuals with H1/H1 (n=77). Haplotype H1 is major allele for rs10935838G>A, rs2046934A>G, rs5853517 -/T, and rs6809699 C>A. No difference was found in the genotypes of responders and non-responders. Healthy individuals were given a single 300 mg dose and analysis was conducted at 4 hours.	clopidogrel
1448603388	rs2046934	PMCID:PMC5331771	P2RY12	Genotypes AG + GG are associated with increased platelet reactivity when treated with aspirin and clopidogrel as compared to genotype AA.	yes	= 0.002	336		East Asian	Efficacy	false	This variant is associated with high on-treatment platelet reactivity (HTPR) in Han Chinese patients treated with percutaneous coronary intervention.	aspirin; clopidogrel
1184349755	CYP2C19*1; CYP2C19*2	PMCID:PMC4104276	CYP2C19	CYP2C19 *2 is not associated with increased bleeding events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	no	= 0.43	1632		European	Toxicity	false		clopidogrel
769258868	rs4244285	PMID:21527445	CYP2C19	Genotype AA is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	= 0.03	127	1439	Unknown	Toxicity	false		clopidogrel
982032933	rs1126643	PMID:15205592	ITGA2	Genotypes CT + TT are associated with increased collagen-induced platelet aggregation when treated with aspirin and clopidogrel in patients undergoing coronary stenting as compared to genotype CC.	yes	= 0.04	44		Unknown	Other	false	All patients were on aspirin (100¿250 mg/daily; > 90% of patients received 250 mg) for at least 7 days and received a 300 mg clopidogrel loading dose at intervention time. Platelet aggregation was assessed by light transmittance aggregometry following adenosine diphosphate or collagen stimuli at baseline, and 10 min, 4 h and 24 h after clopidogrel front loading. Adenosine diphosphate-induced platelet aggregation (P < 0.01), which was similar in carriers and non-carriers of the T allele throughout the study (P = 0.73).	aspirin; clopidogrel
1448603367	CYP2C19*1; CYP2C19*2	PMCID:PMC5331771	CYP2C19	CYP2C19 *2 is associated with increased platelet reactivity when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.007	336		East Asian	Efficacy	false	CYP2C19*2 is associated with high on-treatment platelet reactivity (HTPR) in Han Chinese patients treated with percutaneous coronary intervention.	aspirin; clopidogrel
1184349734	CYP1A2*1A; CYP1A2*1C	PMCID:PMC4104276	CYP1A2	CYP1A2 *1C is associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP1A2 *1A/*1A.	yes	= 0.014	430		African American/Afro-Caribbean	Toxicity	false	log-rank p = 0.0064 among African American patients discharged on clopidogrel following  acute Myocardial Infarction in Kaplan-Meier analysis. The authors state that the interaction between CYP1A2*1C SNP and clopidogrel treatment for mortality in African American TRIUMPH patients discharged on clopidogrel was borderline significant (p= 0.122).	clopidogrel
1183704635	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:23517020	CYP2C19	CYP2C19 *1/*3 is associated with increased ADP-induced platelet aggregation (PA) when treated with clopidogrel as compared to CYP2C19 *1/*2.	yes	= 0.006	155		East Asian	Efficacy	false	in Korean patients undergoing percutaneous coronary intervention. The influence of the CYP2C19*3 allele on the level of PA appeared greater than the CYP2C19*2 allele during standard- (beta coefficient: 7.8% vs. 7.1%) and high-dose clopidogrel treatments (beta coefficient: 12.7% vs. 9.7%). The CYP2C19*1/*3 carriers showed greater PA compared with subjects with the CYP2C19*1/*2 gene, and the CYP2C19*2/*3 vs. *2/*2 carriers exhibited an enhanced level of PA. This suggests that the influence of the CYP2C19*3 allele on the clopidogrel response may be more relevant compared with the CYP2C19*2 allele.	clopidogrel
1448124134	rs662	PMCID:PMC4752331	PON1	Allele C is associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to allele T.	yes	= 0.029	39	229	East Asian	Efficacy	false	in patients with extracranial or intracranial stenting.	clopidogrel
1183704627	CYP2C19*1; CYP2C19*3	PMID:23517020	CYP2C19	CYP2C19 *1/*3 is associated with increased ADP-induced platelet aggregation (PA) when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	< 0.001	155		East Asian	Efficacy	false	in Korean patients undergoing percutaneous coronary intervention.	clopidogrel
604843186	rs12248560	PMID:20826260	CYP2C19	Allele T is associated with decreased rates of target lesion revascularization and major adverse cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.	yes	= 0.002	928		Unknown	Efficacy	false	T-allele carriers with acute MI and increased clopidogrel activation had significantly reduced clinical event rates.	clopidogrel
1447986830	rs2046934	PMID:25730082	P2RY12	Genotypes AG + GG are associated with increased likelihood of platelet aggregation inhibition when treated with clopidogrel in people with Coronary Disease as compared to genotype AA.	yes	= 0.0199	118		East Asian	Efficacy	false		clopidogrel
1043818226	rs12248560	PMID:23922007	CYP2C19	Genotype CT is not associated with bleeding events when treated with clopidogrel in patients undergoing percutaneous coronary intervention (PCI) as compared to genotype CC.	no		2188		East Asian	Toxicity	false	No association with differences in 2-year cumulative event rates for bleeding was found.	clopidogrel
982032974	rs776746	PMID:19106083	CYP3A5	Allele T is not associated with risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.	no	= 0.69	2208		Unknown	Toxicity	false		clopidogrel
1184349776	CYP1A2*1A; CYP1A2*1C	PMCID:PMC4104276	CYP1A2	CYP1A2 *1C is associated with increased risk of bleeding events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP1A2 *1A/*1A.	yes	= 0.0039			African American/Afro-Caribbean	Toxicity	false	Overall significant genotype effect (p= 0.013).	clopidogrel
1448115863	rs6809699	PMID:26526111	P2RY12	Genotype AA is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to genotypes AC + CC.	no	= 0.490	209		European	Efficacy	false	All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting. Alleles given as T and G.	clopidogrel
1444701909	CYP2C19*1; CYP2C19*2	PMID:25828136	CYP2C19	CYP2C19 *2 is associated with increased risk of when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	= 0.036	85		Unknown	Toxicity	false	The CYP2C19*2 allele was significantly associated with ischemic adverse events in the total study population.	clopidogrel
1184349789	CYP2B6*1; CYP2B6*5	PMCID:PMC4104276	CYP2B6	CYP2B6 *5 is not associated with increased risk of Death when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2B6 *1/*1.	no	= 0.046	1632		European	Toxicity	false		clopidogrel
1043818236	rs12248560	PMID:23922007	CYP2C19	Genotype CT is not associated with increased risk of stent thrombosis when treated with clopidogrel in patients undergoing percutaneous coronary intervention (PCI) as compared to genotype CC.	no		2188		East Asian	Toxicity	false		clopidogrel
982032965	rs5918	PMID:19106083	ITGB3	Allele C is not associated with risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to allele T.	no	= 0.86	2208		Unknown	Toxicity	false	The mean loading dose of clopidogrel was 300 mg per day (<300 mg per day in 36% of patients, 300 to 375 mg per day in 50%, and 450 to 900 mg per day in 15%), and the mean maintenance dose at the time of hospital discharge was 75 mg per day. 98% of the patients also received aspirin.	clopidogrel
1448631958	CYP2C19*1; CYP2C19*2	PMID:28329746	CYP2C19	CYP2C19 *2 is associated with increased risk of adverse cardiovascular events when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.03	408		European	Toxicity	false	"in Caucasian patients with stable coronary artery disease (CAD) after Percutaneous Coronary Intervention. The primary end point was a composite of
death from cardiovascular causes, nonfatal myocardial infarction,
urgent target vessel revascularization, nonfatal stroke, or hospitalization
for cardiovascular causes, including stroke, (severe) recurrent
cardiac ischemia, or transient ischemic attack."	clopidogrel
1448631945	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:28377187	CYP2C19	CYP2C19 *2 + *3 are not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.771	5820		East Asian	Toxicity	false	in Chinese patients undergoing percutaneous coronary intervention. The end point of this study was a composite of major cardiovascular events including cardiovascular death (CV death), nonfatal myocardial infarction (MI) and stroke.	clopidogrel
1184349763	CYP2C19*1; CYP2C19*17	PMCID:PMC4104276	CYP2C19	CYP2C19 *17/*17 is associated with increased risk of bleeding events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	yes	=  0.027	430		African American/Afro-Caribbean	Toxicity	false	Overall significant genotype effect (p= 0.034).	clopidogrel
1447986842	rs4244285	PMID:25730082	CYP2C19	Genotypes AA + AG are associated with decreased likelihood of platelet aggregation inhibition when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.	yes	= 0.0141	118		East Asian	Efficacy	false		clopidogrel
1183614554	CYP2C19*1; CYP2C19*2	PMID:23640828	CYP2C19	CYP2C19 *1/*2 + *2/*2 are associated with decreased response to clopidogrel and poorer outcomes in Chinese patients with acute ischemic stroke when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.020	259		East Asian	Efficacy	false	*2 and *3 alleles are analyzed together.	clopidogrel
982032991	rs16846673	PMID:19106083	P2RY12	Allele C is not associated with risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to allele T.	no	= 0.96	2208		Unknown	Toxicity	false		clopidogrel
1451974227	rs3760364	PMCID:PMC9801627	ITGA2B	Genotype AT is not associated with increased resistance to clopidogrel in people with Coronary Disease as compared to genotype TT.	no	= 0.853	144	86	East Asian	Efficacy	false		clopidogrel
1447986836	rs776746	PMID:25730082	CYP3A5	Genotypes CT + TT is associated with decreased likelihood of platelet aggregation inhibition when treated with clopidogrel in people with Coronary Disease as compared to genotype CC.	yes	= 0.038	118		East Asian	Efficacy	false	Alleles given as A and G.	clopidogrel
1448101515	rs1045642	PMID:26071277	ABCB1	Allele A is not associated with metabolism of clopidogrel in men with Coronary Artery Disease as compared to allele G.	no		106		Unknown	Metabolism/PK	false		clopidogrel
1448994492	rs1045642	PMCID:PMC5373545	ABCB1	Genotype GG is associated with increased resistance to clopidogrel in people with Hypertension as compared to genotype AA.	yes	= 0.024	64	58	East Asian	Efficacy	false	"There was no significant association between rs1045642 and the risk of clopidogrel resistance across the whole study cohort (p=0.288).

Genotype GG is associated with resistance to clopidogrel in people without hypoproteinaemia as compared to genotype AA (p=0.045).

Allele G is associated with increased resistance to clopidogrel in patients with hypertension compared to allele A (p=0.040) and in patients without hypoproteinaemia compared to allele A (p=0.033).

Genotypes AA + GG are not associated with resistance to clopidogrel in people with hypertension as compared to genotype AA (p=0.085) or in people without hypoproteinaemia as compared to genotype AA (p=0.644).

Genotype GG is not associated with resistance to clopidogrel in people with hypertension as compared to genotype AA+AG (p=0.104) or in people without hypoproteinaemia as compared to genotype AA (p=0.153).

Please note that alleles have been complemented to the positive strand."	clopidogrel
1448631993	rs6785930	PMID:28329746	P2RY12	Allele A is not associated with increased risk of adverse cardiovascular events when treated with clopidogrel as compared to allele G.	no	= 0.17	408		European	Toxicity	false	"in Caucasian patients with stable coronary artery disease (CAD) after Percutaneous Coronary Intervention. The primary end point was a composite of
death from cardiovascular causes, nonfatal myocardial infarction,
urgent target vessel revascularization, nonfatal stroke, or hospitalization
for cardiovascular causes, including stroke, (severe) recurrent
cardiac ischemia, or transient ischemic attack."	clopidogrel
982028906	rs4244285	PMID:19106084	CYP2C19	Allele A is associated with decreased plasma exposure to the active metabolite of clopidogrel when exposed to clopidogrel in healthy individuals as compared to allele G.	yes	< 0.001	162		Unknown	Metabolism/PK	false	Significance measured as per carrying at least one CYP2C19 reduced-function allele. CYP2C19 Genotyping Results in Clopidogrel Allocated Subjects: Intermediate metabolizer (N=43) -*1A/*2A, *1A/*3, *1A/*4, *1A/*8; Poor metabolizer (N=8) *2A/*2A, *2A/*3, *2A/*4, *2A/*5A, *2A/*8	clopidogrel
1184349813	CYP2C9*1; CYP2C9*8	PMCID:PMC4104276	CYP2C9	CYP2C9 *8 is not associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C9 *1/*1.	no	= 0.046	1632		European	Toxicity	false		clopidogrel
982033003	rs6809699	PMID:19106083	P2RY12	Allele A is not associated with risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.	no	= 0.42	2208		Unknown	Toxicity	false		clopidogrel
1183614568	CYP2C19*1; CYP2C19*3	PMID:23640828	CYP2C19	CYP2C19 *1/*3 + *3/*3 are associated with decreased response to clopidogrel and poorer outcomes in Chinese patients with acute ischemic stroke when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes		259		East Asian	Efficacy	false	*2 and *3 alleles are analyzed together.	clopidogrel
1448631999	CYP2C19*1; CYP2C19*2	PMID:28329746	CYP2C19	CYP2C19 *2/*2 is associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1 + *1/*2.	yes	= 0.007	408		European	Efficacy	false	in Caucasian patients with stable coronary artery disease (CAD) after Percutaneous Coronary Intervention.	clopidogrel
1448115897	CYP2B6*1; CYP2B6*9	PMID:26526111	CYP2B6	CYP2B6 *9 is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2B6 *1.	no	= 0.187	209		European	Efficacy	false	All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting.	clopidogrel
1184349821	CYP2C19*1; CYP2C19*9	PMCID:PMC4104276	CYP2C19	CYP2C19 *9 is not associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	no	= 0.046	1632		European	Toxicity	false		clopidogrel
1448097468	CYP2C19*1; CYP2C19*2	PMID:27233747	CYP2C19	CYP2C19 *2 is associated with increased resistance to clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.	yes	= 0.018	375		East Asian	Efficacy	false	CYP2C19*2(rs4244285) variant was independently associated with clopidogrel resistance and risk of adverse events after adjusting covariates.	clopidogrel
1184349797	CYP2B6*1; CYP2B6*6	PMCID:PMC4104276	CYP2B6	CYP2B6 *6 is not associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2B6 *1/*1.	no	= 0.046	1632		European	Toxicity	false		clopidogrel
1448631983	rs6785930	PMID:28329746	P2RY12	Allele A is not associated with increased risk of Hemorrhage when treated with clopidogrel as compared to allele G.	no	= 0.52	408		European	Toxicity	false	in Caucasian patients with stable coronary artery disease (CAD) after Percutaneous Coronary Intervention.	clopidogrel
1448115881	rs6785930	PMID:26526111	P2RY12	Genotype AA is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to genotypes AG + GG.	no	= 0.479	209		European	Efficacy	false	All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting. Alleles given as C and T,	clopidogrel
1184349805	CYP2C9*1; CYP2C9*3	PMCID:PMC4104276	CYP2C9	CYP2C9 *3 is not associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C9 *1/*1.	no	= 0.046	1632		European	Toxicity	false		clopidogrel
982028917	rs4244285	PMID:19106084	CYP2C19	Allele A is associated with decreased pharmacodynamic response when exposed to clopidogrel in healthy individuals as compared to allele G.	yes	< 0.001	162		Unknown	Efficacy	false	Significance measured as per carrying at least one CYP2C19 reduced-function allele. CYP2C19 Genotyping Results in Clopidogrel Allocated Subjects: Intermediate metabolizer (N=43) -*1A/*2A, *1A/*3, *1A/*4, *1A/*8; Poor metabolizer (N=8) *2A/*2A, *2A/*3, *2A/*4, *2A/*5A, *2A/*8	clopidogrel
1448631973	CYP2C19*1; CYP2C19*2	PMID:28329746	CYP2C19	CYP2C19 *2 is not associated with increased risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.45	408		European	Toxicity	false	in Caucasian patients with stable coronary artery disease (CAD) after Percutaneous Coronary Intervention.	clopidogrel
1448115887	CYP2B6*1; CYP2B6*5	PMID:26526111	CYP2B6	CYP2B6 *5 is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2B6 *1.	no	= 0.137	209		European	Efficacy	false	All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting.	clopidogrel
1450370939	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMID:29536505	CYP2C19	CYP2C19 *1/*17 + *17/*17 (assigned as ultrarapid metabolizer phenotype phenotype) is associated with increased risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1 + *1/*2 + *2/*2 + *2/*17 (assigned as intermediate metabolizer and normal metabolizer phenotype) .	yes	= 0.041	123		European	Toxicity	false	"in patients who underwent percutaneous neurointervention. ""The highest prevalence of hemorrhagic events was detected in the UM group (13.2%) compared to NM (3.8%) and IM-PM (0%) (P=0.041)""."	clopidogrel
1448261491	rs1045642	PMID:27464309	ABCB1	Genotype AA is associated with increased likelihood of Coronary Restenosis when treated with clopidogrel in people with Peripheral Vascular Diseases as compared to genotypes AG + GG.	yes	= 0.045			European	Efficacy	false	but this is only significant after controlling for the presence of CYP2C19 loss of function allele.	clopidogrel
1451347874	CYP2C19*1; CYP2C19*2	PMCID:PMC7689744	CYP2C19	CYP2C19 *2 is not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.20	2592		European	Toxicity	false	There was a nonsignificant trend toward a worse outcome for carriers of the CYP2C19*2 allele (5.8 vs. 4.2%; adjusted odds ratio (OR) 1.31; 95% confidence interval (CI) 0.87–1.99; P value = 0.20).	clopidogrel
1450112843	rs4244285	PMID:30487649	CYP2C19	Genotypes AA + AG are not associated with increased likelihood of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	no	= 0.9463	115		East Asian	Efficacy	false	This variant is not associated with MACE.	clopidogrel
1450112832	rs12913988	PMID:30487649	ATP10A	Genotypes AA + AG are associated with increased likelihood of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	= 0.0011	115		East Asian	Efficacy	false	This variant is associated with MACE.	clopidogrel
1448261475	CYP2C19*1; CYP2C19*2	PMID:27464309	CYP2C19	CYP2C19 *2 is associated with increased likelihood of Coronary Restenosis when treated with clopidogrel in people with Peripheral Vascular Diseases as compared to CYP2C19 *1/*1.	yes	= 0.039	25	47	European	Efficacy	false		clopidogrel
1043818242	rs12248560	PMID:23922007	CYP2C19	Genotype CT is not associated with increased risk of cardiovascular events when treated with clopidogrel in patients undergoing percutaneous coronary intervention (PCI) as compared to genotype CC.	no		2188		East Asian	Efficacy,Toxicity	false		clopidogrel
1450370889	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMID:29536505	CYP2C19	CYP2C19 *1/*1 (assigned as normal metabolizer phenotype phenotype) is not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*2 + *2/*2 + *2/*17 + *17/*17 + *1/*17.	no	= 0.358	123		European	Toxicity	false	"in patients who underwent percutaneous neurointervention. The outcome assessed is total ischemic events. ""The prevalence of ischemic events was similar in the NM group (11.3%) compared to IM-PM (6.3%) and UM (10.5%), P=0.358. Overall, no significant differences were found between the survival functions of the three groups. Thus, there is no evidence of differences with regard to ischemic event onset time between the IM-PM, NM, and UM groups."""	clopidogrel
1450112850	rs12456693	PMID:30487649	SLC14A2	Genotypes CT + TT are associated with decreased likelihood of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	no	= 0.0953	115		East Asian	Efficacy	false	This variant is marginally associated with MACE.	clopidogrel
1451347900	CYP2C19*1; CYP2C19*2	PMCID:PMC7689744	CYP2C19	CYP2C19 *2 is associated with increased high on-treatment platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 3.51E-35	2592		European	Efficacy	false	CYP2C19*2 is significantly associated with adenosine diphosphate stimulated platelet reactivity, however no single-nucleotide polymorphism reached genomewide significance for major adverse cardiovascular event end points. The CYP2C19*2 variant rs4244285 is in high LD with rs35835168, one the top hits that reached genomewide significance p=3.51e-35.	clopidogrel
1451743160	rs17064642	PMCID:PMC8602039	MYOM2	Genotypes CC + CT are associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to genotype TT.	yes	= 3.26E-5	1703		East Asian	Efficacy	false	Patients with the CC or CT genotypes were more likely to experience MACE in 18 months of follow-up.	aspirin; clopidogrel
769146008	rs4244285	PMID:19106084	CYP2C19	Allele A is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	yes	= 0.01	1477		"Multiple groups, Region of enrollment: (original TRITON-TIMI 38 paper) North America; Western Europe; Eastern Europe; Middle East; Africa; Asia; Pacific 
"	Toxicity	false	Death from cardiovascular causes, myocardial infarction, or stroke. Significance measured as per carrying at least one CYP2C19 reduced-function allele. CYP2C19 Genotyping Results in Clopidogrel Allocated Subjects: Intermediate metabolizer (N=357) -*1A/*2A, *1A/*3, *1A/*4, *1A/*8; Poor metabolizer (N=38) *2A/*2A, *2A/*3, *2A/*4, *2A/*5A, *2A/*8. The *2 allele (rs4244285) accounted for 95% of the subjects who were classified as carriers of a reduced-function allele. Carriers of a *2 allele (rs4244285) had a higher rate of the primary efficacy outcome (HR: 1.42; 95% CI, 0.98 to 2.05; P=0.04) and of stent thrombosis (HR: 3.33; 95% CI, 1.28 to 8.62; P=0.004) than did noncarriers.	clopidogrel
1448603415	rs2046934	PMCID:PMC5331771	P2RY12	Genotypes AG + GG are associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel as compared to genotype AA.	yes	= 0.001	336		East Asian	Toxicity	false	This variant is associated with increased risk of adverse events in Han Chinese patients treated with percutaneous coronary intervention. There were more endpoints in P2Y12 mutant type than in wild-type (50.00% vs. 35.71%, P = 0.001).	aspirin; clopidogrel
1043818357	CYP2C19*1; CYP2C19*3	PMID:21345843	CYP2C19	CYP2C19 *3 is associated with increased risk of high on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.	yes	< 0.001	236		East Asian	Efficacy	false	Study compared loss-of-function carrier (*2, *3) versus non-carrier (*1/*1) in patients receiving dual antiplatelet therapy (DAT, aspirin plus clopidogrel) versus triple antiplatelet therapy (TAT, DAT plus cilostazol).	aspirin; clopidogrel
1451935694	rs1042192	PMID:32077582	CYP2C18	Allele A is associated with increased platelet reactivity when treated with clopidogrel in people with Cardiovascular Diseases as compared to allele G.	yes	= 0.0003	96		Unknown	Efficacy	false	"Authors list rs numbers that were differently represented in high platelet reactivity group and low platelet reactivity group after clopidogrel. Authors do not state which allele is associated and whether is associated with increased reactivity or decreased reactivity, wrote sentence as minor allele associated with increased reactivity (ie. reduced clopidogrel effect). Authors state ""CYP2C18 and 2C8 variants were in linkage disequilibrium with CYP2C19*2 (rs4244285)"""	clopidogrel
1450370871	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMID:29536505	CYP2C19	CYP2C19 *1/*2 + *2/*2 + *2/*17 (assigned as poor metabolizer and intermediate metabolizer genotypes phenotype) are associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer and ultra-metabolizer phenotype) .	yes	= 0.013	123		European	Efficacy	false	in patients who underwent percutaneous neurointervention.	clopidogrel
1451935680	rs1058932	PMID:32077582	CYP2C8	Allele A is associated with increased platelet reactivity when treated with clopidogrel in people with Cardiovascular Diseases as compared to allele G.	yes	= 0.00157	94		Unknown	Efficacy	false	"Authors list rs numbers that were differently represented in high platelet reactivity group and low platelet reactivity group after clopidogrel. Authors do not state which allele is associated and whether is associated with increased reactivity or decreased reactivity, wrote sentence as minor allele associated with increased reactivity (ie. reduced clopidogrel effect). Authors state ""CYP2C18 and 2C8 variants were in linkage disequilibrium with CYP2C19*2 (rs4244285)"""	clopidogrel
1043818363	CYP2C19*1; CYP2C19*2	PMID:21345843	CYP2C19	CYP2C19 *2 is not associated with increased risk of high on-treatment platelet reactivity when treated with aspirin, cilostazol and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.	no	= 0.167	238		East Asian	Efficacy	false	Study compared loss-of-function carrier (*2, *3) versus non-carrier (*1/*1) in patients receiving dual antiplatelet therapy (DAT, aspirin plus clopidogrel) versus triple antiplatelet therapy (TAT, DAT plus cilostazol).	aspirin; cilostazol; clopidogrel
1029227540	rs4244285	PMID:19531897	CYP2C19	Genotypes AA + AG are associated with increased platelet reactivity when treated with clopidogrel in PCI-scheduled patients as compared to genotype GG.	yes	= 0.02	25		East Asian	Efficacy	false		clopidogrel
1447943967	CYP2C9*1; CYP2C9*2	PMID:25916518	CYP2C9	CYP2C9 *2 is associated with increased likelihood of Inflammation when treated with aspirin, clopidogrel and prasugrel in people with Tobacco Use Disorder as compared to CYP2C9 *1.	yes	= 0.005	429		Unknown	Efficacy	false	As measured by plasma CRP. Patients received either clopidogrel (75 or 150mg/day) plus aspirin (75 mg/day) or prasugrel (10 mg/day) plus aspirin (75 mg/day). Difference in platelet reactivity measured by VASP PRI was not significant.	aspirin; clopidogrel; prasugrel
1448603394	CYP2C19*1; CYP2C19*2	PMCID:PMC5331771	CYP2C19	CYP2C19 *2 is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	yes	< 0.001	336		East Asian	Toxicity	false	CYP2C19*2 is associated with increased risk of adverse events in Han Chinese patients treated with percutaneous coronary intervention. CYP2C19*2 represented 43.20% of the endpoints-free group and 76.19% of the endpoints group, respectively (P < 0.001).	aspirin; clopidogrel
1448617742	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:27653892	CYP2C19	CYP2C19 *2 + *3 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.017	321		East Asian	Toxicity	false	Patients with the CYP2C19 LOF alleles (*2, *3) had increased recurrent risk of ischemic events (primary endpoint was a composite of nonfatal ischemic stroke, myocardial infarction, or vascular death).	clopidogrel
1448124169	rs1330344	PMCID:PMC4752331	PTGS1	Allele T is associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to allele C.	yes	= 0.017	39	229	East Asian	Efficacy	false	in patients with extracranial or intracranial stenting.	clopidogrel
1043818349	CYP2C19*1; CYP2C19*2	PMID:21345843	CYP2C19	CYP2C19 *2 is associated with increased risk of high on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.	yes	< 0.001	236		East Asian	Efficacy	false	Study compared loss-of-function carrier (*2, *3) versus non-carrier (*1/*1) in patients receiving dual antiplatelet therapy (DAT, aspirin plus clopidogrel) versus triple antiplatelet therapy (TAT, DAT plus cilostazol).	aspirin; clopidogrel
1448603404	CYP2C19*1; CYP2C19*17	PMCID:PMC5331771	CYP2C19	CYP2C19 *17 is associated with decreased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.001	336		East Asian	Toxicity	false	CYP2C19*17 is associated with decreased risk of adverse events in Han Chinese patients treated with percutaneous coronary intervention. CYP2C19*17 mutant alleles demonstrated a significant reverse association with clinical endpoints (11.90% vs. 56.46%, P = 0.001).	aspirin; clopidogrel
1450112816	rs2254638	PMID:30487649	N6AMT1	Genotypes AG + GG are associated with increased likelihood of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype AA.	no	= 0.0653	115		East Asian	Efficacy	false	This variant is marginally associated with MACE.	clopidogrel
769146043	rs4244285	PMID:20801498	CYP2C19	Allele A is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	yes	= 0.028	5148		Multiple groups, predominantly white (98%)	Toxicity	false	"The higher rate of ischaemic events was determined during the first 30 days of treatment. The study reports association for CYP2C19 loss-of-function alleles, which includes rs4244285 (CYP2C19*2). Further loss-of-function alleles CYP2C19*3, *4, *5, *6, *7, and *8 were genotyped. In 5148 patients on clopidogrel the CYP2C19 genotypes were following:*1/*1=1862 (36%); *1/*2=898 (17%); *1/*3= 6 (<1%); *1/*4=8 (<1%); *1/*6=2 (<1%); *1/*8=21 (<1%); *2/*2=115 (2%); *2/*4	=3 (<1%); *2/*5=1 (<1%); *2/*8=6 (<1%).
However, when the full follow-up period (1 year) was considered, the difference in outcomes between patients with and without any loss-of-function allele was not significant."	clopidogrel
1043760981	rs4244285	PMID:19624462	CYP2C19	Genotypes AA + AG are associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel as compared to genotype GG.	yes	= 0.039	153		European	Efficacy	false		clopidogrel
655388276	rs4244285	PMID:19106083	CYP2C19	Allele A is associated with increased risk of cardiovascular event when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.	yes	= 0.003	2208		Unknown	Toxicity	false	(significance measured as per two CYP2C19 loss of function alleles)	clopidogrel
982035437	rs4244285	PMID:21168310	CYP2C19	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.	yes		123		East Asian	Efficacy,Toxicity	false	Study grouped *1/*1 carrier vs. carriers with loss-of-function allele (*2,*3). Population size was to small to show significance. Genotyped for CYP2C19*2 (681G > A) and CYP2C19*3 (636G > A). The subjects were divided into 2 groups, (1) dual antiplatelet therapy (DAT) group (100 mg/day aspirin plus 75 mg/day clopidogrel as a maintenance dose after 300 mg of clopidogrel loading) and (2) aspirin group (100 mg/day). On-treatment platelet reactivity showed a lower value in the DAT group than in the aspirin group (<0.05). CYP2C19 association study was done in dual antiplatelet therapy group.	clopidogrel
1447943979	CYP2C19*1; CYP2C19*17	PMID:25916518	CYP2C19	CYP2C19 *17/*17 + *1/*17 is associated with decreased likelihood of Inflammation when treated with aspirin, clopidogrel and prasugrel in people with Tobacco Use Disorder as compared to CYP2C19 *1/*1.	yes	= 0.077	429		Unknown	Efficacy	false	As measured by plasma CRP. Authors describe this as borderline significant. Patients received either clopidogrel (75 or 150mg/day) plus aspirin (75 mg/day) or prasugrel (10 mg/day) plus aspirin (75 mg/day). Difference in platelet reactivity measured by VASP PRI was not significant.	aspirin; clopidogrel; prasugrel
769146047	rs12248560	PMID:20801498	CYP2C19	Allele T is associated with increased risk of bleeding events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele C.	yes	= 0.022	5148		Multiple groups, predominantly white (98%)	Toxicity	false		clopidogrel
982035424	rs4244285	PMID:21168310	CYP2C19	Allele A is associated with increased residual platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.	yes	< 0.05	123		East Asian	Efficacy	false	Study grouped *1/*1 carrier vs. carriers with loss-of-function allele (*2,*3). Genotyped for CYP2C19*2 (681G > A) and CYP2C19*3 (636G > A). The subjects were divided into 2 groups, (1) dual antiplatelet therapy (DAT) group (100 mg/day aspirin plus 75 mg/day clopidogrel as a maintenance dose after 300 mg of clopidogrel loading) and (2) aspirin group (100 mg/day). On-treatment platelet reactivity showed a lower value in the DAT group than in the aspirin group (<0.05). CYP2C19 association study was done in dual antiplatelet therapy group.	clopidogrel
769146034	rs4244285	PMCID:PMC3641569	CYP2C19	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with percutaneous coronary intervention as compared to allele G.	yes	= 0.02	227		Multiple groups, 140 (61.7%) were white, 83 (36.6%) were African American, and 4 (1.8%) were other race/ethnicity	Toxicity	false	(significance measured as per carrying at least one CYP2C19 reduced-function allele) The association was determined for cardiovascular ischemic event or death during 1 year of follow-up.	clopidogrel
1450370841	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMID:29536505	CYP2C19	CYP2C19 *1/*2 + *2/*2 + *2/*17 (assigned as poor metabolizers and intermediate metabolizers phenotype) are associated with increased platelet aggregation when treated with clopidogrel as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer and ultra-metabolizer phenotype) .	yes	= 0.006	123		European	Efficacy	false	in patients who underwent percutaneous neurointervention. CYP2C19 IM-PM had a higher aggregation value and, thus, a lower rate of response when compared to CYP2C19 NM and UM.	clopidogrel
982033401	rs2242480	PMID:16645157	CYP3A4	Genotypes CT + TT are associated with reduced GP IIb/IIIa activation and lower platelet activation when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	yes	= 0.02	82		European	Efficacy	false	Patients who were in a steady phase (more than 1 month) of clopidogrel (75 mg/daily) treatment were included. Patients were combined aspirin and clopidogrel therapy.  The T allele carrier had a reduced GP IIb/IIIa activation and a better response to clopidogrel compared with noncarriers of the variant allele.	clopidogrel
982035455	rs4986893	PMID:21168310	CYP2C19	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.	yes		123		East Asian	Efficacy,Toxicity	false	Study grouped *1/*1 carrier vs. carriers with loss-of-function allele (*2,*3). Population size was to small to show significance. Genotyped for CYP2C19*2 (681G > A) and CYP2C19*3 (636G > A). The subjects were divided into 2 groups, (1) dual antiplatelet therapy (DAT) group (100 mg/day aspirin plus 75 mg/day clopidogrel as a maintenance dose after 300 mg of clopidogrel loading) and (2) aspirin group (100 mg/day). On-treatment platelet reactivity showed a lower value in the DAT group than in the aspirin group (<0.05). CYP2C19 association study was done in dual antiplatelet therapy group.	clopidogrel
1451935741	rs4244285	PMID:32077582	CYP2C19	Allele A is associated with increased platelet reactivity when treated with clopidogrel in people with Cardiovascular Diseases as compared to allele G.	yes	= 0.0003	96		Unknown	Efficacy	false	Authors list rs numbers that were differently represented in high platelet reactivity group and low platelet reactivity group after clopidogrel. Authors do not state which allele is associated and whether is associated with increased reactivity or decreased reactivity, wrote sentence based on prior established phenotypes for rs4244285/*2.	clopidogrel
1451935730	rs12572897	PMID:32077582	NOC3L	Allele A is associated with increased platelet reactivity when treated with clopidogrel in people with Cardiovascular Diseases as compared to allele G.	yes	= 0.01857	96		Unknown	Efficacy	false	Authors list rs numbers that were differently represented in high platelet reactivity group and low platelet reactivity group after clopidogrel. Authors do not state which allele is associated and whether is associated with increased reactivity or decreased reactivity, wrote sentence as minor allele associated with increased reactivity (ie. reduced clopidogrel effect).	clopidogrel
655388271	rs1045642	PMID:19106083	ABCB1	Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.	yes	= 0.007	2208		Unknown	Toxicity	false		clopidogrel
982035447	rs4986893	PMID:21168310	CYP2C19	Allele A is associated with increased residual platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.	yes	< 0.05	123		East Asian	Efficacy	false	Study grouped *1/*1 carrier vs. carriers with loss-of-function allele (*2,*3). Genotyped for CYP2C19*2 (681G > A) and CYP2C19*3 (636G > A). The subjects were divided into 2 groups, (1) dual antiplatelet therapy (DAT) group (100 mg/day aspirin plus 75 mg/day clopidogrel as a maintenance dose after 300 mg of clopidogrel loading) and (2) aspirin group (100 mg/day). On-treatment platelet reactivity showed a lower value in the DAT group than in the aspirin group (<0.05). CYP2C19 association study was done in dual antiplatelet therapy group.	clopidogrel
1451737080	rs11640115	PMCID:PMC8602039	WDR24	Allele G is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele A.	yes	= 3.21E-7	1871		East Asian	Efficacy	false	Patients carrying the G allele were more likely to experience MACE in 18 months of follow-up.	aspirin; clopidogrel
982033160	rs4244285	PMID:18577829	CYP2C19	Genotypes AA + AG are associated with decreased platelet function when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	= 0.002	105		Unknown	Other	false	"The presented association is for subjects of group1 which are carriers of the C allele of P2Y12 and the A allele of CYP2C19. Patients were genotyped for CYP2C19*2 and P2RY12 i-T744C. Patients were divided into 4 groups: carriers of the C allele of P2Y12 and the A allele of CYP2C19 (group 1), carriers of the A allele of CYP2C19 and the wild TT genotype of P2Y12 (group 2), carriers of the C allele of P2Y12 and the wild GG genotype of CYP2C19 (group 3) and  carriers of the wild TT genotype of P2Y12 and the wild GG genotype
of CYP2C19 (controls). Platelet function was measured and registered as closure time in the test with collagen and adenosine diphosphate (CADP-CT)."	clopidogrel
827814107	CYP2C19*17	PMID:21806387	CYP2C19	CYP2C19 *17 is associated with decreased likelihood of platelet reactivity when treated with clopidogrel in people with Angina Pectoris.	no	= 0.26	189		European	Efficacy	false	Gain-of-function alleles were associated with decreased platelet activity (not statistically significant).	clopidogrel
982029062	rs28399504	PMID:19463375	CYP2C19	Allele G is associated with decreased platelet inhibition after a clopidogrel 600-mg loading dose when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.	yes	= 0.029	60		Unknown	Efficacy	false	Study compared non-carriers (*1/*1) with carriers of the CYP2C19*2 or *4 alleles. CYP2C19*1*1 carriers have greater platelet inhibition 2 h after a 600-mg dose compared with platelet inhibition in CYP2C19*2 or *4 carriers. CYP2C19*2 or *4 carrier had a greater platelet inhibition with 1200 mg loading dose compared to 600 mg (p=0.002). Platelet inhibition was greater 150 mg daily maintenance dose compared to 75 mg (0.042). For CYP2C19*1/*1 carrier the platelet inhibition did not differ comparing the treatment regimes.	clopidogrel
1043818407	rs4986893	PMID:20724801	CYP2C19	Genotypes AG + GG are associated with high post-clopidogrel platelet reactivity when treated with clopidogrel in undergoing scheduled percutaneous coronary intervention as compared to genotype AA.	yes	< 0.001	176		East Asian	Efficacy	false	Post-clopidogrel platelet reactivity (HPPR) was analyzed after a routine loading dose of 300-mg clopidogrel.	clopidogrel
827814086	rs2032582	PMID:21806387	ABCB1	Allele A is not associated with response to clopidogrel in people with Angina Pectoris as compared to allele C.	no		181		European	Efficacy	false	Variant 2677G>A/T (minus chromosomal strand). As measured by platelet reactivity and clinical outcomes; risk of myocardial infarction, cardiovascular death or target vessel revascularization.	clopidogrel
1043818402	rs4244285	PMID:20724801	CYP2C19	Genotypes AG + GG are associated with high post-clopidogrel platelet reactivity when treated with clopidogrel in undergoing scheduled percutaneous coronary intervention as compared to genotype AA.	yes	< 0.001	176		East Asian	Efficacy	false	Post-clopidogrel platelet reactivity (HPPR) was analyzed after a routine loading dose of 300-mg clopidogrel.	clopidogrel
982029072	rs4244285	PMID:19463375	CYP2C19	Allele A is associated with decreased platelet inhibition after a clopidogrel 600-mg loading dose when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	yes	= 0.029	60		Unknown	Efficacy	false	Study compared non-carriers (*1/*1) with carriers of the CYP2C19*2 or *4 alleles. CYP2C19*1*1 carriers have greater platelet inhibition 2 h after a 600-mg dose compared with platelet inhibition in CYP2C19*2 or *4 carriers. CYP2C19*2 or *4 carrier had a greater platelet inhibition with 1200 mg loading dose compared to 600 mg (p=0.002). Platelet inhibition was greater 150 mg daily maintenance dose compared to 75 mg (0.042). For CYP2C19*1/*1 carrier the platelet inhibition did not differ comparing the treatment regimes.	clopidogrel
1043763118	rs4244285	PMID:20845077	CYP2C19	Genotypes AA + AG are associated with increased risk of cardiovascular events when treated with clopidogrel as compared to genotype GG.	yes	= 0.007	8280		Unknown	Toxicity	false		clopidogrel
1183491857	CYP2C19*1	PMID:23428009	CYP2C19	CYP2C19 *1/*1 is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*2 + *2/*2.	yes	= 0.043	76		Unknown	Efficacy	false	"Patients with stable coronary artery disease and high-on-treatment platelet reactivity (HTPR). Those with the *1/*1 genotype had better response to clopidogrel after 30 days of treatment, as compared to *2 carriers. Patients were segregated into ""optimal responders"" (P2Y12 reaction units <235) or those whose high-on-treatment platelet reactivity (P2Y12 reaction units >= 235) persisted. Those with *1/*1 were more likely to be optimal responders."	clopidogrel
1043818411	rs4244285	PMID:20708365	CYP2C19	Genotypes AG + GG are associated with increased VASP index when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype AA.	yes	< 0.001	411		Unknown	Efficacy	false	VASP index was assayed after clopidogrel loading dose of 600 mg. A VASP index greater than 50% was used to define high on-treatment platelet reactivity. G allele carriage was associated with high on-treatment platelet reactivity after the first 600-mg LD of clopidogrel. Following, dose adjustment was performed by using up to 3 additional 600 mg LDs to obtain a VASP index <50%.	clopidogrel
827814135	rs662	PMID:21819538	PON1	Genotype CC is associated with decreased on-clopidogrel platelet reactivity (PR) at 1 month and at 6 months after percutaneous coronary intervention (PCI) when treated with clopidogrel in people with Myocardial Ischemia as compared to genotypes CT + TT.	yes	= 0.03	300		Unknown	Efficacy	false	PON1 Q192R polymorphism did not show any influence on pre-PCI PR. In all patients, the study observed a significant decrease in on-clopidogrel PR, and PON1 Q192R minimally modulates this pattern. No relationship between PON1 genotypes and adverse events (either ischemic or bleeding) was found.	clopidogrel
1043818388	CYP2C19*2	PMID:21511217	CYP2C19	CYP2C19 *2 is not associated with increased risk of High on-treatment platelet reactivity when treated with aspirin, cilostazol and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.	no	= 0.174	64		East Asian	Efficacy	false	Study compared loss-of-function carrier (*2, *3) versus non-carrier (*1/*1) in patients receiving dual antiplatelet therapy (DAT, aspirin plus clopidogrel) versus triple antiplatelet therapy (TAT, DAT plus cilostazol).	aspirin; cilostazol; clopidogrel
982033197	rs2046934	PMID:18577829	P2RY12	Genotypes AG + GG are associated with decreased platelet function when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype AA.	yes	= 0.002	105		Unknown	Other	false	"The presented association is for subjects of group1 which are carriers of the C allele of P2Y12 and the A allele of CYP2C19. Patients were genotyped for CYP2C19*2 and P2RY12 i-T744C (A/G on positive strand). Patients were divided into 4 groups: carriers of the C allele of P2Y12 and the A allele of CYP2C19 (group 1), carriers of the A allele of CYP2C19 and the wild TT genotype of P2Y12 (group 2), carriers of the C allele of P2Y12 and the wild GG genotype of CYP2C19 (group 3) and  carriers of the wild TT genotype of P2Y12 and the wild GG genotype
of CYP2C19 (controls). Platelet function was measured and registered as closure time in the test with collagen and adenosine diphosphate (CADP-CT)."	clopidogrel
1043818394	CYP2C19*3	PMID:21511217	CYP2C19	CYP2C19 *3 is not associated with increased risk of High on-treatment platelet reactivity when treated with aspirin, cilostazol and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.	no	= 0.174	64		East Asian	Efficacy	false	Study compared loss-of-function carrier (*2, *3) versus non-carrier (*1/*1) in patients receiving dual antiplatelet therapy (DAT, aspirin plus clopidogrel) versus triple antiplatelet therapy (TAT, DAT plus cilostazol).	aspirin; cilostazol; clopidogrel
1043818375	CYP2C19*2	PMID:21511217	CYP2C19	CYP2C19 *2 is associated with increased risk of High on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.	yes	= 0.002	62		East Asian	Efficacy	false	Study compared loss-of-function carrier (*2, *3) versus non-carrier (*1/*1) in patients receiving dual antiplatelet therapy (DAT, aspirin plus clopidogrel) versus triple antiplatelet therapy (TAT, DAT plus cilostazol).	aspirin; clopidogrel
1043818369	CYP2C19*1; CYP2C19*3	PMID:21345843	CYP2C19	CYP2C19 *3 is not associated with increased risk of high on-treatment platelet reactivity when treated with aspirin, cilostazol and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.	no	= 0.167	238		East Asian	Efficacy	false	Study compared loss-of-function carrier (*2, *3) versus non-carrier (*1/*1) in patients receiving dual antiplatelet therapy (DAT, aspirin plus clopidogrel) versus triple antiplatelet therapy (TAT, DAT plus cilostazol).	aspirin; cilostazol; clopidogrel
1043818382	CYP2C19*3	PMID:21511217	CYP2C19	CYP2C19 *3 is associated with increased risk of High on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.	yes	= 0.002	62		East Asian	Efficacy	false	Study compared loss-of-function carrier (*2, *3) versus non-carrier (*1/*1) in patients receiving dual antiplatelet therapy (DAT, aspirin plus clopidogrel) versus triple antiplatelet therapy (TAT, DAT plus cilostazol).	aspirin; clopidogrel
1448634256	rs2032582	PMID:28589365	ABCB1	Allele T is associated with increased risk of Hemorrhage when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.	yes	= 0.036	211		European	Toxicity	false	Please note: alleles have been complemented to the + strand.	clopidogrel
1448634240	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMID:28589365	CYP2C19	CYP2C19 *2 + *17 are not associated with likelihood of adverse cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.	no	> 0.05	211		Unknown	Efficacy	false	Cardiovascular adverse events at 6 months were not associated with these gene variants.	clopidogrel
1450123149	rs12456693	PMID:30487649	SLC14A2	Allele T is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to allele C.	yes	= 6.83e-5	115		East Asian	Efficacy	false	This variant is associated with increased H4 concentration.	clopidogrel
1185234754	rs1045642	PMID:25430046	ABCB1	Genotype AA is associated with decreased exposure to clopidogrel as compared to genotypes AG + GG.	yes	= 0.012	42		European	Metabolism/PK	false	"in patients undergoing elective coronary angiography and percutaneous coronary intervention. The exposure to the unchanged clopidogrel was measured by the AUC(0-t) of the drug. Moreover, T/T carriers exhibited significantly lower Cmax
of clopidogrel than C/C carriers (P=0.003)."	clopidogrel
1185234764	rs1045642	PMID:25430046	ABCB1	Genotype AA is not associated with platelet aggregation when treated with clopidogrel as compared to genotypes AG + GG.	no	= 0.582	42		European	Efficacy	false		clopidogrel
827814073	rs1045642	PMID:21806387	ABCB1	Allele A is not associated with response to clopidogrel in people with Angina Pectoris as compared to allele G.	no		181		European	Efficacy	false	Variant 3435C>T (minus chromosomal strand). As measured by platelet reactivity and clinical outcomes; risk of myocardial infarction, cardiovascular death or target vessel revascularization.	clopidogrel
1448634286	CYP2C19*1; CYP2C19*2	PMID:28604225	CYP2C19	CYP2C19 *1/*1 is associated with decreased platelet aggregation when treated with aspirin and clopidogrel in people with Acute coronary syndrome and Myocardial Infarction as compared to CYP2C19 *1/*2 + *2/*2.	yes	= 0.002	253		Unknown	Efficacy	false		aspirin; clopidogrel
827814062	rs662	PMID:21806387	PON1	Allele C is not associated with response to clopidogrel in people with Angina Pectoris as compared to allele T.	no		189		European	Efficacy	false	As measured by platelet reactivity and clinical outcomes; risk of myocardial infarction, cardiovascular death or target vessel revascularization.	clopidogrel
827814058	CYP2C19*2	PMID:21806387	CYP2C19	CYP2C19 *2/*2 is associated with increased risk of Death and Myocardial Infarction when treated with clopidogrel in people with Angina Pectoris.	yes	= 0.01	189		European	Efficacy	false	*2/*2 subjects had an increased risk of myocardial infarction, cardiovascular death or target vessel revascularization.	clopidogrel
1448258646	rs1045642	PMID:25060201	ABCB1	Genotypes AA + AG is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	no	= 0.109	26		European	Efficacy	false	Alleles are given as C and T. Response measured as platelet reactivity index using the vasodilator-stimulated phosphoprotein index and a cut-off value of >=60% was defined as hypo-responsiveness.	clopidogrel
1448567891	rs11871251	PMID:28091702	ITGB3	Genotype AA is not associated with risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to genotypes AG + GG.	no	= 0.52	46	380	East Asian	Toxicity	false	"in Chinese patients with minor ischemic stroke (MIS). The primary clinical endpoint was defined as composite of recurrent ischemic stroke, myocardial infarction and death. ""The estimated risks of adverse events were significantly higher in patients carrying rs16863323TT and rs2317676GG or rs16863323TT and rs2317676GG/AG, compared to those harboring rs16863323CC and rs2317676AA"", suggesting that gene interactions conferred a higher risk for adverse events than did any single variant alone."	clopidogrel
699638709	rs12248560	PMID:20083681	CYP2C19	Allele T is associated with increased risk of bleeding when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	yes	= 0.006	1524		Unknown	Toxicity	false	within 30 days of PCI.	clopidogrel
1450806399	CYP3A5*1; CYP3A5*3	PMID:29998574	CYP3A5	CYP3A5 *1/*3 is not associated with platelet aggregation inhibition when exposed to clopidogrel in healthy individuals as compared to CYP3A5 *1/*1.	no	= 0.390	19		European	Efficacy	false	The CYP3A5 genotype did not affect the platelet inhibitory activity of clopidogrel.	clopidogrel
981344377	rs4244285	PMID:22990067	CYP2C19	Genotype AA is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	< 0.001	447		East Asian	Efficacy	false	"Chinese patients undergoing PCI with drug-eluting stents after acute coronary syndrome. The finding is reported on carriers with two loss-of-function alleles (CYP2C19*2/*2, *2/*3, and *3/*3 combined) and are after adjustment for confounding factors (including sex, age, BMI, smoking status, hypertension, diabetes mellitus, and use of a proton pump inhibitor). No significant difference was found between patients with
the CYP2C19*2/*2 genotype and those with the CYP2C19*2/*3 genotype. Patients received a loading dose of 300mg clopidogrel, followed by a daily regimen of 75mg and a loading dose of 300mg aspirin, followed by 100mg daily."	clopidogrel
982034575	rs4986893	PMCID:PMC3159941	CYP2C19	Genotypes AA + AG are associated with higher P2Y12 reaction units (PRU) and lower percent inhibition when treated with clopidogrel in people with Cerebrovascular Disorders as compared to genotype GG.	yes	< 0.001	166		East Asian	Efficacy	false	The study compared extensive metabolizer (*1/*1 allele) vs. intermediate (one loss-of-function allele; *1/*2, *1/*3) or poor (two loss-of-function alleles ;*2/*2, *2/*3, *3/*3) metabolizers. The numbers of patients with the CYP2C19 *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3 genotype were 68 (40.9%), 56 (33.7%), 18 (10.8%), 14 (8.4%), 9 (5.4%) and 1 (0.6%), respectively.	clopidogrel
982009985	CYP2C19*1; CYP2C19*3	PMID:22374717	CYP2C19	CYP2C19 *1/*3 is associated with decreased antiplatelet response and reduced clopidogrel active metabolite formation when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.	yes	= 0.02	21		Unknown	Efficacy	false	Reduced function alleles (*1/*2, *2/*2 or *1/*3) are grouped together  for analysis vs. the extensive metabolizer alleles (*1/*1, *1/*17).	clopidogrel
1451973760	rs6809699	PMCID:PMC9801627	P2RY12	Genotypes AA + AC is associated with increased resistance to clopidogrel in people with Coronary Disease as compared to genotype CC.	yes	= 0.016	141	86	East Asian	Efficacy	false	"was significant in Recessive and co-dominant models. This was also seen when examined in just CYP2C19*1/*1 in discovery cohort but not whole cohort. Paper talks about using 2 cohorts, one for discovery and one for replication but it is not explicit about which are in which table of results. ""Patients carrying the P2RY12 rs6809699 CA genotype or the rs6809699 A allele also showed significantly increased risk of CR (CA vs CC genotype: OR 2.270, 95% CI 1.019–5.059, P = 0.045; CA + AA vs CC genotype: OR 2.636, 95% CI 1.199–5.796; P = 0.016). """	clopidogrel
1448531034	rs7634096	PMID:27450232	P2RY12	Allele C is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	no	= 0.809	64	313	East Asian	Efficacy	false		clopidogrel
981344366	rs4244285	PMID:22990067	CYP2C19	Genotype AG is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	= 0.002	447		East Asian	Efficacy	false	Please note, the finding is reported on carriers with one loss-of-function allele (CYP2C19*2 or*3 combined) and are after adjustment for confounding factors (including sex, age, BMI, smoking status, hypertension, diabetes mellitus, and use of a proton pump inhibitor). No significant difference in platelet aggregation between patients with the CYP2C19*1/*2 genotype and patients with the CYP2C19*1/*3 genotype was found. Chinese patients undergoing PCI with drug-eluting stents after acute coronary syndrome. Patients received a loading dose of 300mg clopidogrel, followed by a daily regimen of 75mg and a loading dose of 300mg aspirin, followed by 100mg daily.	clopidogrel
1043762214	rs4244285	PMID:20510210	CYP2C19	Genotypes AA + AG are associated with increased risk of insufficient antiplatelet response to clopidogrel when treated with clopidogrel in patients undergoing elective coronary stent implantation as compared to genotype GG.	yes		760		European	Efficacy	false		clopidogrel
982032538	rs28399504	PMID:20801498	CYP2C19	Allele G is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele A.	yes	= 0.028	5148		Multiple groups, predominantly white (98%)	Toxicity	false	"The association for increased risk of a higher rate of ischaemic events was during the first 30 days of treatment. The study reports association for CYP2C19 loss-of-function alleles, which includes rs4244285 (CYP2C19*2). Further loss-of-function alleles CYP2C19*3, *4, *5, *6, *7, and *8 were genotyped. In 5148 patients on clopidogrel the CYP2C19 genotypes were following:*1/*1=1862 (36%); *1/*2=898 (17%); *1/*3= 6 (<1%); *1/*4=8 (<1%); *1/*6=2 (<1%); *1/*8=21 (<1%); *2/*2=115 (2%); *2/*4	=3 (<1%); *2/*5=1 (<1%); *2/*8=6 (<1%).
However, when the full follow-up period (1 year) was considered, the difference in outcomes between patients with and without any loss-of-function allele was not significant."	clopidogrel
1448531012	rs1491974	PMID:27450232	P2RY12	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.511	64	313	East Asian	Efficacy	false		clopidogrel
1450806379	CYP3A4*1; CYP3A4*22	PMID:29998574	CYP3A4	CYP3A4 *1/*22 is not associated with platelet aggregation inhibition when exposed to clopidogrel in healthy individuals as compared to CYP3A4 *1/*1.	no	= 0.123	17		European	Efficacy	false	"The CYP3A4 genotype did not affect the platelet inhibitory activity of clopidogrel. ""However, there was a tendency for reduced average and maximum platelet
inhibition after clopidogrel ingestion in CYP3A4*22 carriers compared to the controls (P = 0.123 and P = 0.078, espectively)."""	clopidogrel
1448258628	rs1799853	PMID:25060201	CYP2C9	Genotype CT is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	no	= 0.495	26		European	Efficacy	false	Response measured as platelet reactivity index using the vasodilator-stimulated phosphoprotein index and a cut-off value of >=60% was defined as hypo-responsiveness.	clopidogrel
981844125	rs4244285	PMID:22265638	CYP2C19	Allele A is not associated with decreased platelet inhibition when treated with clopidogrel as compared to genotype GG.	no		112		Near Eastern	Efficacy	false	Blood samples to measure platelet aggregation were taken 2h after the loading dose, 24h after PCI and 30 days after PCI. Patients were undergoing elective PCI. The patients received a loading dose of 600mg clopidogrel before PCI and 75 mg maintenance dose. *2 (rs4244285) and *3 were genotyped (10.09% and 0.91%). Due to low frequency of *3 analysis was performed comparing *1/*1 vs carriage of at least one loss-of-function allele.	clopidogrel
1448531023	rs9859538	PMID:27450232	P2RY12	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.849	64	313	East Asian	Efficacy	false		clopidogrel
982032530	rs4986893	PMID:20801498	CYP2C19	Allele A is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	yes	= 0.028	5148		Multiple groups, predominantly white (98%)	Toxicity	false	"The higher rate of ischaemic events was determined during the first 30 days of treatment. The study reports association for CYP2C19 loss-of-function alleles, which includes rs4244285 (CYP2C19*2). Further loss-of-function alleles CYP2C19*3, *4, *5, *6, *7, and *8 were genotyped. In 5148 patients on clopidogrel the CYP2C19 genotypes were following:*1/*1=1862 (36%); *1/*2=898 (17%); *1/*3= 6 (<1%); *1/*4=8 (<1%); *1/*6=2 (<1%); *1/*8=21 (<1%); *2/*2=115 (2%); *2/*4	=3 (<1%); *2/*5=1 (<1%); *2/*8=6 (<1%).
However, when the full follow-up period (1 year) was considered, the difference in outcomes between patients with and without any loss-of-function allele was not significant."	clopidogrel
699638703	rs12248560	PMID:20083681	CYP2C19	Allele T is associated with decreased ADP-induced platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	yes	= 0.009	1524		Unknown	Efficacy	false		clopidogrel
769163207	rs762551	PMID:21148426	CYP1A2	Genotypes AA + AC are associated with decreased on-treatment platelet reactivity when treated with clopidogrel in people with cigarette smokers as compared to genotype CC.	yes	< 0.001	1115		East Asian	Efficacy,Metabolism/PK	false		clopidogrel
1448258637	rs1057910	PMID:25060201	CYP2C9	Genotype AC is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype AA.	no	= 0.362	65		European	Efficacy	false	Response measured as platelet reactivity index using the vasodilator-stimulated phosphoprotein index and a cut-off value of >=60% was defined as hypo-responsiveness.	clopidogrel
1448729670	CYP2C9*1; CYP2C9*2	PMID:28745576	CYP2C9	CYP2C9 *2/*2 is associated with increased platelet aggregation when treated with clopidogrel as compared to CYP2C9 *1/*1.	yes	= 0.06	274		Multiple groups, 45% Chinese, 22% Malay, 23% Iban, 10% others	Efficacy	false	in patients undergoing elective percutaneous coronary intervention. This was significant when comparing *2/*2 vs *1/*2 vs *1/*1 but not significant when looking at *2/*2 +*1/*2 vs *1/*1	clopidogrel
1448531056	rs16863336	PMID:27450232	P2RY12	Allele C is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	no	= 0.145	64	313	East Asian	Efficacy	false		clopidogrel
1448602737	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMCID:PMC4937952	CYP2C19	CYP2C19 *2 + *3 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.022	1349		East Asian	Toxicity	false	"in patients treated with first-generation drug-eluting stent (DES), but not in patients treated with newer-generation DES. The first-generation drug-eluting stents (DES) include sirolimus-eluting stent (SES) or paclitaxel-eluting stent (PES); while the newer-generation DESs include everolimus-eluting stent (EES) and zotarolimus-eluting stent for better efficacy and safety.
(ZES)"	clopidogrel
1028218721	rs4244285	PMID:19193675	CYP2C19	Genotypes AA + AG are associated with increased risk of stent thrombosis when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to genotype GG.	yes	= 0.006	2485		European	Efficacy,Toxicity	false	The primary endpoint of the study was the incidence of definite ST within 30 days following PCI.	clopidogrel
1444607027	CYP2C19*1; CYP2C19*2	PMID:25542807	CYP2C19	CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	< 0.05	305		East Asian	Metabolism/PK	false	"The carriers of CYP2C19*2 were associated with lower exposure to its active (clopi-H4) and inactive (CLPM) metabolites which are associated with a higher magnitude of platelet aggregation in ACS patients treated with either a
75 mg maintenance dose daily of clopidogrel or a 300 mg loading dose following 75 mg maintenance dose daily of clopidogrel. However, the maximal plasma concentration of clopidogrel was not statistically different between the carriers and non-carriers of CYP2C19*2."	clopidogrel
982034594	rs4244285	PMCID:PMC3116006	CYP2C19	Allele A is associated with increased risk of non-response to clopidogrel when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	< 1.0E-4	114		East Asian	Efficacy	false	Study compared carrier of any loss-of-function allele (*2, *3) vs wildtype (*1/*1). CYP2C19*2 (681G>A; rs42-44285) and CYP2C19*3 (636G>A; rs4986893) were genotyped. (60%) were carriers for the CYP2C19*2 or CYP2C19*3.	clopidogrel
1448531069	rs12497330	PMID:27450232	P2RY12	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.499	64	313	East Asian	Efficacy	false		clopidogrel
981844136	rs776746	PMID:22265638	CYP3A5	Genotype CC is not associated with decreased platelet inhibition when treated with clopidogrel as compared to genotypes CT + TT.	no		112		Near Eastern	Efficacy	false	Blood samples to measure platelet aggregation were taken 2h after the loading dose, 24h after PCI and 30 days after PCI. Patients were undergoing elective PCI. The patients received a loading dose of 600mg clopidogrel before PCI and 75 mg maintenance dose.	clopidogrel
982036665	rs1126643	PMID:17157856	ITGA2	Genotypes CT + TT are associated with increased risk of residual platelet reactivity when treated with aspirin and clopidogrel in people with Myocardial Infarction as compared to genotype CC.	yes	< 0.05	289		Unknown	Efficacy	false	The association is significant for carriers of the T allele together with a A at rs1062535. The residual platelet reactivity (RPR) is defined by AA induced platelet aggregation (OR = 3.0, 95%CI 1.17 - 7.89, p = 0.022) or by PFA100/epinephrine (OR = 4.1, 95%CI 1.53 - 10.89, p = 0.005). Cohort are myocardial infarction (MI) patients undergoing percutaneous coronary intervention (PCI) on dual antiplatelet treatment.	aspirin; clopidogrel
827784037	rs662	PMCID:PMC3250350	PON1	Allele C is not associated with ADP-stimulated platelet aggregation when treated with clopidogrel as compared to allele T.	no	= 0.21	566		European	Efficacy	false		clopidogrel
1448531045	rs12487835	PMID:27450232	P2RY12	Allele C is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	no	= 0.415	64	313	East Asian	Efficacy	false		clopidogrel
982034621	rs4244285	PMCID:PMC3071307	CYP2C19	Allele A is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	= 0.001	219		Unknown	Efficacy	false	"The ""loss-of-function"" cytochrome 2C19*2 G/A polymorphism (rs 4244285) was investigated."	clopidogrel
982034612	rs4986893	PMCID:PMC3116006	CYP2C19	Allele A is associated with increased risk of non-response to clopidogrel when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	< 1.0E-4	114		East Asian	Efficacy	false	Study compared carrier of any loss-of-function allele (*2, *3) vs wildtype (*1/*1). CYP2C19*2 (681G>A; rs42-44285) and CYP2C19*3 (636G>A; rs4986893) were genotyped. (60%) were carriers for the CYP2C19*2 or CYP2C19*3.	clopidogrel
1448258670	CYP2C19*1; CYP2C19*2	PMID:26311225	CYP2C19	CYP2C19 *2 is not associated with severity of Inflammation when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	no	= 0.36	408		Unknown	Toxicity	false	in stable CAD patients receiving clopidogrel treatment. CYP2C19*2 causes no effect on vascular function and endothelial Function either.  Measurement of flow-mediated dilation (FMD) of the brachial artery was used to evaluate endothelial function. Carotid-femoral pulse wave velocity (PWV) and augmentation index (AIx) was measured to estimate arterial stiffness. Levels of tumor necrosis factor alpha (TNF-a) and interleukin 6 (IL-6) were measured to assess inflammation.	aspirin; clopidogrel
1444607066	rs1045642	PMID:25542807	ABCB1	Genotypes AA + AG are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	< 0.05	305		East Asian	Efficacy	false	The carriers of ABCB1  C3435T were associated with a higher magnitude of platelet aggregation in ACS patients when treated with either a 75 mg maintenance dose daily of clopidogrel or a 300 mg loading dose following 75 mg maintenance dose daily of clopidogrel.	clopidogrel
1448567830	rs1371097	PMID:28091702	P2RY1	Genotype CC is not associated with risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to genotypes CT + TT.	no	= 0.44	46	380	East Asian	Toxicity	false	"in Chinese patients with minor ischemic stroke (MIS). The primary clinical endpoint was defined as composite of recurrent ischemic stroke, myocardial infarction and death. ""The estimated risks of adverse events were significantly higher in patients carrying rs16863323TT and rs2317676GG or rs16863323TT and rs2317676GG/AG, compared to those harboring rs16863323CC and rs2317676AA"", suggesting that gene interactions conferred a higher risk for adverse events than did any single variant alone."	clopidogrel
1448119317	rs662	PMID:27380588	PON1	Allele C is not associated with platelet reactivity when treated with clopidogrel as compared to allele T.	no	< 0.001	67		East Asian	Efficacy	false	in Korean patients both pre and post PCI overall; however, 2-carriers had reduced platelet inhibition compared with platelet inhibition in 0-carrier after 600 mg loading dose before and after PCI.	clopidogrel
1448530963	rs6798347	PMID:27450232	P2RY12	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.405	64	313	East Asian	Efficacy	false		clopidogrel
1450806320	CYP3A5*1; CYP3A5*3	PMID:29998574	CYP3A5	CYP3A5 *1/*3 is not associated with exposure to clopidogrel in healthy individuals as compared to CYP3A5 *1/*1.	no	= 0.335	20		European	Metabolism/PK	false	"""The CYP3A5 genotype did not significantly affect the pharmacokinetics of clopidogrel or any of its metabolites, although there was a trend toward increased rate of oxidative metabolism of clopidogrel in CYP3A5 expressors. For example, the clopidogrel active metabolite to clopidogrel AUC0–8 ratio was 69% higher in CYP3A5 expressors than in the controls, but the difference was not statistically significant (P = 0.153)""."	clopidogrel
1448530973	rs1907637	PMID:27450232	P2RY12	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.946	64	313	East Asian	Efficacy	false		clopidogrel
1448567836	rs9859538	PMID:28091702	P2RY12	Genotype GG is not associated with risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to genotypes AA + AG.	no	= 0.66	46	380	East Asian	Toxicity	false	"in Chinese patients with minor ischemic stroke (MIS). The primary clinical endpoint was defined as composite of recurrent ischemic stroke, myocardial infarction and death. ""The estimated risks of adverse events were significantly higher in patients carrying rs16863323TT and rs2317676GG or rs16863323TT and rs2317676GG/AG, compared to those harboring rs16863323CC and rs2317676AA"", suggesting that gene interactions conferred a higher risk for adverse events than did any single variant alone."	clopidogrel
699638755	rs2046934	PMID:16769602	P2RY12	Allele G is not associated with response to clopidogrel.	not stated		109		Unknown	Efficacy	false	This is one of four SNPs that comprise H1/H2 haplotypes. The four SNPs (C139T, T744C, ins801A, G52T(=G50T) are in perfect LD, and T744C is frequently used as the tagging SNP. H1 is 139C/744T/no ins at 801A/52G. H2(minor haplotype) is 139T/744C/ins801A//52T.  could not access full-text.	clopidogrel
1444607054	rs1045642	PMID:25542807	ABCB1	Genotypes AA + AG are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	< 0.05	305		East Asian	Efficacy	false	The A allele carriers are associated with a higher magnitude of platelet aggregation in ACS patients treated with clopidogrel as compared to non-carriers.	clopidogrel
1448119303	CYP3A5*1; CYP3A5*3	PMID:27380588	CYP3A5	CYP3A5 *3 is not associated with platelet reactivity when treated with clopidogrel as compared to CYP3A5 *1/*1.	no	= 0.41	136		East Asian	Efficacy	false	in Korean patients both pre and post PCI.	clopidogrel
1444607043	rs1045642	PMID:25542807	ABCB1	Genotypes AA + AG are associated with decreased metabolism of clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	< 0.05	305		East Asian	Metabolism/PK	false	The carriers of ABCB1  C3435T were associated with lower levels of plasma clopidogrel and its active (clopi-H4) and inactive (CLPM) metabolites in ACS patients treated with either a 75 mg maintenance dose daily of clopidogrel or a 300 mg loading dose following 75 mg maintenance dose daily of clopidogrel.	clopidogrel
1451123748	rs778068631	PMID:23275066	CES1	Allele del is associated with decreased catalytic activity of CES1 when assayed with 2-oxo-clopidogrel or clopidogrel as compared to allele A.	not stated					Other	false	In-vitro experiments, in a cell line stably expressing CES1 D260fs variant.	2-oxo-clopidogrel; clopidogrel
1448530954	rs6798637	PMID:27450232	P2RY12	Allele G is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele C.	no	= 0.792	64	313	East Asian	Efficacy	false		clopidogrel
1448567819	rs1439010	PMID:28091702		Genotype AA is not associated with risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to genotypes AG + GG.	no	= 0.54	46	380	East Asian	Toxicity	false	"in Chinese patients with minor ischemic stroke (MIS). The primary clinical endpoint was defined as composite of recurrent ischemic stroke, myocardial infarction and death. ""The estimated risks of adverse events were significantly higher in patients carrying rs16863323TT and rs2317676GG or rs16863323TT and rs2317676GG/AG, compared to those harboring rs16863323CC and rs2317676AA"", suggesting that gene interactions conferred a higher risk for adverse events than did any single variant alone."	clopidogrel
699638765	rs2046934	PMID:16581111	P2RY12	Allele G is not associated with response to clopidogrel as compared to allele A.	no		120		"Multiple groups, Caucasian 76; African-American 4; Hispanic origin 29; Asian origin 11.  38 women.  Avg age 65.5 +/- 10.9 .  Patients were at Baylor College of Medicine, Houston,
TX, United States.  Patients were scheduled for elective
percutaneous coronary intervention (PCI). All
patients had received aspirin 81¿325mg daily for
z1week before the PCI and had not received a
thienopyridine or GP IIb/IIIa inhibitor in the week
prior to enrollment"	Dosage	false	"This is one of four SNPs that comprise H1/H2 haplotypes. The four SNPs (C139T, T744C, ins801A, G52T(=G50T) are in perfect LD, and T744C is frequently used as the tagging SNP. H1 is 139C/744T/no ins at 801A/52G. H2(minor haplotype) is 139T/744C/ins801A//52T.  Authors state that the study has sufficient power to have detected a difference of at least 20% between
the genotype groups in the indices for response to
aspirin or clopidogrel, with 80% power and at a
significance level of 0.05."	clopidogrel
1450806311	CYP3A4*1; CYP3A4*22	PMID:29998574	CYP3A4	CYP3A4 *1/*22 is not associated with exposure to clopidogrel in healthy individuals as compared to CYP3A4 *1/*1.	no	= 0.426	18		European	Metabolism/PK	false	"""The CYP3A4 genotype had no statistically significant effect on the pharmacokinetic variables of clopidogrel, its active metabolite, or acyl glucuronide metabolite. However, clopidogrel carboxylic acid metabolite AUC0–8 was 35% higher (90% CI = 9–67; P = 0.026) in the CYP3A4*22 carriers than in the controls."""	clopidogrel
1451031580	rs6798347	PMID:20031628	MED12L	Allele G is associated with decreased residual on-clopidogrel platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.	yes	< 0.05	1031		Multiple groups, 95% of the study population was of Caucasian origin	Efficacy	false	"as part of haplotype F (CcCAGT) vs reference haplotype A (tTCgGT). Haplotype rs6798347, rs6787801, rs9859552, rs6801273, rs9848789, and rs2046934, respectively, with the minor alleles in lower case. Alleles in sentence complemented to plus chromosomal strand. 
Maintenance therapy of 75 mg daily for >5 days together with a loading dose of 300 mg of clopidogrel at least 24 hours before PCI  or a loading dose of 600 mg of clopidogrel at least 6 hours before PCI. Ninety percent of the patients were on aspirin (80 to 100 mg daily) and 10% were on coumadins."	clopidogrel
1448530999	rs4603933	PMID:27450232	P2RY12	Allele G is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	no	= 0.549	64	313	East Asian	Efficacy	false		clopidogrel
1448258608	rs4986893	PMID:25060201	CYP2C19	Genotype AG is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	no	= 0.362	65		European	Efficacy	false	Response measured as platelet reactivity index using the vasodilator-stimulated phosphoprotein index and a cut-off value of >=60% was defined as hypo-responsiveness.	clopidogrel
1448567871	rs2317676	PMID:28091702	ITGB3	Genotype AA is not associated with risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to genotypes AG + GG.	no	= 0.12	46	380	East Asian	Toxicity	false	"in Chinese patients with minor ischemic stroke (MIS). The primary clinical endpoint was defined as composite of recurrent ischemic stroke, myocardial infarction and death. ""The estimated risks of adverse events were significantly higher in patients carrying rs16863323TT and rs2317676GG or rs16863323TT and rs2317676GG/AG, compared to those harboring rs16863323CC and rs2317676AA"", suggesting that gene interactions conferred a higher risk for adverse events than did any single variant alone."	clopidogrel
1448258619	rs12248560	PMID:25060201	CYP2C19	Genotypes CT + TT are not associated with response to clopidogrel in people with Acute coronary syndrome.	no	= 0.140	93		European	Efficacy	false	Response measured as platelet reactivity index using the vasodilator-stimulated phosphoprotein index and a cut-off value of >=60% was defined as hypo-responsiveness.	clopidogrel
1184167161	rs4244285	PMCID:PMC4113831	CYP2C19	Allele A (assigned as poor metabolizer phenotype) is associated with increased dose of clopidogrel in healthy individuals as compared to allele G (assigned as normal metabolizer phenotype) .	yes	< 0.05	18		European	Metabolism/PK	false	Assays done in blood samples of six each of *1/*1 (EM/GG),*1/*2(IM/AG) and *2/*2(PM/AA) [based on only assaying for *2; 2 EMs were *1/*17 and one IM was a *2/*17] were compared for MPA4 (maximal platelet aggregation 4 hrs post-dose) and for active metabolite area under the curve. For the EMs, this result was significant for both the 150 and 300 mg/day doses; for the IMs and PMs, it was significant for the 300 mg/day dose.  At day 8, PMs needed 300 mg/day and IMs needed 150 mg/day to attain a similar MPA4 as EMs on the 75 mg/day dose.	clopidogrel
1451973860	rs11015149	PMCID:PMC9801627	APBB1IP	Genotypes AA + AC is associated with increased resistance to clopidogrel in people with Coronary Disease as compared to genotype CC.	no	= 0.024	141	86	East Asian	Efficacy	false	was significant in dominant and co-dominant models in discovery. This was not replicated.	clopidogrel
1448567847	rs16863323	PMID:28091702	P2RY12	Genotype CC is not associated with risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to genotypes CT + TT.	no	= 0.27	46	380	East Asian	Toxicity	false	"in Chinese patients with minor ischemic stroke (MIS). The primary clinical endpoint was defined as composite of recurrent ischemic stroke, myocardial infarction and death. ""The estimated risks of adverse events were significantly higher in patients carrying rs16863323TT and rs2317676GG or rs16863323TT and rs2317676GG/AG, compared to those harboring rs16863323CC and rs2317676AA"", suggesting that gene interactions conferred a higher risk for adverse events than did any single variant alone."	clopidogrel
1448258595	rs4244285	PMID:25060201	CYP2C19	Genotypes AA + AG are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	= 0.001	65		European	Efficacy	false	Response measured as platelet reactivity index using the vasodilator-stimulated phosphoprotein index and a cut-off value of >=60% was defined as hypo-responsiveness.	clopidogrel
699638721	rs2046934	PMID:16961627	P2RY12	Allele G is not associated with response to clopidogrel as compared to allele A.	not stated		29		European	Efficacy	false	in people with good health. This is one of four SNPs that comprise H1/H2 haplotypes. The four SNPs (C139T, T744C, ins801A, G52T(=G50T) are in perfect LD, and T744C is frequently used as the tagging SNP. H1 is 139C/744T/no ins at 801A/52G. H2(minor haplotype) is 139T/744C/ins801A//52T.  The authors state that a minor effect was seen with the H2/H2 haplotype(GG for this SNP), but there were not enough of these subjects for this to be significant.	clopidogrel
1448119331	rs2046934	PMID:27380588	P2RY12	Allele G is not associated with platelet reactivity when treated with clopidogrel as compared to allele A.	no	= 0.54	136		East Asian	Efficacy	false	in Korean patients both pre and post PCI.	clopidogrel
1451031561	rs6801273	PMID:20031628	MED12L; P2RY12	Allele T is associated with decreased residual on-clopidogrel platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	yes	< 0.05	1031		Multiple groups, 95% of the study population was of Caucasian origin	Efficacy	false	"as part of haplotype F (CcCAGT) vs reference haplotype A (tTCgGT). Haplotype rs6798347, rs6787801, rs9859552, rs6801273, rs9848789, and rs2046934, respectively, with the minor alleles in lower case. Alleles in sentence complemented to plus chromosomal strand. 
Maintenance therapy of 75 mg daily for >5 days together with a loading dose of 300 mg of clopidogrel at least 24 hours before PCI  or a loading dose of 600 mg of clopidogrel at least 6 hours before PCI. Ninety percent of the patients were on aspirin (80 to 100 mg daily) and 10% were on coumadins."	clopidogrel
981801214	rs4244285	PMCID:PMC3304338	CYP2C19	Allele A is associated with increased on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	= 0.014	151		Multiple groups, White and African American participants	Efficacy	false		clopidogrel
1448119339	rs1045642	PMID:27380588	ABCB1	Genotype AG is associated with increased platelet reactivity when treated with clopidogrel as compared to genotypes AA + GG.	yes	= 0.03	136		East Asian	Efficacy	false	in Korean patients pre and post PCI. The 1-carrier of ABCB1 genotype exhibited significantly decreased platelet inhibition compared to 0 or 2-carriers independently of the clopidogrel loading dose. 1-carrier of ABCB1 showed sporadic association, although the numbers in subgroups were very small.	clopidogrel
1448530986	rs10935842	PMID:27450232	P2RY12	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	no	= 0.927	64	313	East Asian	Efficacy	false		clopidogrel
982032630	rs1045642	PMID:20801498	ABCB1	Genotype GG is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AA + AG.	yes	= 0.0104	5148		Multiple groups	Toxicity	false		clopidogrel
1184167146	CYP2C19*1; CYP2C19*2	PMCID:PMC4113831	CYP2C19	CYP2C19 *2 (assigned as poor metabolizer phenotype) is associated with increased dose of clopidogrel in healthy individuals as compared to CYP2C19 *1 (assigned as normal metabolizer phenotype) .	yes	< 0.05	18		European	Metabolism/PK	false	Assays done in blood samples of six each of *1/*1 (EM),*1/*2(IM) and *2/*2(PM) [based on only assaying for *2; 2 EMs were *1/*17 and one IM was a *2/*17] were compared for MPA4 (maximal platelet aggregation 4 hrs post-dose) and for active metabolite area under the curve. For the EMs, this result was significant for both the 150 and 300 mg/day doses; for the IMs and PMs, it was significant for the 300 mg/day dose.  At day 8, PMs needed 300 mg/day and IMs needed 150 mg/day to attain a similar MPA4 as EMs on the 75 mg/day dose.	clopidogrel
1444607076	CYP2C19*1; CYP2C19*2	PMID:25542807	CYP2C19	CYP2C19 *1/*2 + *2/*2 are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	< 0.05	305		East Asian	Efficacy	false	The carriers of CYP2C19*2 were associated with a higher magnitude of platelet aggregation in ACS patients when treated with either a 75 mg maintenance dose daily of clopidogrel or a 300 mg loading dose following 75 mg maintenance dose daily of clopidogrel.	clopidogrel
981344509	rs2046934	PMID:22990067	P2RY12	Genotypes AG + GG are not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype AA.	no	= 0.341	447		East Asian	Efficacy	false	Study population are Chinese patients undergoing PCI with drug-eluting stents after acute coronary syndrome. Patients received a loading dose of 300mg clopidogrel, followed by a daily regimen of 75mg and a loading dose of 300mg aspirin, followed by 100mg daily.	clopidogrel
981344500	rs2740574	PMID:22990067	CYP3A4	Genotype CT is not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype TT.	no	= 0.698	447		East Asian	Efficacy	false	Study population are Chinese patients undergoing PCI with drug-eluting stents after acute coronary syndrome. Patients received a loading dose of 300mg clopidogrel, followed by a daily regimen of 75mg and a loading dose of 300mg aspirin, followed by 100mg daily.	clopidogrel
1183681542	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:24019397	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3 + *2/*17 + *3/*17.	yes	= 0.007	532		East Asian	Toxicity	false	During the first month after percutaneous coronary intervention ONLY. This result was no longer significant when considering major adverse cardiac and cerebrovascular events after the first month and up to 1 year of treatment with clopidogrel. Major adverse cardiac and cerebrovascular events consisted of death from any cause, non-fatal myocardial infarction or stroke. *2/*2, *2/*3 and *3/*3 were analyzed as a group (poor metabolizers) and *1/*1, *1/*17, *1/*2, *1/*3, *2/*17 and *3/*17 were analyzed as a group (intermediate and extensive metabolizers).	clopidogrel
1184470036	rs4244285	PMID:19926050	CYP2C19	Genotypes AA + AG is associated with decreased response to clopidogrel in people with percutaneous coronary intervention as compared to genotype GG.	yes	= 0.01	38		Multiple groups, out of an initial 40 patients(2 of whom did not complete the study), there were 35 Caucasian,2 Maori,2 Fijian Indian and 1 Chinese from the Australian New Zealand Clinical Trials registry.	Dosage,Efficacy	false	Platelet inhibition at study baseline was (median) 18%, range 0% to 72% for carriers of the *2 determining variant, compared with wildtype: (median) 59%, range 11% to 95%, (p = 0.01), and at 1 week of dose escalation(p = 0.03).  Genotyping was done for  *2,*3,*4, *5,*6,*7,*8,*10 and *17.	clopidogrel
1184349208	rs2108622	PMID:24418943	CYP4F2	Genotype CT is associated with increased platelet aggregation with epinephrine when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to genotypes CC + TT.	yes	= 0.04	89		Unknown	Other	false	Dual antiplatelet therapy with aspirin and clopidogrel for at least of 14 days and came to test platelet aggregation were included into the further study. A standard 75 mg/day clopidogrel and 100 mg/day aspirin doses were prescribed to all study participants. Platelet aggregation was measured by comparing the intensity of light transmission in platelet-rich and in platelet-poor plasma after induction with 3.6 µmol/l of ADP or with 4.5 µmol/l of epinephrine.	aspirin; clopidogrel
981848084	rs701265	PMID:16581111	P2RY1	Allele G is not associated with response to clopidogrel as compared to allele A.	no		120		Multiple groups, White, African-American, Asian, and Hispanic origin	Efficacy	false	Patients were undergoing elective PCI and were treated with aspirin and clopidogrel.	clopidogrel
1449002191	rs4244285	PMCID:PMC5684285	CYP2C19	Allele A is not associated with exposure to clopidogrel as compared to allele G.	no	> 0.05	63		European	Metabolism/PK	false	Full pharmacokinetic profile was obtained from 17 subjects at  0.5, 1, 2, 3, and 4 h post clopidogrel dose. From 46 subjects samples were collected at 0.5 and 2 h or 1 and 3 h post-dose. Subjects were receiving PCI or elective coronarography.	clopidogrel
1449002186	rs1045642	PMCID:PMC5684285	ABCB1	Allele A is not associated with exposure to clopidogrel or clopidogrel thiol metabolite H4 as compared to allele G.	no	> 0.05	63		European	Metabolism/PK	false	Full pharmacokinetic profile was obtained from 17 subjects at  0.5, 1, 2, 3, and 4 h post clopidogrel dose. From 46 subjects samples were collected at 0.5 and 2 h or 1 and 3 h post-dose. Subjects were receiving PCI or elective coronarography.	clopidogrel; clopidogrel thiol metabolite H4
1184472078	CYP2C19*1; CYP2C19*17	PMID:22123356	CYP2C19	CYP2C19 *1/*17 + *17/*17 is associated with increased risk of Hemorrhage when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	= 0.006	9240		Multiple groups, mostly Caucasian.  Individual studies were conducted in Europe or North America.	Toxicity	false	In this meta-analysis of four studies, any non-*17 alleles were considered to be *1.  The risk of bleeding for carriers of *17 was 8.0% vs. 6.5% in non-carriers.	clopidogrel
981344486	rs3892097	PMID:22990067	CYP2D6	Genotype CT is not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	no	= 1.0	447		East Asian	Efficacy	false	Study population are Chinese patients undergoing PCI with drug-eluting stents after acute coronary syndrome. Patients received a loading dose of 300mg clopidogrel, followed by a daily regimen of 75mg and a loading dose of 300mg aspirin, followed by 100mg daily.	clopidogrel
1184349199	CYP2C19*1; CYP2C19*2	PMID:24418943	CYP2C19	CYP2C19 *1/*2 is associated with increased platelet aggregation with ADP when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	= 0.01	89		Unknown	Other	false	"Dual antiplatelet therapy with aspirin and clopidogrel for at least of 14 days and came to test platelet aggregation were included into the further study. A standard 75 mg/day clopidogrel and 100 mg/day aspirin doses were prescribed to all study participants. No *3 carrier was found.
Platelet aggregation was measured by comparing the intensity of light transmission in platelet-rich and in platelet-poor plasma after induction with 3.6 µmol/l of ADP or with 4.5 µmol/l of epinephrine."	clopidogrel
1449002181	rs2242480	PMCID:PMC5684285	CYP3A4	Allele T is not associated with exposure to clopidogrel or clopidogrel thiol metabolite H4 as compared to allele C.	no	> 0.05	63		European	Metabolism/PK	false	Full pharmacokinetic profile was obtained from 17 subjects at  0.5, 1, 2, 3, and 4 h post clopidogrel dose. From 46 subjects samples were collected at 0.5 and 2 h or 1 and 3 h post-dose. Subjects were receiving PCI or elective coronarography.	clopidogrel; clopidogrel thiol metabolite H4
1450945760	rs72819363	PMID:31854260	CDH15	Allele C is associated with increased likelihood of Coronary Restenosis or Disease Progression when treated with aspirin and clopidogrel in people with Coronary Disease as compared to allele A.	yes	= 0.00899	43	100	Unknown	Efficacy	false	when studying repeat revascularization in patients using dual antiplatelet therapy after first PCI.	aspirin; clopidogrel
981848091	rs776746	PMID:16769602	CYP3A5	Allele C is not associated with response to clopidogrel as compared to allele T.	no		109		Unknown	Efficacy	false		clopidogrel
1449002176	rs12248560	PMCID:PMC5684285	CYP2C19	Allele T is not associated with exposure to clopidogrel or clopidogrel thiol metabolite H4 as compared to allele C.	no	> 0.05	63		European	Metabolism/PK	false	Full pharmacokinetic profile was obtained from 17 subjects at  0.5, 1, 2, 3, and 4 h post clopidogrel dose. From 46 subjects samples were collected at 0.5 and 2 h or 1 and 3 h post-dose. Subjects were receiving PCI or elective coronarography.	clopidogrel; clopidogrel thiol metabolite H4
827892728	rs2046934	PMID:17337040	P2RY12	Allele G is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele A.	not stated	= 0.39	597		European	Efficacy	false	This is one of four SNPs that comprise H1/H2 haplotypes. The four SNPs (C139T, T744C, ins801A, G52T(=G50T) are in perfect LD, and T744C is frequently used as the tagging SNP. H1 is 139C/744T/no ins at 801A/52G.  The study did not show any influence of the T744C polymorphism of the P2Y12 receptor gene on clopidogrel response assessed by ADP-Ag, PRI VASP or P-selectin expression in NSTE ACS (non ST elevation acute coronary syndrome) patients. [stat_test:chi-squared].	clopidogrel
981344476	rs1057910	PMID:22990067	CYP2C9	Genotype AC is not associated with high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype AA.	no	= 0.568	447		East Asian	Efficacy	false	Study population are Chinese patients undergoing PCI with drug-eluting stents after acute coronary syndrome. Patients received a loading dose of 300mg clopidogrel, followed by a daily regimen of 75mg and a loading dose of 300mg aspirin, followed by 100mg daily.	clopidogrel
1184472125	rs4244285	PMID:22028352	CYP2C19	Genotypes AA + AG is associated with increased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotype GG.	yes	< 0.001	123	246	"Multiple groups, mostly White; 10 French centers;Cases:96.0% ""European(White)"";4.1% Asian.  Controls:96.3% ""European(White)""; 0.8% Black; 2.9% Asian."	Efficacy,Other	false	The rates of early stent thrombosis were compared.  Allele A = *2.  Other CYP2C19 alleles assayed were *3,*4,*5, and *6.	aspirin; clopidogrel
1449751756	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:29520080	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 are associated with decreased response to aspirin and clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	yes	= 0.03	1476		Unknown	Efficacy	false	Patients who were classified as carrying loss-of-function (LOF) alleles *2 and *3 had an increased risk for hemorrhagic stroke, ischemic stroke and combined vascular event (ischemic stroke, hemorrhagic stroke, myocardial infarction, vascular death) during a 90-day follow-up period when treated with clopidogrel and aspirin as compared to those without LOF alleles. The authors also found that when separating patients into 5 quintiles based on their eGFR (kidney function), results in Quintile 5 (eGFR<75 ml/min/1.73^2; n=296) were also significant for all three outcome measures (p=0.02, HR=7.39 (1.44-37.95) for all), but the results in Quintiles 1-4 were not. No significant association with bleeding events was found.	aspirin; clopidogrel
1184472114	CYP2C19*1; CYP2C19*17	PMID:22123356	CYP2C19	CYP2C19 *1/*17 + *17/*17 is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	= 0.0003	951		Multiple groups, mostly Caucasian.  Individual studies were conducted in Europe or North America.	Efficacy	false	In this meta-analysis of three studies, any non-*17 alleles were considered to be *1. *17 carriers had a lower prevalence of high platelet reactivity as compared to non-carriers (37.9% vs. 50.8 %)	clopidogrel
981344466	rs3745274	PMID:22990067	CYP2B6	Genotypes GT + TT are not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	no	= 0.201	447		East Asian	Efficacy	false	Study population are Chinese patients undergoing PCI with drug-eluting stents after acute coronary syndrome. Patients received a loading dose of 300mg clopidogrel, followed by a daily regimen of 75mg and a loading dose of 300mg aspirin, followed by 100mg daily.	clopidogrel
981344455	rs1045642	PMID:22990067	ABCB1	Genotypes AA + AG are not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	no	= 0.505	447		East Asian	Efficacy	false	Study population are Chinese patients undergoing PCI with drug-eluting stents after acute coronary syndrome. Patients received a loading dose of 300mg clopidogrel, followed by a daily regimen of 75mg and a loading dose of 300mg aspirin, followed by 100mg daily.	clopidogrel
1184472098	CYP2C19*1; CYP2C19*17	PMID:22123356	CYP2C19	CYP2C19 *1/*17 + *17/*17 is associated with decreased risk of non-fatal myocardial infarction,stroke, revascularization or death when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	= 0.005	9428		Multiple groups, mostly Caucasian.  Individual studies were conducted in Europe or North America.	Efficacy	false	In this meta-analysis of six studies, any non-*17 alleles were considered to be *1.  The risk of an event for carriers of *17 was 10.0% vs. 11.9% in non-carriers.	clopidogrel
981483583	rs662	PMCID:PMC3377663	PON1	Allele T is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to allele C.	no	= 0.597	20	40	East Asian	Toxicity	false		clopidogrel
1184470054	rs4244285	PMID:19926050	CYP2C19	Genotypes AA + AG is associated with dose of clopidogrel in people with percutaneous coronary intervention as compared to genotype GG.	yes	= 0.03	38		Multiple groups, out of an initial 40 patients(2 of whom did not complete the study), there were 35 Caucasian,2 Maori,2 Fijian Indian and 1 Chinese from the Australian New Zealand Clinical Trials registry.	Dosage,Efficacy	false	In this dose escalation study, CYP2C19*2 allele carriers had an increase in platelet inhibition of (mean) +9 +/- 11%, p = 0.03, and reduction in platelet reactivity (mean) -26 +/- 38 platelet response unit, p = 0.04 with a higher dose. Genotyping was done for *2,*3,*4, *5,*6,*7,*8,*10 and *17.  The authors state that the small change may not translate into clinical significance.	clopidogrel
827784087	rs4244285	PMCID:PMC3250350	CYP2C19	Allele A is associated with increased ADP-stimulated platelet aggregation when treated with clopidogrel as compared to allele G.	yes	= 5.6E-18	566		European	Efficacy	false		clopidogrel
1448531088	rs2046934	PMID:27450232	P2RY12	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.197	64	313	East Asian	Efficacy	false		clopidogrel
1184472145	rs662	PMID:22028352	PON1	Genotypes CC + CT is not associated with increased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotype TT.	no	= 0.07	123	246	"Multiple groups, mostly White; 10 French centers;Cases:96.0% ""European(White)"";4.1% Asian.  Controls:96.3% ""European(White)""; 0.8% Black; 2.9% Asian."	Efficacy,Other	false	The rates of early stent thrombosis were compared.	aspirin; clopidogrel
981483593	rs854560	PMCID:PMC3377663	PON1	Allele A is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to allele T.	no	= 0.423	20	40	East Asian	Toxicity	false		clopidogrel
1451973700	CYP2C19*1; CYP2C19*2	PMCID:PMC9801627	CYP2C19	CYP2C19 *2 is associated with increased resistance to clopidogrel in people with Coronary Disease as compared to CYP2C19 *1.	yes	= 0.020	149	90	East Asian	Efficacy	false	*2 was significant in Co-dominat, Dominant, and Recessive models.	clopidogrel
981844053	rs4244285	PMID:18004210	CYP2C19	Genotypes AA + AG are associated with increased platelet aggregation when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	< 1.0E-4	1419		Unknown	Efficacy	false		clopidogrel
1184472137	rs1045642	PMID:22028352	ABCB1	Genotype AA is associated with increased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotypes AG + GG.	yes	= 0.04	123	246	"Multiple groups, mostly White; 10 French centers;Cases:96.0% ""European(White)"";4.1% Asian.  Controls:96.3% ""European(White)""; 0.8% Black; 2.9% Asian."	Efficacy,Other	false	The rates of early stent thrombosis were compared.	aspirin; clopidogrel
981483601	rs705379	PMCID:PMC3377663	PON1	Allele A is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to allele G.	no	= 0.686	20	40	East Asian	Toxicity	false		clopidogrel
1184472141	rs5918	PMID:22028352	ITGB3	Genotypes CC + CT is associated with decreased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotype TT.	yes	= 0.007	123	246	"Multiple groups, mostly White; 10 French centers;Cases:96.0% ""European(White)"";4.1% Asian.  Controls:96.3% ""European(White)""; 0.8% Black; 2.9% Asian."	Efficacy,Other	false	The rates of early stent thrombosis were compared.	aspirin; clopidogrel
982034526	rs4244285	PMCID:PMC3159941	CYP2C19	Genotypes AA + AG are associated with higher P2Y12 reaction units (PRU) and lower percent inhibition when treated with clopidogrel in people with Cerebrovascular Disorders as compared to genotype GG.	yes	< 0.001	166		East Asian	Efficacy	false	The study compared extensive metabolizer (*1/*1 allele) vs. intermediate (one loss-of-function allele; *1/*2, *1/*3) or poor (two loss-of-function alleles ;*2/*2, *2/*3, *3/*3) metabolizers. The numbers of patients with the CYP2C19 *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3 genotype were 68 (40.9%), 56 (33.7%), 18 (10.8%), 14 (8.4%), 9 (5.4%) and 1 (0.6%), respectively.	clopidogrel
1043764448	rs4244285	PMID:21099121	CYP2C19	Genotypes AA + AG are associated with increased risk of subclinical intra-stent thrombus when treated with clopidogrel in patients undergoing drug-eluting stent (DES) implantation as compared to genotype GG.	yes	= 2.0E-4	100		East Asian	Efficacy	false		clopidogrel
981483607	rs1045642	PMCID:PMC3377663	ABCB1	Allele A is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to allele G.	no	= 0.112	20	40	East Asian	Toxicity	false		clopidogrel
827784078	rs662	PMCID:PMC3250350	PON1	Allele C is not associated with High Platelet Reactivity (HPR) when treated with clopidogrel as compared to allele T.	no	= 0.19	566		European	Efficacy	false		clopidogrel
1184472133	rs12248560	PMID:22028352	CYP2C19	Genotypes CT + TT is associated with decreased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotype CC.	yes	= 0.02	123	246	"Multiple groups, mostly White; 10 French centers;Cases:96.0% ""European(White)"";4.1% Asian.  Controls:96.3% ""European(White)""; 0.8% Black; 2.9% Asian."	Efficacy,Other	false	The rates of early stent thrombosis were compared. Allele T = *17.  Other CYP2C19 alleles assayed were *3,*4,*5, and *6.	aspirin; clopidogrel
1448531080	rs12637988	PMID:27450232	P2RY12	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	no	= 0.295	64	313	East Asian	Efficacy	false		clopidogrel
981344417	rs4986893	PMID:22990067	CYP2C19	Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	= 0.011	447		East Asian	Toxicity	false	Cardiovascular events defined by death, myocardial infarction, or strokePlease note, the finding is reported on carriers with two loss-of-function alleles (CYP2C19*2/*2, *2/*3, and *3/*3 combined) based on a multivariable Cox regression analysis. Carriage of one CYP2C19 loss-of-function allele had no significant independent effect. Chinese patients undergoing PCI with drug-eluting stents after acute coronary syndrome. Patients received a loading dose of 300mg clopidogrel, followed by a daily regimen of 75mg and a loading dose of 300mg aspirin, followed by 100mg daily.	clopidogrel
1450945700	rs11859453	PMID:31854260	CDH13	Genotypes AA + AG is associated with decreased likelihood of Coronary Restenosis or Disease Progression when treated with aspirin and clopidogrel in people with Coronary Disease as compared to genotype GG.	yes	= 0.016	43	100	Unknown	Efficacy	false	when studying repeat revascularization in patients using dual antiplatelet therapy after first PCI. After adjustment for smoking statuses, gender and baseline age, compared with rs11859453 GG, the multivariate HR (95% CI) for AG was 5.83 (0.76–44.7) and for AA was 11.2 (1.46–85.4) within 5 years.	aspirin; clopidogrel
981483617	rs3213619	PMCID:PMC3377663	ABCB1	Allele G is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to allele A.	no	= 0.341	20	40	East Asian	Toxicity	false		clopidogrel
827784115	rs854560	PMCID:PMC3250350	PON1	Allele A is not associated with ADP-stimulated platelet aggregation when treated with clopidogrel as compared to allele T.	no					Efficacy	false		clopidogrel
981844064	rs2242480	PMID:18004210	CYP3A4	Genotypes CT + TT are not associated with increased platelet aggregation when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	no		1419		Unknown	Efficacy	false		clopidogrel
1449002171	rs12248560	PMCID:PMC5684285	CYP2C19	Allele A is not associated with exposure to clopidogrel or clopidogrel thiol metabolite H4 as compared to allele C.	no	> 0.05	63		European	Metabolism/PK	false	Full pharmacokinetic profile was obtained from 17 subjects at  0.5, 1, 2, 3, and 4 h post clopidogrel dose. From 46 subjects samples were collected at 0.5 and 2 h or 1 and 3 h post-dose. Subjects were receiving PCI or elective coronarography.	clopidogrel; clopidogrel thiol metabolite H4
981344408	rs4986893	PMID:22990067	CYP2C19	Genotype AA is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	< 0.001	447		East Asian	Efficacy	false	Please note, the finding is reported on carriers with two loss-of-function alleles (CYP2C19*2/*2, *2/*3, and *3/*3 combined) and are after adjustment for confounding factors (including sex, age, BMI, smoking status, hypertension, diabetes mellitus, and use of a proton pump inhibitor). No significant difference was found between patients with the CYP2C19*2/*2 genotype and those with the CYP2C19*2/*3 genotype. Chinese patients undergoing PCI with drug-eluting stents after acute coronary syndrome. Patients received a loading dose of 300mg clopidogrel, followed by a daily regimen of 75mg and a loading dose of 300mg aspirin, followed by 100mg daily.	clopidogrel
1451697249	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:35042400	CYP2C19	CYP2C19 *1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3 is associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	< 0.00001	24512		Unknown	Efficacy	false	association is stated for patients with one or two loss of function CYP2C19 alleles noting that the studies tested for *2 or *2 and *3 and compared against patients lacking these plus some also tested for *17.	clopidogrel
1183681642	CYP2C19*2; CYP2C19*3	PMCID:PMC3760447	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with decreased response to clopidogrel in people with Cardiovascular Diseases.	yes	= 0.03	96		East Asian	Efficacy	false	Subjects with the *2/*2, *2/*3 or *3/*3 genotype had a greater likelihood of being a non-responder to clopidogrel (a platelet inhibition percentage of < 10% pre- and post-treatment) than a responder (a platelet inhibition percentage of >= 10% pre- and post-treatment).	clopidogrel
981483624	rs2032582	PMCID:PMC3377663	ABCB1	Allele A is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to allele C.	no	= 0.763	20	40	East Asian	Toxicity	false		clopidogrel
981848168	rs6809699	PMID:15933261	P2RY12	Allele A is not associated with increased risk of neurological events when treated with clopidogrel in people with Peripheral Vascular Diseases as compared to allele C.	no		137		Unknown	Toxicity	false		clopidogrel
981844074	rs2046934	PMID:18004210	P2RY12	Genotypes AG + GG are not associated with increased platelet aggregation when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype AA.	no		1419		Unknown	Efficacy	false		clopidogrel
827784103	rs4244285	PMCID:PMC3250350	CYP2C19	Allele A is associated with High Platelet Reactivity (HPR) when treated with clopidogrel as compared to allele G.	yes					Efficacy	false		clopidogrel
981344397	rs4244285	PMID:22990067	CYP2C19	Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	= 0.011	447		East Asian	Toxicity	false	Cardiovascular events defined by death, myocardial infarction, or stroke. Please note, the finding is reported on carriers with two loss-of-function alleles (CYP2C19*2/*2,  *2/*3, and *3/*3 combined) based on a multivariable Cox regression analysis. Carriage of one CYP2C19 loss-of-function allele had no significant independent effect. Chinese patients undergoing PCI with drug-eluting stents after acute coronary syndrome. Patients received a loading dose of 300mg clopidogrel, followed by a daily regimen of 75mg and a loading dose of 300mg aspirin, followed by 100mg daily.	clopidogrel
982009979	CYP2C19*2	PMID:22374717	CYP2C19	CYP2C19 *2/*2 is associated with decreased antiplatelet response and reduced clopidogrel active metabolite formation when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.	yes	= 0.02	21		Unknown	Efficacy	false	Reduced function alleles (*1/*2, *2/*2 or *1/*3) are grouped together  for analysis vs. the extensive metabolizer alleles (*1/*1, *1/*17).	clopidogrel
981483636	CYP2C19*1; CYP2C19*2	PMCID:PMC3377663	CYP2C19	CYP2C19 *2 is associated with increased risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1.	yes	= 0.031	20	40	East Asian	Toxicity	false		clopidogrel
981483641	CYP2C19*1; CYP2C19*3	PMCID:PMC3377663	CYP2C19	CYP2C19 *3 is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1.	no	= 0.577	20	40	East Asian	Toxicity	false		clopidogrel
981344388	rs4986893	PMID:22990067	CYP2C19	Genotype AG is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	= 0.002	447		East Asian	Efficacy	false	The finding is reported on carriers with one loss-of-function allele (CYP2C19*1/*2 and *1/*3 combined) and are after adjustment for confounding factors (including sex, age, BMI, smoking status, hypertension, diabetes mellitus, and use of a proton  pump inhibitor). No significant difference in platelet aggregation between patients with the CYP2C19*1/*2 genotype and patients with the CYP2C19*1/*3 genotype was found. Study population are Chinese patients undergoing PCI with drug-eluting stents after acute coronary syndrome. Patients received a loading dose of 300mg clopidogrel, followed by a daily regimen of 75mg and a loading dose of 300mg aspirin, followed by 100mg daily.	clopidogrel
981844094	rs4244285	PMID:18004210	CYP2C19	Genotypes AA + AG are associated with increased residual platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	= 0.015	1419		Unknown	Efficacy	false		clopidogrel
982032776	rs4244285	PMID:17900275	CYP2C19	Allele A is associated with decreased exposure to clopidogrel active metabolite when treated with clopidogrel in healthy individuals as compared to allele G.	yes	= 0.004	74		"Multiple groups, predominantly Caucasian (n = 80), with six of African
descent, two Asian and one Mongolian¿Caucasian"	Metabolism/PK	false	Exposure to clopidogrel's active metabolite was measured as the area under the concentration curve (AUC(0-24) (P=0.004) and and maximal plasma concentration (C(max); P = 0.020). Patients received a 300 mg loading dose of clopidogrel.	clopidogrel
1183702413	rs2134688	PMCID:PMC3862586	ARNT	Genotypes AG + GG is not associated with increased on-treatment platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype AA.	no	= 0.025	211		Multiple groups, 72% of patients were Caucasian; 27% were African American and 1% were Asian.	Efficacy	false	This was assayed by light transmittance aggregometry (LTA) in blood samples.	clopidogrel
1184349591	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24140730	CYP2C19	CYP2C19 *2 + *3 are associated with increased P2Y12 reaction unit(PRU) values when treated with atorvastatin and clopidogrel in patients undergoing percutaneous coronary intervention as compared to CYP2C19 *1/*1.	not stated	= 0.078	211		Unknown	Other	false	Included patients taking either atorvastatin(20 mg/day, n=295) or rosuvastatin(10 mg/day, n=261) in addition to clopidogrel during the entire study period and underwent measurement of the P2Y12 reaction unit(PRU) values at six months after PCI. No significant interactions regarding the PRU values between the number of CYP 2C19 *2 and *3 alleles and atorvastatin or rosuvastatin (p for interaction=0.56) was found. In the multivariate analysis, the use of rosuvastatin was a significant predictor of high PRU value (OR 1.67, 95% confidence interval 1.05-2.65, p=0.031).	atorvastatin; clopidogrel
1183702409	rs4823613	PMCID:PMC3862586	PPARA	Genotypes AG + GG is not associated with increased on-treatment platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype AA.	no	= 0.025	211		Multiple groups, 72% of patients were Caucasian; 27% were African American and 1% were Asian.	Efficacy	false	This was assayed by light transmittance aggregometry (LTA) in blood samples.	clopidogrel
1450253685	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:30061570	CYP2C19	CYP2C19 *2 + *3 are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	< 0.0001	3295		East Asian	Efficacy	false	Patients with acute coronary syndrome undergoing percutaneous coronary intervention. Patients with the *2 and *3 alleles had higher platelet reactivity as compared to those with the *1/*1 genotype.	clopidogrel
1183702405	rs4253728	PMCID:PMC3862586	PPARA	Genotypes AA + AG is not associated with increased on-treatment platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	no	= 0.025	211		Multiple groups, 72% of patients were Caucasian; 27% were African American and 1% were Asian.	Efficacy	false	This was assayed by light transmittance aggregometry (LTA) in blood samples.	clopidogrel
1183702401	rs35599367	PMCID:PMC3862586	CYP3A4	Genotype AG is not associated with increased on-treatment platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	no	= 0.025	211		Multiple groups, 72% of patients were Caucasian; 27% were African American and 1% were Asian.	Efficacy	false	This was assayed by light transmittance aggregometry (LTA) in blood samples.	clopidogrel
1448615253	rs1045642	PMID:28378058	ABCB1	Allele A is not associated with platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to allele G.	no	= 0.725	23243		Multiple groups	Other	false	No association found when platelet reactivity where standardized mean difference (SMD) was assessed between genotypes when using dominant, recessive, or other models.  No association was found in subgroup analyses either. Alleles have been complemented to the positive strand.	clopidogrel
1184349572	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24140730	CYP2C19	CYP2C19 *2 + *3 are associated with increased P2Y12 reaction unit(PRU) values when treated with clopidogrel and rosuvastatin in patients undergoing percutaneous coronary intervention as compared to CYP2C19 *1/*1.	yes	= 0.013	176		Unknown	Other	false	Included patients taking either atorvastatin(20 mg/day, n=295) or rosuvastatin(10 mg/day, n=261) in addition to clopidogrel during the entire study period and underwent measurement of the P2Y12 reaction unit(PRU) values at six months after PCI. No significant interactions regarding the PRU values between the number of CYP 2C19 *2 and *3 alleles and atorvastatin or rosuvastatin (p for interaction=0.56) was found. In the multivariate analysis, the use of rosuvastatin was a significant predictor of high PRU value (OR 1.67, 95% confidence interval 1.05-2.65, p=0.031).	clopidogrel; rosuvastatin
982032787	rs4244285	PMID:17900275	CYP2C19	Allele A is associated with decreased inhibition of platelet aggregation and poor-responder status when treated with clopidogrel in healthy individuals as compared to allele G.	yes	= 0.03	74		"Multiple groups, predominantly Caucasian (n = 80), with six of African
descent, two Asian and one Mongolian¿Caucasian"	Efficacy	false	Patients received a 300 mg loading dose of clopidogrel. Inhibition of platelet aggregation at 4 h (P = 0.003) and poor-responder status (P = 0.030). A pharmacodynamic poor-responder was defined as a subject with less than 20% IPA to 20 lM ADP at either 4 or 24 h. CYP2C19 *2,*3, *4, *5 were genotyped in the study but only CYP2C19*2 was found in the study population.	clopidogrel
1448615235	rs1045642	PMID:28378058	ABCB1	Allele A is associated with increased risk of Hemorrhage when treated with clopidogrel in people with Coronary Disease as compared to allele G.	yes	= 0.015	1388		East Asian	Other	false	Subgroup analysis (N= 1388/ 23,243) of bleeding risk in 3 studies of Clopidogrel done exclusively in Asian patients. Allele was not significant when assessed in 'All' groups (OR: 1.121, 95% CI 0.568 - 1.064, P= 0.116) Alleles have been complemented to the positive strand.	clopidogrel
1451974032	rs2295795	PMCID:PMC9801627	TLN1	Allele A is not associated with increased resistance to clopidogrel in people with Coronary Disease as compared to allele G.	no	= 0.672	145	85	East Asian	Efficacy	false		clopidogrel
1184472453	CYP2C19*1; CYP2C19*2	PMCID:PMC3448899	CYP2C19	CYP2C19 *2/*2 is associated with decreased metabolism of clopidogrel as compared to CYP2C19 *1/*1.	not stated		3		Unknown	Metabolism/PK	false	This comparison was done in pooled human liver microsomes.  Production of clopidogrel's active metabolite from 2-oxo-clopidogrel was measured.	clopidogrel
1448617284	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*8; CYP2C19*17	PMID:27806998	CYP2C19	CYP2C19 *2 + *3 + *8 are not associated with risk of Hemorrhage when treated with clopidogrel in people with Ischemic Attack, Transient and Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	no	= 0.59	3522		Multiple groups	Toxicity	false		clopidogrel
769255162	rs4986893	PMID:21178986	CYP2C19	Genotype AA is associated with decreased response to clopidogrel.	yes	< 0.05	97		East Asian	Efficacy	false		clopidogrel
1448633723	CYP2C19*1; CYP2C19*2	PMID:28135763	CYP2C19	CYP2C19 *2 is associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1.	yes	< 0.001	347		Near Eastern	Efficacy	false	in Turkish patients who underwent percutaneous coronary interventions with stent implantation.  Patients with PRU values >208 were classified as non-responsiveness to clopidogrel therapy.	clopidogrel
1184472508	rs4244285	PMID:22285300	CYP2C19	Genotypes AA + AG is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	= 0.02	498		Unknown	Efficacy	false	This was based upon measuring the rate of high on-treatment platelet reactivity.	clopidogrel
769255152	rs4244285	PMID:21178986	CYP2C19	Genotype AA is associated with decreased response to clopidogrel.	yes	< 0.05	97		East Asian	Efficacy	false		clopidogrel
1184349625	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24080325	CYP2C19	CYP2C19 *2 + *3 are associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	< 0.00001	9745		Multiple groups	Toxicity	false	Meta-analysis. Studies with cohorts of : acute coronary syndrome (some +PCI); coronary artery disease (some +PCI); myocardial infarction and subjects undergoing percutaneous coronary intervention (PCI) are pooled. No statistical heterogeneity was found in this analysis (P = 0.13, I2 = 33%), Authors selected a fixed-effect model for analysis.	clopidogrel
1184472493	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:21716274	CYP2C19	CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	not stated		20		Multiple groups, EM:9 Caucasian;1 Chinese (Asian).  PM:2 Caucasian; 5 Chinese and 3 Japanese (8 Asian).	Metabolism/PK	false	Exposure to the active metabolite of clopidogrel was lower in PMs than in EMs.	clopidogrel
1184349602	rs2242480	PMID:24140730	CYP3A4	Genotype CC is not associated with increased P2Y12 reaction unit(PRU) values when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to genotypes CT + TT.	no	= 0.67	176		Unknown	Other	false	Included patients taking either atorvastatin(20 mg/day, n=295) or rosuvastatin(10 mg/day, n=261) in addition to clopidogrel during the entire study period and underwent measurement of the P2Y12 reaction unit(PRU) values at six months after PCI. In the multivariate analysis, the use of rosuvastatin was a significant predictor of high PRU value (OR 1.67, 95% confidence interval 1.05-2.65, p=0.031).	clopidogrel
982032830	rs1057910	PMID:17900275	CYP2C9	Genotypes AC + CC are associated with decreased inhibition of platelet aggregation and poor-responder status when treated with clopidogrel in healthy individuals as compared to genotype AA.	yes	= 0.046	74		"Multiple groups, predominantly Caucasian (n = 80), with six of African
descent, two Asian and one Mongolian¿Caucasian"	Efficacy	false	The association was shown for the presence of CYP2C9 decreased function alleles (*2/*2, *2/*3). Patients received a 300 mg loading dose of clopidogrel. Inhibition of platelet aggregation at 4 h (P = 0.046) and poor-responder status (P = 0.024). A pharmacodynamic poor-responder was defined as a subject with less than 20% IPA to 20 lM ADP at either 4 or 24 h. CYP2C9 *2,*3, and *11 were genotyped in the study but only CYP2C9*2 and *3 were present in the study population.	clopidogrel
982032817	rs1057910	PMID:17900275	CYP2C9	Genotypes AC + CC are associated with decreased exposure to clopidogrel active metabolite when treated with clopidogrel in healthy individuals as compared to genotype AA.	yes	= 0.043	74		Multiple groups	Metabolism/PK	false	The association was shown for the presence of CYP2C9 decreased function alleles (*2/*2, *2/*3). Exposure was measured as  AUC0¿24 (P = 0.043) and Cmax (P = 0.006). Patients received a 300 mg loading dose of clopidogrel.	clopidogrel
1184349609	CYP3A5*1; CYP3A5*3	PMID:24140730	CYP3A5	CYP3A5 *3/*3 is not associated with increased P2Y12 reaction unit(PRU) values when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to CYP3A5 *1/*3 + *1/*1.	no	= 0.63	176		Unknown	Other	false	Included patients taking either atorvastatin(20 mg/day, n=295) or rosuvastatin(10 mg/day, n=261) in addition to clopidogrel during the entire study period and underwent measurement of the P2Y12 reaction unit(PRU) values at six months after PCI. In the multivariate analysis, the use of rosuvastatin was a significant predictor of high PRU value (OR 1.67, 95% confidence interval 1.05-2.65, p=0.031).	clopidogrel
1449712939	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMID:30020015	CYP2C19	CYP2C19 *2 is associated with increased platelet aggregation when treated with aspirin and clopidogrel as compared to CYP2C19 *1 + *17.	yes	= 0.04	173		Unknown	Efficacy	false		aspirin; clopidogrel
1184349649	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24080325	CYP2C19	CYP2C19 *2 + *3 are associated with increased risk of adverse clinical events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	= 0.03	17350		European	Toxicity	false	Meta-analysis. Studies with cohorts of : acute coronary syndrome (some +PCI); coronary artery disease (some +PCI); myocardial infarction and subjects undergoing percutaneous coronary intervention (PCI) are pooled. statistical heterogeneity among the included studies was found (I2 = 68%; P = 0.0002) and a random-effect model was selected.	clopidogrel
1446899066	CYP2C19*1; CYP2C19*2; CYP2C19*4; CYP2C19*17	PMID:26265231	CYP2C19	CYP2C19 *2 + *4 are associated with decreased response to clopidogrel as compared to CYP2C19 *1 + *17.	yes	< 0.0001	700		Unknown	Efficacy	false	"The authors use the term ""slow metabolizer"" to mean any individuals carrying the *2, *4 alleles and do not differentiate between homo- and heterozygotes. The authors use the term ""rapid metabolizer"" to mean any individuals NOT carrying the *2 or *4 alleles, and include individuals carrying the *17 allele. They do not differentiate between homo- and heterozygotes. Patients were administered clopidogrel before stent implantation and were randomized to a group with monitoring by platelet reactivity or a group without monitoring. Only patients within the monitered group were analyzed for correlation with platelet reactivity. Comparison of clopidogrel response (platelet reactivity) by genotype group was done retrospectively and correlated well with metabolizer status. Within the ""slow metabolizer"" group 58.4% were ""good responders"" and within the ""rapid metabolizer"" group 31.6% were ""poor responders""."	clopidogrel
1449712930	rs1061781	PMID:30020015	B4GALT2	Genotypes CT + TT is associated with decreased platelet aggregation when treated with aspirin and clopidogrel as compared to genotype CC.	yes	= 0.01	126		Unknown	Efficacy	false	This was only significant in the dual antiplatelet subgroup (clopidogrel plus aspirin) not whole cohort or clopidogrel alone. Indication not specified.	aspirin; clopidogrel
1184349659	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24080325	CYP2C19	CYP2C19 *2 + *3 are associated with increased risk of adverse clinical events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	< 0.00001	3947		East Asian	Efficacy,Toxicity	false	Endpoints were fatal or non-fatal myocardial infarction, cardiovascular or all-cause death, definite or probable stent thrombosis, target vessel revascularization, target lesion revascularization, urgent revascularization, ischaemic stroke and bleeding. Meta-analysis. Studies with cohorts of : acute coronary syndrome (some +PCI); coronary artery disease (some +PCI); myocardial infarction and subjects undergoing percutaneous coronary intervention (PCI) are pooled. no statistical heterogeneity was found in the Asian group (I2 = 0%; P = 0.61)	clopidogrel
1448617237	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*8; CYP2C19*17	PMID:27806998	CYP2C19	CYP2C19 *2 + *3 + *8 are associated with increased risk of Stroke when treated with clopidogrel in people with Ischemic Attack, Transient or Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	yes	< 0.001	4762		Multiple groups	Efficacy	false	"Metaanalysis with 4762 patients from 15 studies showed that ""Carriers of CYP2C19 loss-of-function alleles (*2, *3, and *8) were at increased risk of stroke in comparison with noncarriers (12.0% versus 5.8%; risk ratio, 1.92, 95% confidence interval, 1.57–2.35; P<0.001). Composite vascular events were also more frequent in carriers of CYP2C19 loss-of-function alleles than in noncarriers."""	clopidogrel
1450806582	CYP2C19*1; CYP2C19*17	PMID:30652301	CYP2C19	CYP2C19 *17/*17 is associated with decreased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.036	100		European	Toxicity	false	"in patients treated with clopidogrel undergoing neurointerventional procedures. The phenotype measured was ""total ischemic events"" (includes: Transient ischemic attack, ischemic stroke and Stent restenosis).  ""The  incidence  of  ischemic  events  was  lower  in  the   ultrarapid   metabolizer   (UM)   group,   which  was  significant  in  the  survival  analysis. Moreover, the comparison by pairs did not detect significant differences in IM-PM vs.  normal  metabolizer  (NM):  P  =  0.996  and  IM-PM  vs.  UM:  P  =  0.076,  whereas  there was a difference in NM vs. UM: P = 0.017.""  ""In a multiple logistic regression analysis, CYP2C19 UM phenotype  remained  as  a  protector  factor  (odds ratio = 0.091; 95% confidence interval 0.010–0.850; P = 0.036), whereas being CYP2C19 NM was not a risk predictor of having an ischemic event."""	clopidogrel
1184349639	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24080325	CYP2C19	CYP2C19 *2 + *3 are associated with increased risk of adverse clinical events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	= 0.0003	21297		Multiple groups	Efficacy,Toxicity	false	Meta-analysis. Studies with cohorts of : acute coronary syndrome (some +PCI); coronary artery disease (some +PCI); myocardial infarction and subjects undergoing percutaneous coronary intervention (PCI) are pooled. statistical heterogeneity among the included studies was found (I2 = 67%, P < 0.00001) and a random-effect model was selected.	clopidogrel
1183702492	CYP2C19*1; CYP2C19*2	PMID:24336898	CYP2C19	CYP2C19 *1/*2 + *2/*2 is associated with increased risk of high platelet reactivity when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to CYP2C19 *1/*1.	yes	< 0.007	197		Multiple groups, 63.5% Caucasian; 34.5% African American; 2.0% Other.  patients undergoing non-emergency PCI at the Sinai Hospital of Baltimore (NCT00799396).	Efficacy	false	CYP2C19 genotype and MA-thrombin (thrombin-induced platelet-fibrin clot strength) in combination were correlated with risk for high platelet reactivity.  The following ORs are with respect to CYP2C9*1/*1 subjects who had MA-thrombin < 68 mm.  Carriers of CYP2C19*2 who also had MA-thrombin >= 68 mm had OR = 13.89(95% CI 3.41-55.56; p < 0.001).  Carriers of CYP2C19*2 who  had MA-thrombin < 68 mm had OR = 6.77(95% CI 1.29-27.03; p = 0.007). CYP2C19*1/*1 patients who had MA-thrombin >= 68 mm had OR = 7.69(95% CI 1.80-33.33; p = 0.006).  HPR was defined as 5 microM ADP-induced PR >= 46% as measured by conventional aggregometry.  Patients with both HPR and high MA-thrombin showed increased risk for long-term major adverse cardiovascular events (adjusted hazard ratio: 5.56; 95% confidence interval: 1.85 to 16.67; p = 0.002).	aspirin; clopidogrel
1184472513	rs662	PMID:22285300	PON1	Allele C is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele T.	no	= 0.8	498		Unknown	Efficacy	false	This was based upon measuring high on-treatment platelet reactivity.  The CC, TT and CT groups were compared to each other.	clopidogrel
1184472517	rs1045642	PMID:22285300	ABCB1	Allele G is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele A.	no	= 0.9	498		Unknown	Efficacy	false	This was based upon measuring high on-treatment platelet reactivity.  The GG, AA and AG groups were compared to each other.  However, carriage of the A allele was significantly associated with increased efficacy of a dose-adjustment strategy based upon HPR monitoring.	clopidogrel
1451974100	rs10814270	PMCID:PMC9801627	TLN1	Allele T is not associated with increased resistance to clopidogrel in people with Coronary Disease as compared to allele C.	no	= 0.241	147	85	East Asian	Efficacy	false		clopidogrel
1450806559	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:30652301	CYP2C19	CYP2C19 *17/*17 is associated with increased risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1 + *2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17.	yes	= 0.038	100		European	Toxicity	false	"in patients treated with clopidogrel undergoing neurointerventional procedures. ""In the multiple logistic regression analysis, CYP2C19 UM was the only covariate that remained significant as a risk predictor of hemorrhagic events (odds  ratio  =  3.6;  95%  confidence  interval  1.07–12.04; P = 0.038""."	clopidogrel
1448617264	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*8; CYP2C19*17	PMID:27806998	CYP2C19	CYP2C19 *2 + *3 + *8 are associated with increased risk of composite endpoints (stroke, myocardial infarction, or vascular death) when treated with clopidogrel in people with Ischemic Attack, Transient and Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	yes	= 0.01	3778		Multiple groups	Efficacy,Toxicity	false	"Metaanalysis showed that ""Carriers of CYP2C19 loss-of-function alleles (*2, *3, and *8) were at increased risk of stroke in comparison with noncarriers (12.0% versus 5.8%; risk ratio, 1.92, 95% confidence interval, 1.57–2.35; P<0.001). Composite vascular events were also more frequent in carriers of CYP2C19 loss-of-function alleles than in noncarriers."""	clopidogrel
1446907223	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMCID:PMC4833149	CYP2C19	CYP2C19 *2 + *3 are associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1.	yes	< 0.001	27		East Asian	Metabolism/PK	false	either when clopidogrel was administered alone or in combination with cilostazole. The authors observed no differences in AUC (ng*hr/ml) or Cmax (ng/ml) values of clopidogrel thiol metabolite when comparing within the same metabolizer group [extensive (CYP2C19 *1/*1), intermediate (CYP2C19 *1/*2, *1/*3), and poor (CYP2C19 *2/*2, *2/*3, *3/*3)] but between treatment groups. Differences in clopidogrel thiol metabolite concentrations were only observed when comparing between CYP2C19 metabolizer groups.	clopidogrel
1184349692	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24080325	CYP2C19	CYP2C19 *2 + *3 are not associated with increased risk of Mortality when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	= 0.5	11023		Multiple groups	Toxicity	false	Meta-analysis. Studies with cohorts of : acute coronary syndrome (some +PCI); coronary artery disease (some +PCI); myocardial infarction and subjects undergoing percutaneous coronary intervention (PCI) are pooled. No evidence of significant heterogeneity (I2 = 36) was found. Authors selected a fixed-effect model for analysis.	clopidogrel
1184349669	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24080325	CYP2C19	CYP2C19 *2 + *3 are associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	< 0.00001	14261		Multiple groups	Toxicity	false	Meta-analysis. Studies with cohorts of : acute coronary syndrome (some +PCI); coronary artery disease (some +PCI); myocardial infarction and subjects undergoing percutaneous coronary intervention (PCI) are pooled. No evidence of significant heterogeneity (I2 = 28%; P = 0.16) was found. Authors selected a fixed-effect model for analysis.	clopidogrel
982032893	rs1799853	PMID:17900275	CYP2C9	Genotypes CT + TT are associated with decreased inhibition of platelet aggregation and poor-responder status when treated with clopidogrel in healthy individuals as compared to genotype CC.	yes	= 0.046	74		"Multiple groups, predominantly Caucasian (n = 80), with six of African
descent, two Asian and one Mongolian¿Caucasian"	Efficacy	false	The association was shown for the presence of CYP2C9 decreased function alleles (*2/*2, *2/*3). Patients received a 300 mg loading dose of clopidogrel. Inhibition of platelet aggregation at 4 h (P = 0.046) and poor-responder status (P = 0.024). A pharmacodynamic poor-responder was defined as a subject with less than 20% IPA to 20 lM ADP at either 4 or 24 h. CYP2C9 *2,*3, and *11 were genotyped in the study but only CYP2C9*2 and *3 were present in the study population.	clopidogrel
981344520	rs12248560	PMID:22990067	CYP2C19	Genotype CT is not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	no	= 0.376	447		East Asian	Efficacy	false	Study population are Chinese patients undergoing PCI with drug-eluting stents after acute coronary syndrome. Patients received a loading dose of 300mg clopidogrel, followed by a daily regimen of 75mg and a loading dose of 300mg aspirin, followed by 100mg daily.	clopidogrel
1184349679	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24080325	CYP2C19	CYP2C19 *2 + *3 are associated with increased risk of ischaemic stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	= 0.001	6708		Multiple groups	Toxicity	false	Meta-analysis. Studies with cohorts of : acute coronary syndrome (some +PCI); coronary artery disease (some +PCI); myocardial infarction and subjects undergoing percutaneous coronary intervention (PCI) are pooled. No evidence of significant heterogeneity (I2 = 33%) was found. Authors selected a fixed-effect model for analysis.	clopidogrel
1450806529	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:30652301	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17 are associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.007	100		European	Efficacy	false	in patients undergoing a percutaneous neurointervention. CYP2C19 intermediate metabolizer (IM)-poor  metabolizer  (PM)  patients  showed  a  significant lower response to clopidogrel. Based onCYP2C19genotype, individualsare categorized into different phenotypes: *2/*2, *2/*3, or *3/*3as poor metabolizers (PM); *1/*2, *1/*3, or *2/*17 as intermedi-ate metabolizers (IM); *1/*1 as normal metabolizers (NM);*1/*17 as rapid metabolizers, and *17/*17 as ultrarapid metaboliz-ers (UM).	clopidogrel
982032884	rs1799853	PMID:17900275	CYP2C9	Genotypes CT + TT are associated with decreased exposure to clopidogrel active metabolite when treated with clopidogrel in healthy individuals as compared to genotype CC.	yes	= 0.043	74		Multiple groups	Metabolism/PK	false	The association was shown for the presence of CYP2C9 decreased function alleles (*2/*2, *2/*3). Exposure was measured as  AUC0¿24 (P = 0.043) and Cmax (P = 0.006). Patients received a 300 mg loading dose of clopidogrel.	clopidogrel
1448613336	rs11264580	PMID:26962983	PEAR1	Allele C is associated with high on-treatment platelet reactivity when treated with aspirin and clopidogrel as compared to allele T.	yes	= 0.033	204	201	East Asian	Efficacy	false	in Chinese patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) by univariate analysis.	aspirin; clopidogrel
1451285760	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:32897581	CYP2C19	CYP2C19 *2 + *3 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.003	1599		Unknown	Efficacy	false	In patients treated with clopidogrel, IM/PMs exhibited a significantly higher risk of major atherothrombotic events compared with NMs (adjusted HR 1.56, 95% CI, 1.16–2.10, P=0.003).	clopidogrel
982034697	rs4244285	PMID:18532997	CYP2C19	Allele A is associated with decreased Cmax of the active metabolite when treated with clopidogrel in healthy individuals as compared to genotype GG.	yes	< 0.05	47		East Asian	Efficacy	false	The study grouped extensive metabolizers (EMs; CYP2C19*1/*1, n = 18) versus intermediate metabolizers (IMs; *1/*2 or *1/*3, n = 20), and poor metabolizers (PMs; *2/*2 or *2/*3, n = 9).	clopidogrel
1184472347	CYP2C19*1; CYP2C19*2	PMID:22390861	CYP2C19	CYP2C19 *2 is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	yes	= 0.003	1187		Unknown	Efficacy	false	At six months of therapy, CYP2C19 *2 and high on-clopidogrel platelet reactivity by ADP were both associated with increased risk of major adverse coronary events (death and non-fatal myocardial infarction).   From 7-12 months, HPR was associated but *2 was not.   Genotype distribution: CYP2C19 *1/*1 n =892; *1/*2 n = 264; *2/*2 n=31 .	aspirin; clopidogrel
1448256976	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:27348249	CYP2C19	CYP2C19 *2 + *3 are associated with decreased response to aspirin and clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.02	2933		East Asian	Efficacy	false	"in patients with minor stroke or transient ischemic attack. as compared to aspirin alone. The use of clopidogrel plus aspirin compared with aspirin alone reduced the risk of a new stroke only in the subgroup of patients who were not carriers of the CYP2C19 loss-of-function alleles. The CYP2C19 loss-of-function carrier genotypes
were associated with less protection from subsequent stroke and composite vascular events for patients with acute minor stroke or TIA treated with clopidogrel and aspirin as compared with non-carrier status. The differences in response to therapy were largely driven by that within the non-carriers. The primary efficacy outcome was new stroke. The secondary efficacy outcome was a composite of new composite vascular events (ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death)."	aspirin; clopidogrel
827814610	rs4244285	PMID:21700758	CYP2C19	Allele A is associated with higher composite har outcome (cardiac death, non fatal myocardial infarction and stent thrombosis) up to 12 months' follow up when treated with aspirin and clopidogrel in people with drug-eluting stents as compared to allele G.	yes	= 0.02	2146		East Asian	Toxicity	false	There is no difference in clinical outcome after 12 months.	aspirin; clopidogrel
1448109526	rs4244285	PMID:26151596	CYP2C19	Allele A is associated with response to clopidogrel, prasugrel and ticagrelor in people with Acute coronary syndrome.	yes					Efficacy	false	This variant annotation is part of an Rx annotation, which compared personalized anti-platelet therapy to empiric treatment. Patients undergoing personalized therapy were given prasugrel if they carried 1 or 2 copies of the CYP2C19*2 allele and clopidogrel if they did not. Patients not receiving personalized therapy received ticagrelor.	clopidogrel; prasugrel; ticagrelor
1447949770	rs776746	PMCID:PMC5098919	CYP3A5	Genotypes CC + CT are associated with increased resistance to clopidogrel in people with Stroke as compared to genotype TT.	yes	= 0.016	375		East Asian	Efficacy	false	Frequency of CC+TC genotypes was significantly higher in clopidogrel-resistant patients than in clopidogrel-sensitive patients.	clopidogrel
1184470291	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:22045970	CYP2C19	CYP2C19 *2/*2 + *2/*3 is associated with decreased response to clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	yes	= 0.016	266		East Asian	Efficacy	false	The risk of high on-treatment platelet reactivity increased with the number of *2 or *3 (LOF) alleles.  For carriage of 1 such allele, the result was not significant [1 LOF allele: OR = 1.8;95% CI 0.8-4.2;p=0.152]. The statistics listed in the attached study parameters are for patients with two LOF alleles.   *2 was determined by assaying rs4244285.  *3 was determined by assaying rs4986893.  *17 (rs12248560) was also assayed. There were 103 *1/*1,one *1/*17,two *2/*17, one *3/*17, 96 *1/*2, 29 *1/*3, 20 *2/*2 and 14 *2/*3.	clopidogrel
1447949788	CYP2C19*1; CYP2C19*2	PMCID:PMC5098919	CYP2C19	CYP2C19 *1/*2 + *2/*2 are associated with increased likelihood of adverse events when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.	yes	= 0.003	37	326	East Asian	Toxicity	false	The frequency of primary adverse events was higher in patients who carry the *2 genotype than in patients without. Cox regression analysis also revealed that CYP2C19*2 is an independent risk factors for primary adverse events (HR=2.01, p=0.006, 95%CI:1.46-5.66).	clopidogrel
1448613321	rs57731889	PMID:26962983	PEAR1	Genotype TT is associated with low on-treatment platelet reactivity when treated with aspirin and clopidogrel as compared to genotypes CC + CT.	yes	= 0.003	204	201	East Asian	Efficacy	false	in Chinese patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI).	aspirin; clopidogrel
982036762	rs1062535	PMID:17157856	ITGA2	Genotypes AA + AG are associated with increased risk of residual platelet reactivity when treated with aspirin and clopidogrel in people with Myocardial Infarction as compared to genotype GG.	yes	< 0.05	289		Unknown	Efficacy	false	The association is significant for carriers of the A allele together with a T at rs1126643. The residual platelet reactivity (RPR) is defined by AA induced platelet aggregation (OR = 3.0, 95%CI 1.17 - 7.89, p = 0.022) or by PFA100/epinephrine (OR = 4.1, 95%CI 1.53 - 10.89, p = 0.005). Cohort are myocardial infarction (MI) patients undergoing percutaneous coronary intervention (PCI) on dual antiplatelet treatment.	aspirin; clopidogrel
1448633804	CYP2C19*1; CYP2C19*17	PMID:28135763	CYP2C19	CYP2C19 *17 is not associated with response to clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.375	347		Near Eastern	Efficacy	false	in Turkish patients who underwent percutaneous coronary interventions with stent implantation.  Patients with PRU values >208 were classified as non-responsiveness to clopidogrel therapy. CT genotype frequency of the CYP2C19*17 (C806T, rs12248560) was found to be higher in the patients responding to clopidogrel. However, this high rate was not statistically significant (p = 0.375).	clopidogrel
1446899112	CYP2C19*1; CYP2C19*2; CYP2C19*4; CYP2C19*17	PMID:26265231	CYP2C19	CYP2C19 *2 + *4 are associated with increased risk of Myocardial Infarction when treated with clopidogrel as compared to CYP2C19 *1 + *17.	yes	= 0.0017	700		Unknown	Other	false	"Patients were administered clopidogrel before stent implantation and were randomized to a group with monitoring by platelet reactivity or a group without monitoring. When comparing between the monitored (platelet reactivity units) and non-monitored group, it was the slow metabolizers within the monitored group that had the higher incidence of myocardial infarction type 4a (troponin 10x ULN) and need of urgent revascularization when compared to the slow metabolizers in the non-monitored group. Incidence of these cardiovascular events 1 year after stent placement. The authors use the term ""slow metabolizer"" to mean any individuals carrying the *2, *4 alleles and do not differentiate between homo- and heterozygotes. The authors use the term ""rapid metabolizer"" to mean any individuals NOT carrying the *2 or *4 alleles, and include individuals carrying the *17 allele. They do not differentiate between homo- and heterozygotes."	clopidogrel
982034718	rs4244285	PMID:18532997	CYP2C19	Allele A is associated with increased platelet reactivity index (PRI) at 4 h after the dosing when treated with clopidogrel in healthy individuals as compared to genotype GG.	yes	< 0.05	47		East Asian	Efficacy	false	The study grouped extensive metabolizers (EMs; CYP2C19*1/*1, n = 18) versus intermediate metabolizers (IMs; *1/*2 or *1/*3, n = 20), and poor metabolizers (PMs; *2/*2 or *2/*3, n = 9).	clopidogrel
1448633794	rs662	PMID:28135763	PON1	Allele C is not associated with response to clopidogrel as compared to allele T.	no	= 0.2	347		Near Eastern	Efficacy	false	in Turkish patients who underwent percutaneous coronary interventions with stent implantation.  Patients with PRU values >208 were classified as non-responsiveness to clopidogrel therapy.	clopidogrel
982034708	rs4986893	PMID:18532997	CYP2C19	Allele A is associated with decreased Cmax of the active metabolite when treated with clopidogrel in healthy individuals as compared to genotype GG.	yes	< 0.05	47		East Asian	Efficacy	false	The study grouped extensive metabolizers (EMs; CYP2C19*1/*1, n = 18) versus intermediate metabolizers (IMs; *1/*2 or *1/*3, n = 20), and poor metabolizers (PMs; *2/*2 or *2/*3, n = 9).	clopidogrel
1451285789	CYP2C19*1; CYP2C19*17	PMID:26790469	CYP2C19	CYP2C19 *17 is not associated with increased risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.334	287		East Asian	Toxicity	false		clopidogrel
1447949779	rs776746	PMCID:PMC5098919	CYP3A5	Genotypes CC + CT are associated with increased likelihood of adverse events when treated with clopidogrel in people with Stroke as compared to genotype TT.	yes	= 0.018	37	326	East Asian	Toxicity	false	The frequency of primary adverse events was higher in patients who carry the CC or CT genotype than in patients who carry the TT genotype.	clopidogrel
1448633799	rs854560	PMID:28135763	PON1	Allele A is not associated with response to clopidogrel as compared to allele T.	no	= 0.466	347		Near Eastern	Efficacy	false	in Turkish patients who underwent percutaneous coronary interventions with stent implantation.  Patients with PRU values >208 were classified as non-responsiveness to clopidogrel therapy.	clopidogrel
982034728	rs4986893	PMID:18532997	CYP2C19	Allele A is associated with increased platelet reactivity index (PRI) at 4 h after the dosing when treated with clopidogrel in healthy individuals as compared to genotype GG.	yes	< 0.05	47		East Asian	Efficacy	false	The study grouped extensive metabolizers (EMs; CYP2C19*1/*1, n = 18) versus intermediate metabolizers (IMs; *1/*2 or *1/*3, n = 20), and poor metabolizers (PMs; *2/*2 or *2/*3, n = 9).	clopidogrel
1448613369	rs6785930	PMCID:PMC5411211	P2RY12	Genotypes AA + AG is associated with increased risk of adverse events when treated with clopidogrel as compared to genotype GG.	yes	= 0.035	498		East Asian	Toxicity	false	in Chinese patients with acute coronary syndrome undergoing PCI.  The A allele carriers had a significantly higher risk of total cardiovascular events as compared to non-carriers. This variant is also called P2RY12 C34T.	clopidogrel
1184472379	CYP2C19*1; CYP2C19*2	PMID:22390861	CYP2C19	CYP2C19 *2 is not associated with response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	no	> 0.05	1187		Unknown	Efficacy	false	At six months of therapy, CYP2C19 *2 and high on-clopidogrel platelet reactivity by ADP were both associated with increased risk of major adverse coronary events (death and non-fatal myocardial infarction).   From 7-12 months,high on-clopidogrel platelet reactivity by ADP was associated with increased risk of major adverse coronary events (death and non-fatal myocardial infarction) but *2 was not associated.   Genotype distribution: CYP2C19 *1/*1 n =892; *1/*2 n = 264; *2/*2 n=31 .	aspirin; clopidogrel
1451285801	rs12248560	PMID:32897581	CYP2C19	Genotypes CT + TT are not associated with risk of Hemorrhage when treated with clopidogrel as compared to genotype CC.	no	= 0.224	1933		Unknown	Toxicity	false	In patients treated with clopidogrel, no difference in bleeding risk was observed between CYP2C19 UM/RMs and NMs (7.9 vs. 6.0 events per 100 patient-years, respectively; adjusted HR 1.34, 95% CI, 0.83–2.17, P=0.224) or between clopidogrel-treated UMs and RMs (7.3 and 8.0 events per 100 patient-years).	clopidogrel
1451973946	rs2046934	PMCID:PMC9801627	P2RY12	Genotype AG is not associated with increased resistance to clopidogrel in people with Coronary Disease as compared to genotype GG.	no	= 0.945	141	86	East Asian	Efficacy	false	no AA individuals were observed.	clopidogrel
1446899082	CYP2C19*1; CYP2C19*2; CYP2C19*4; CYP2C19*17	PMID:26265231	CYP2C19	CYP2C19 *2 + *4 are not associated with risk of Death, Ischemic Attack, Transient, Stroke or Thrombosis when treated with clopidogrel as compared to CYP2C19 *1 + *17.	no	= 0.90	1394		Unknown	Other	false	"Incidence of these cardiovascular events 1 year after stent placement was not different between rapid and slow metabolizers (32.3% vs 32.7%, respectively). The authors use the term ""slow metabolizer"" to mean any individuals carrying the *2, *4 alleles and do not differentiate between homo- and heterozygotes. The authors use the term ""rapid metabolizer"" to mean any individuals NOT carrying the *2 or *4 alleles, and include individuals carrying the *17 allele. They do not differentiate between homo- and heterozygotes. Patients were administered clopidogrel before stent implantation and were randomized to a group with monitoring by platelet reactivity or a group without monitoring."	clopidogrel
1448613345	rs2644592	PMID:26962983	PEAR1	Allele G is associated with high on-treatment platelet reactivity when treated with aspirin and clopidogrel as compared to allele A.	yes	= 0.048	204	201	East Asian	Efficacy	false	in Chinese patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) by univariate analysis.	aspirin; clopidogrel
1448257000	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:27348249	CYP2C19	CYP2C19 *2 + *3 are not associated with likelihood of Hemorrhage when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.78	2933		East Asian	Toxicity	false	"in patients with minor stroke or transient ischemic attack. as compared to aspirin alone. ""The effect of treatment assignment on bleeding did not vary significantly between the carriers and the non-carriers of the loss-of-function alleles (2.3% for carriers and 2.5% for non-carriers in the clopidogrel-aspirin group vs 1.4% for carriers and 1.7% for non-carriers in the aspirin only group; P=0.78 for interaction)."""	aspirin; clopidogrel
1451285820	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:26790469	CYP2C19	CYP2C19 *2 + *3 are not associated with increased risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.130	287		East Asian	Toxicity	false		clopidogrel
1448613351	rs3737224	PMID:26962983	PEAR1	Allele T is associated with high on-treatment platelet reactivity when treated with aspirin and clopidogrel as compared to allele C.	yes	= 0.033	204	201	East Asian	Efficacy	false	in Chinese patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) by univariate analysis.	aspirin; clopidogrel
1451973940	CYP2C19*1; CYP2C19*3	PMCID:PMC9801627	CYP2C19	CYP2C19 *1/*3 is associated with increased resistance to clopidogrel in people with Coronary Disease as compared to CYP2C19 *1/*1.	no	= 0.227	149	90	East Asian	Efficacy	false	*3 was not significant alone, there were no *3/*3 individuals in the discovery sample set.	clopidogrel
1184470360	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:22045970	CYP2C19	CYP2C19 *2/*2 + *2/*3 is associated with increased risk of cardiovascular event occurrence when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	yes	= 0.008	266		East Asian	Efficacy	false	Cardiovascular event occurrence after acute myocardial infarction increased according to the number of loss of function alleles (*2,*3) but was not significant with carriage of one such allele [HR= 3.1; 95% CI=0.8-11.6; p=0.089].  Statistics listed in the attached study parameters are for patients with two LOF alleles.	clopidogrel
1447949708	rs2242480	PMCID:PMC5098919	CYP3A4	Genotypes CT + TT is not associated with resistance to clopidogrel in people with Stroke as compared to genotype CC.	no	= 0.91	375		East Asian	Efficacy	false		clopidogrel
1448633755	CYP2C19*1; CYP2C19*3	PMID:28135763	CYP2C19	CYP2C19 *3 is not associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.215	347		Near Eastern	Efficacy	false	in Turkish patients who underwent percutaneous coronary interventions with stent implantation.  Patients with PRU values >208 were classified as non-responsiveness to clopidogrel therapy.	clopidogrel
1448633744	CYP2C19*1; CYP2C19*17	PMID:28135763	CYP2C19	CYP2C19 *1/*17 is associated with increased platelet aggregation inhibition when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.008	347		Near Eastern	Efficacy	false	"in Turkish patients who underwent percutaneous coronary interventions with stent implantation. ""PRU values of CT genotypes were lower (p = 0.029) and % inhibition values of CT genotypes were higher (p = 0.008) compared with CC genotypes for the CYP2C19*17 (C806T) polymorphism."""	clopidogrel
981477709	rs71647871	PMCID:PMC3682407	CES1	Genotype CT is associated with increased levels of clopidogrel active metabolite when treated with clopidogrel in healthy individuals as compared to genotype CC.	yes	= 0.001	506		European	Metabolism/PK	false		clopidogrel
1043858934	CYP2C19*1; CYP2C19*4	PMID:19106083	CYP2C19	CYP2C19 *4 is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	yes	= 0.003	2208		European	Toxicity	false	Patients carrying any two CYP2C19 loss-of-function alleles (*2,*3,*4,*5) had a higher event(all cause death,nonfatal stroke, myocardial infarction) rate than patients with none. Patients with one loss-of-function allele had a slightly lower risk in the overall population compared to those with none. Stats given are for any two loe alleles vs. none.	clopidogrel
1451285840	rs12248560	PMID:32897581	CYP2C19	Genotypes CT + TT are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to genotype CC.	no	= 0.808	1933		Unknown	Efficacy	false	No difference was observed between clopidogrel-treated UM/RMs vs. NMs with regards to risk of major atherothrombotic events (adjusted HR 0.97, 95% CI, 0.73–1.29, P=0.808).	clopidogrel
982045018	CYP2C9*1; CYP2C9*2	PMCID:PMC3860862	CYP2C9	CYP2C9 *2 is not associated with increased risk of major bleeding events when treated with clopidogrel as compared to CYP2C9 *1.	no	= 0.83	19601		Multiple groups	Toxicity	false		clopidogrel
1184470351	rs1045642	PMID:22045970	ABCB1	Allele G is not associated with response to clopidogrel in people with Myocardial Infarction as compared to allele A.	no	= 0.016	266		East Asian	Efficacy	false	The comparison was for risk of high on-treatment platelet reactivity.	clopidogrel
1447949723	rs1934980	PMCID:PMC5098919	CYP2C8	Genotypes AA + AG is not associated with resistance to clopidogrel in people with Stroke as compared to genotype GG.	no	= 0.91	375		East Asian	Efficacy	false		clopidogrel
1447949716	rs17110453	PMCID:PMC5098919	CYP2C8	Genotypes AC + CC is not associated with resistance to clopidogrel in people with Stroke as compared to genotype AA.	no	= 0.68	375		East Asian	Efficacy	false		clopidogrel
981477722	rs71647871	PMCID:PMC3682407	CES1	Genotype CT is associated with decreased on-treatment ADP-induced platelet aggregation when treated with clopidogrel in healthy individuals as compared to genotype CC.	yes	= 0.003	506		European	Efficacy	false		clopidogrel
982045010	CYP2C9*1; CYP2C9*2	PMCID:PMC3860862	CYP2C9	CYP2C9 *2 is associated with increased risk of adverse cardiovascular events when treated with clopidogrel as compared to CYP2C9 *1.	yes	= 0.009	19601		Multiple groups	Toxicity	false	In this metaanalysis from14 trials, CYP2C9*2 was associated with higher risk of MACE [RR: 1.28, CI: 1.06-1.54; p=0.009], CV death [RR: 3.21, CI: 1.65-6.23; p=0.001], MI [RR: 1.36, CI: 1.12-1.65; p=0.002], ST [RR: 2.41, CI: 1.69-3.41; p<0.001].	clopidogrel
1448615298	rs1045642	PMID:28378058	ABCB1	Allele A is not associated with risk of Hemorrhage, major adverse cardiac events (mace) and Thrombosis when treated with clopidogrel in people with Coronary Disease as compared to allele G.	no	= 0.116			European	Other	false	Association assessed using dominant, recessive, homozygous, or heterozygous models. Only the dominant model is presented here. Analysis using dominant model (AA+AG vs GG). Alleles have been complemented to the positive strand.	clopidogrel
1451973968	rs67562832	PMCID:PMC9801627	PIK3CA	Allele G is not associated with increased resistance to clopidogrel in people with Coronary Disease as compared to allele A.	no	= 0.336	146	84	East Asian	Efficacy	false		clopidogrel
1183702381	CYP2C19*1; CYP2C19*2	PMCID:PMC3862586	CYP2C19	CYP2C19 *1/*2 + *2/*2 is associated with increased on-treatment platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	= 0.025	211		Multiple groups, 72% of patients were Caucasian; 27% were African American and 1% were Asian.	Efficacy	false	This was assayed by light transmittance aggregometry (LTA) in blood samples.  Carriers of CYP2C19*2 had increased platelet aggregation at 5, 10 and 20 microM ADP; only at 20 microM did this attain significance.	clopidogrel
1448633787	rs5918	PMID:28135763	ITGB3	Allele C is not associated with response to clopidogrel as compared to allele T.	no	= 0.518	347		Near Eastern	Efficacy	false	in Turkish patients who underwent percutaneous coronary interventions with stent implantation.  Patients with PRU values >208 were classified as non-responsiveness to clopidogrel therapy.	clopidogrel
1448613309	rs41273215	PMID:26962983	PEAR1	Allele T is associated with high on-treatment platelet reactivity when treated with aspirin and clopidogrel as compared to allele C.	yes	= 0.038	204	201	East Asian	Efficacy	false	in Chinese patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI).	aspirin; clopidogrel
1444697594	rs7667298	PMID:25738571	KDR	Allele C is not associated with decreased response to clopidogrel in people with Coronary Disease as compared to allele T.	no	> 0.05	275		East Asian	Efficacy	false	"There were no significant differences in the genotype and allele frequency of
VEGFR-2 rs1870377 polymorphism or rs7667298 polymorphism between CR (clopidogrel resistant) group and the NGR group (p>0.05)."	clopidogrel
981477735	rs71647871	PMCID:PMC3682407	CES1	Genotype CT is associated with decreased on-treatment ADP-induced platelet aggregation when treated with clopidogrel in people with Coronary Disease as compared to genotype CC.	yes	= 0.03	350		Unknown	Efficacy	false	"CT allele carrier had a significantly greater clopidogrel response compared with CC allele
carrier (on-clopidogrel maximal platelet aggregation=25 and 45%, respectively; P=0.03)
Outcome after 1 year: 13.7% of patients carrying the CC genotype and 0%
of patients carrying the CT genotype experienced a cardiovascular event; however, this relatively low-powered comparison was not statistically significant (P=0.44)."	clopidogrel
1451285863	CYP2C19*1; CYP2C19*17	PMCID:PMC5331771	CYP2C19	CYP2C19 *17 is not associated with increased risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.41	336		East Asian	Toxicity	false		clopidogrel
1448633778	CYP2B6*1; CYP2B6*9	PMID:28135763	CYP2B6	CYP2B6 *9 is not associated with response to clopidogrel as compared to CYP2B6 *1/*1.	no	= 0.64	347		Near Eastern	Efficacy	false	in Turkish patients who underwent percutaneous coronary interventions with stent implantation.  Patients with PRU values >208 were classified as non-responsiveness to clopidogrel therapy.	clopidogrel
1447949731	CYP2C9*1; CYP2C9*3	PMCID:PMC5098919	CYP2C9	CYP2C9 *1/*3 + *3/*3 is not associated with resistance to clopidogrel in people with Stroke as compared to CYP2C9 *1/*1.	no	= 0.37	375		East Asian	Efficacy	false		clopidogrel
1444697587	rs1870377	PMID:25738571	KDR	Allele A is not associated with decreased response to clopidogrel in people with Coronary Disease as compared to allele T.	no	> 0.05	275		East Asian	Efficacy	false	"There were no significant differences in the genotype and allele frequency of
VEGFR-2 rs1870377 polymorphism or rs7667298 polymorphism between CR (clopidogrel resistant) group and the NGR group (p>0.05)."	clopidogrel
1183702397	rs4244285	PMCID:PMC3862586	CYP2C19	Genotypes AA + AG is associated with increased on-treatment platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	= 0.025	211		Multiple groups, 72% of patients were Caucasian; 27% were African American and 1% were Asian.	Efficacy	false	This was assayed by light transmittance aggregometry (LTA) in blood samples.  Carriers of CYP2C19*2 (A) had increased platelet aggregation at 5, 10 and 20 microM ADP; only at 20 microM did this attain significance.	clopidogrel
1447949757	CYP2C19*1; CYP2C19*2	PMCID:PMC5098919	CYP2C19	CYP2C19 *1/*2 + *2/*2 are associated with increased resistance to clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.	yes	< 0.001	375		East Asian	Efficacy	false	Frequency of CYP2C19*2 (rs4244285) AA/AG genotypes was significantly higher in clopidogrel-resistant patients than in clopidogrel-sensitive patients.	clopidogrel
1448633769	rs2242480	PMID:28135763	CYP3A4	Allele T is not associated with response to clopidogrel as compared to genotype C/C.	no	= 0.324	347		Near Eastern	Efficacy	false	in Turkish patients who underwent percutaneous coronary interventions with stent implantation.  Patients with PRU values >208 were classified as non-responsiveness to clopidogrel therapy. The publication reports the finding for CYP3A4*1G. PharmVar re-assigned CYP3A4*1G to CYP3A4*36. Previously, this annotation used CYP3A4*36 which has been retired by PharmVar. All references to *36 have been replaced by rs2242480 alleles.	clopidogrel
1444697577	rs2305948	PMID:25738571	KDR	Allele T is associated with decreased response to clopidogrel in people with Coronary Disease as compared to allele C.	yes	< 0.01	275		East Asian	Efficacy	false	"Genotype and allele frequency of VEGFR-2 rs2305948 was significantly
higher in the CR (clopidogrel resistant) group than in the NCR group (TT: 55.9% vs. 36.1%, P<0.05; T allele: 78.5% vs. 66.8%,P<0.01, respectively)."	clopidogrel
1446907337	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMCID:PMC4833149	CYP2C19	CYP2C19 *2 + *3 are associated with decreased platelet reactivity when treated with cilostazol and clopidogrel in healthy individuals as compared to CYP2C19 *1.	yes	= 0.041	27		East Asian	Efficacy	false	in individuals who also had the CYP3A5 *1/*3 genotype. Differences in inhibition of platelet aggregation time profiles between the CYP2C19 metabolizer groups  [extensive (CYP2C19 *1/*1), intermediate (CYP2C19 *1/*2, *1/*3), and poor (CYP2C19 *2/*2, *2/*3, *3/*3)] were significant between the CYP2C19 poor metabolizers as compared to the intermediate and extensive metabolizers, but only in individuals with the CYP3A5 *1/*3 genotype in patients. This difference was abolished in individuals with the CYP3A5 *3/*3 genotype.	cilostazol; clopidogrel
1447359923	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMCID:PMC5798599	CYP2C19	CYP2C19 *1/*2 + *2/*17 + *2/*2 are associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17.	yes					Metabolism/PK	false	In the Amish PAPI study, age, BMI, CYP2C19*2 polymorphism and CES1 G143E polymorphism were the only statistically significant (p < 0.01) covariates characterizing interindividual differences in clopidogrel elimination/bioactivation and on-treatment platelet reactivity.	clopidogrel
1451285880	CYP2C19*1; CYP2C19*17	PMID:23364775	CYP2C19	CYP2C19 *17 is not associated with increased risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.75	1004		Multiple groups	Toxicity	false		clopidogrel
1448633764	rs1045642	PMID:28135763	ABCB1	Allele A is not associated with response to clopidogrel as compared to allele G.	no	= 0.581	347		Near Eastern	Efficacy	false	in Turkish patients who underwent percutaneous coronary interventions with stent implantation.  Patients with PRU values >208 were classified as non-responsiveness to clopidogrel therapy.	clopidogrel
1447949744	CYP2C19*1; CYP2C19*3	PMCID:PMC5098919	CYP2C19	CYP2C19 *1/*3 + *3/*3 are not associated with resistance to clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.	no	= 0.24	375		East Asian	Efficacy	false		clopidogrel
1451974006	rs77576241	PMCID:PMC9801627	PIK3CA	Allele T is not associated with increased resistance to clopidogrel in people with Coronary Disease as compared to allele C.	no	= 0.133	146	86	East Asian	Efficacy	false		clopidogrel
1449751959	CYP2C19*3; CYP2C19*17	PMID:30191759	CYP2C19	CYP2C19 *3/*17 is associated with Thrombosis when treated with aspirin and clopidogrel.	no		1		Unknown	Efficacy,Metabolism/PK	false	in a case study of a patient who had stent thrombosis 32 days after PCI.	aspirin; clopidogrel
1451930248	rs4244285	PMCID:PMC9585281	CYP2C19	Genotype AA is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotypes AG + GG.	yes	= 0.015	213		East Asian	Efficacy	false	"""CYP2C19*2 AA carriers presented significantly lower mean PAIR% values (59.60 ± 26.07) than CYP2C19*2 GA carriers (74.84 ± 25.09) (p = 0.015). Our results also indicated that CYP2C19*2 AA carriers presented significantly lower mean PAIR% values (59.60 ± 26.07) than CYP2C19*2 GG carriers (77.63 ± 23.69) (p = 0.003) (Figure 1D)."""	clopidogrel
1184989861	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*8; CYP2C19*17	PMID:25008027	CYP2C19	CYP2C19 *1/*2 + *1/*8 + *2/*2 + *2/*3 is associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	yes	< 0.001	195		Multiple groups, mainly White	Metabolism/PK	false	"Receiving clopidogrel 75-mg, *1/*2 + *1/*8 + *2/*2 + *2/*3 had significantly
lower exposure than *1/*1 + *1/*17 + *17/*17 as evidenced by the elevated EM/IM+PM ratio (GM ratio: 1.37, 95% CI: 1.14, 1.65, p<0.001)."	clopidogrel
1451930254	rs4986893	PMCID:PMC9585281	CYP2C19	Genotype AG is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	= 0.041	213		East Asian	Efficacy	false	"""CYP2C19*3 GA carriers presented significantly lower mean PAIR% values (66.39 ± 25.68) than CYP2C19*3 GG carriers"". There were only 3 AA individuals."	clopidogrel
769173983	rs4244285	PMID:20351750	CYP2C19	Allele A is associated with increased risk of major adverse cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	yes	= 0.02	8043		Multiple groups, European and US	Efficacy	false	(AG + AA) was compared to GG.	clopidogrel
981755523	rs662	PMCID:PMC3572125	PON1	Genotypes CT + TT are not associated with repeat revascularization when treated with clopidogrel as compared to genotype CC.	no	= 0.542	1336		East Asian	Toxicity	false		clopidogrel
981755532	rs662	PMCID:PMC3572125	PON1	Genotypes CT + TT are not associated with clopidogrel on-treatment platelet reactivity (OPR) when treated with clopidogrel as compared to genotype CC.	no	= 0.0342	1336		East Asian	Efficacy	false	QQ/QR: 231686 PRU vs. RR 236682 PRU	clopidogrel
981755541	rs662	PMCID:PMC3572125	PON1	Genotypes CT + TT are associated with increased small-dense LDL levels when treated with clopidogrel as compared to genotype CC.	yes	= 0.027	1336		East Asian	Other	false	1.2060.12 mg/dL vs. 0.7660.15 mg/dL	clopidogrel
1451342480	CYP2C19*1; CYP2C19*17	PMCID:PMC6986167	CYP2C19	CYP2C19 *1/*17 + *17/*17 are associated with decreased platelet reactivity when treated with clopidogrel and rivaroxaban in people with Acute coronary syndrome and Atrial Fibrillation as compared to CYP2C19 *1/*1.	not stated	= 0.044	103		Unknown	Toxicity	false		clopidogrel; rivaroxaban
981843601	rs4244285	PMID:22624833	CYP2C19	Genotype AA is associated with increased risk of primary clinical endpoint of death due to cardiovascular causes, non-fatal MI or stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	= 0.03	490		Unknown	Efficacy,Toxicity	false	Association investigated for primary clinical endpoint of death due to cardiovascular causes, non-fatal MI or stent thrombosis during follow-up.	clopidogrel
1184516748	CYP2C19*1; CYP2C19*11; CYP2C19*13; CYP2C19*15; CYP2C19*18	PMID:25001882	CYP2C19	CYP2C19 *11 + *13 + *15 + *18 are not associated with decreased clearance of clopidogrel in cos-7 cells as compared to CYP2C19 *1.	no	> 0.05			Unknown	Metabolism/PK	false	The association is reported in comparison to *1B. No differences were found in the clearance of clopidogrel between *1 and *11, *13, *15, *18 and *28.	clopidogrel
1043880481	CYP2C19*1; CYP2C19*6	PMID:20801498	CYP2C19	CYP2C19 *6 is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	= 0.028	5148		Multiple groups, predominantly white (98%)	Toxicity	false	"The higher rate of ischaemic events was determined during the first 30 days of treatment. The study reports association for CYP2C19 loss-of-function alleles, which includes rs4244285 (CYP2C19*2). Further loss-of-function alleles CYP2C19*3, *4, *5, *6, *7, and *8 were genotyped. In 5148 patients on clopidogrel the CYP2C19 genotypes were following:*1/*1=1862 (36%); *1/*2=898 (17%); *1/*3= 6 (<1%); *1/*4=8 (<1%); *1/*6=2 (<1%); *1/*8=21 (<1%); *2/*2=115 (2%); *2/*4	=3 (<1%); *2/*5=1 (<1%); *2/*8=6 (<1%).
However, when the full follow-up period (1 year) was considered, the difference in outcomes between patients with and without any loss-of-function allele was not significant."	clopidogrel
981843612	rs4244285	PMID:22624833	CYP2C19	Genotype AG is not associated with increased risk of primary clinical endpoint of death due to cardiovascular causes, non-fatal MI or stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	no	= 0.42	710		Unknown	Toxicity	false	Association investigated for primary clinical endpoint of death due to cardiovascular causes, non-fatal MI or stent thrombosis during follow-up.	clopidogrel
1184516739	CYP2C19*1; CYP2C19*28	PMID:25001882	CYP2C19	CYP2C19 *28 is associated with increased clearance of clopidogrel in cos-7 cells as compared to CYP2C19 *1.	yes	< 0.01			Unknown	Metabolism/PK	false	The association is reported in comparison to *1B. Please note the article separates *1A and *1B. While *28 has a clearance 141% of *1B, *1A has a clearance of 115% of *1B.	clopidogrel
1451930259	rs717620	PMCID:PMC9585281	ABCC2	Genotype CC is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotypes CT + TT.	yes	= 0.001	213		East Asian	Efficacy	false		clopidogrel
1043880487	CYP2C19*1; CYP2C19*8	PMID:20801498	CYP2C19	CYP2C19 *8 is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	= 0.028	5148		Multiple groups, predominantly white (98%)	Toxicity	false	"The higher rate of ischaemic events was determined during the first 30 days of treatment.The study reports association for CYP2C19 loss-of-function alleles, which includes rs4244285 (CYP2C19*2). Further loss-of-function alleles CYP2C19*3, *4, *5, *6, *7, and *8 were genotyped. In 5148 patients on clopidogrel the CYP2C19 genotypes were following:*1/*1=1862 (36%); *1/*2=898 (17%); *1/*3= 6 (<1%); *1/*4=8 (<1%); *1/*6=2 (<1%); *1/*8=21 (<1%); *2/*2=115 (2%); *2/*4	=3 (<1%); *2/*5=1 (<1%); *2/*8=6 (<1%).
However, when the full follow-up period (1 year) was considered, the difference in outcomes between patients with and without any loss-of-function allele was not significant."	clopidogrel
1451930261	rs2273697	PMCID:PMC9585281	ABCC2	Genotype AA is not associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotypes AG + GG.	no	= 0.936	213		East Asian	Efficacy	false	"""neither ABCC2 rs2273697 nor ABCC2 rs3740066 polymorphisms affected PAIR% values """	clopidogrel
1043765783	rs4986893	PMID:20650435	CYP2C19	Genotypes AA + AG are associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to genotype GG.	yes	= 0.018	126		East Asian	Efficacy	false		clopidogrel
981843623	rs662	PMID:22624833	PON1	Genotype CC is not associated with increased risk of primary clinical endpoint of death due to cardiovascular causes, non-fatal MI or stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype TT.	no	= 0.44	1028		Unknown	Efficacy,Toxicity	false	Association investigated for primary clinical endpoint of death due to cardiovascular causes, non-fatal MI or stent thrombosis during follow-up.	clopidogrel
982034084	rs6136	PMID:15968882	SELP	Genotype GT is not associated with differences in response to clopidogrel when treated with clopidogrel in healthy individuals as compared to genotype TT.	no		100		Unknown	Efficacy	false	"No homozygous GG subject was identified. Although not statistically significant, the
GT carriers showed lower PLA-formation under clopidogrel than the TT carriers."	clopidogrel
1448276578	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMCID:PMC4980919	CYP2C9	CYP2C9 *1/*1 is not associated with likelihood of platelet aggregation when exposed to clopidogrel in healthy individuals as compared to CYP2C9 *1/*2 + *1/*3 + *2/*2.	no	= 0.17			Central/South Asian	Efficacy	false	Differences were assessed in delta-maximum platelet aggregation and inhibition of platelet aggregation. Healthy individuals were given a single 300 mg dose and analysis was conducted at 4 hours.	clopidogrel
769173984	rs4244285	PMID:20351750	CYP2C19	Allele A is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	yes	= 1.0E-4	4975		Multiple groups, European and  US	Efficacy	false	(AG + AA) was compared to GG.	clopidogrel
1184471715	rs4244285	PMID:19268736	CYP2C19	Genotypes AA + AG is associated with decreased response to aspirin and clopidogrel in people with percutaneous coronary interventions and drug-eluting stents as compared to genotype GG.	yes	= 0.047	772		Unknown	Efficacy	false	OR of 3.43 is for the occurrence of stent thrombosis, and OR of 2.70 is for the combination of stent thrombosis and cardiac mortality within a 6 month followup period.  The stents eluted sirolimus or paclitaxel.	aspirin; clopidogrel
981802686	rs71647871	PMID:23275066	CES1	Allele T is associated with impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel when exposed to clopidogrel as compared to allele C.	not stated					Metabolism/PK	false	In-vitro experiments are done in a cell line stably expressing CES1 G143E variant.	clopidogrel
981843646	rs4244285	PMCID:PMC3621954	CYP2C19	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele G.	yes	= 0.003	225	468	Multiple groups	Toxicity	false	"This variant was studied as predictors of cardiac events during clopidogrel therapy initiated after myocardial infarction (MI) or percutaneous coronary intervention (PCI).
Cardiovascular events defined as a composite of all-cause mortality, MI, revascularization, and stroke."	clopidogrel
1027950849	rs4244285	PMID:19108880	CYP2C19	Allele A is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.	yes	= 9.0E-4	259		European	Efficacy,Toxicity	false		clopidogrel
981800640	rs662	PMCID:PMC3304338	PON1	Genotype TT is not associated with increased on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	no	= 0.081	151		Multiple groups, White and African American participants	Efficacy	false		clopidogrel
1448112663	CYP2C19*1; CYP2C19*2	PMID:26526111	CYP2C19	CYP2C19 *2 is associated with decreased response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2C19 *1.	yes	= 0.007	209		European	Efficacy	false	All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting.	clopidogrel
827823391	rs4244285	PMID:21628721	CYP2C19	Allele A is associated with increased risk of High Platelet Reactivity when treated with clopidogrel in people with coronary artery disease undergoing stent implantation as compared to allele G.	yes	= 0.001	1024		European	Efficacy	false	The increase is modest.  Results are given in terms of *1 and *2.  The SNP is referred to  as G>A, so this annotation translates *1 >G and *2 > A. [stat_test: Chi-square].  The rate of reactivity for  *2*2  was higher than for *1*2, and that was higher than for *1*1.	clopidogrel
981802700	rs1045642	PMCID:PMC3467260	ABCB1	Genotypes AA + AG are associated with increased risk of early major adverse cardiovascular events (MACE) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	= 0.02			Unknown	Toxicity	false	Meta-analysis included 3 studies that provided data on early MACE (MACE happened in about one month).	clopidogrel
1451965120	CYP2C19 rapid and ultrarapid metabolizer genotypes	PMID:35389962	CYP2C19	CYP2C19 rapid and ultrarapid metabolizer genotypes is associated with increased likelihood of Hemorrhage when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 normal metabolizer genotype.	yes	< 0.0001	191		Near Eastern	Toxicity	false	"""All samples were genotyped for CYP2C19*2 (G681A; rs4244285), CYP2C19*3 (G636A; rs4986893), and CYP2C19*17 (–806C>T; rs12248560) "" RM/UMs (rapid metabolizers *1/*17 n= 61)/ultrarapid metabolizers *17/*17 n=15)  vs normal metabolizers (*1/*1 n= 115)"""	clopidogrel
981843667	rs1045642	PMCID:PMC3621954	ABCB1	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele G.	yes	= 0.018	225	468	Multiple groups	Toxicity	false	This variant was studied as predictors of cardiac events during clopidogrel therapy initiated after myocardial infarction (MI) or percutaneous coronary intervention (PCI). Cardiovascular events defined as a composite of all-cause mortality, MI, revascularization, and stroke.	clopidogrel
1445296755	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	PMID:25258374	CYP2C19	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with decreased response to clopidogrel as compared to CYP2C19 normal metabolizer genotype.	yes		36076		Multiple groups	Efficacy	false	Meta-analysis with 24 studies. Individuals with one or two loss-of-function (LOF) alleles (e.g. *2, *3; poor metabolizer = two LOF, intermediate metabolizer = one LOF) had an increased risk for adverse cardiovascular outcomes when using clopidogrel. When meta-analysis was broken into subgroups, significant results were seen for White and Asian participants using clopidogrel for percutaneous coronary intervention (PCI), but no significant result was seen for White non-PCI participants. An additional analysis on the risk for specifically stent thrombosis was also done in White and Asian PCI participants, with significant results for both. Analysis restricted to studies with >= 500 participants.	clopidogrel
769169793	rs1045642	PMID:17112805	ABCB1	Genotype AA is associated with decreased peak plasma concentration (Cmax) and the total area under the plasma concentration-time curve (AUC) of clopidogrel and its active metabolite after a single oral loading dose of 300 or 600 mg of clopidogrel in people with Coronary Artery Disease as compared to genotypes AG + GG.	not stated	< 0.05	60		European	Metabolism/PK	false		clopidogrel
982034154	rs5918	PMID:19530321	ITGB3	Allele C is associated with less decrease in the platelet reactivity after 600 mg of clopidogrel when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype TT.	yes	= 0.009	95		Unknown	Efficacy	false	Differences in suppression of ADP-induced platelet reactivity were observed twenty-eight hours after 600 mg clopidogrel administration. The proportion of clopidogrel nonresponders (PRI >50%) was higher in C allele carriers in comparison with TT carriers (54 vs. 24%, P = 0.082).	clopidogrel
1184467707	CYP2C19*1; CYP2C19*2	PMID:20833683	CYP2C19	CYP2C19 *1/*2 + *2/*2 is associated with increased risk of stent thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary interventions as compared to CYP2C19 *1/*1.	yes	= 0.018	176	420	Multiple groups, 3 high volume centers in the Netherlands (> 85% Caucasian)	Efficacy	false	Controls were consecutive patients who underwent PCI with stent implantation at one of the participating centers and who did not experience any adverse cardiovascular events within one year after stenting.  40% of the cases had at least one *2 allele, compared with 29.5% of the controls (p = 0.013).  There was a stronger association when compared using subacute stent thrombosis.	aspirin; clopidogrel
1183699694	CYP2C19 normal metabolizers	PMID:24262617	CYP2C19	CYP2C19 normal metabolizers are associated with decreased risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 poor metabolizers and intermediate metabolizers.	yes	= 0.03	1432		Unknown	Other	false	Patients with the extensive metabolizer phenotype have a decreased chance of experiencing a major adverse cardiac event (cardiac death, nonfatal myocardial infarction, stent thrombosis during clopidogrel treatment) as compared to those with the intermediate or poor metabolizer phenotypes. Patients were assessed over 12 months following drug-eluting stent(s) implantation, and received both clopidogrel and aspirin.	clopidogrel
1451965160	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	PMID:35389962	CYP2C19	CYP2C19 poor metabolizer and intermediate metabolizer genotypes is associated with increased likelihood of major adverse cardiac events (mace) when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 normal metabolizer genotype.	yes	< 0.0001	178		Near Eastern	Efficacy	false	"""All samples were genotyped for CYP2C19*2 (G681A; rs4244285), CYP2C19*3 (G636A; rs4986893), and CYP2C19*17 (–806C>T; rs12248560) ""  IM (*1/*2, *1/*3, *2/*17, n=58) and PM (*2/*2, *3/*3, n=5) v *1/*1 (n=115)"	clopidogrel
1444702840	rs342293	PMID:25860557		Genotype GG is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	no	= 0.0014	127		East Asian	Efficacy	false	Not significant after adjusting for covariates including gender, age and smoking under additive genetic model.	clopidogrel
981843680	rs12248560	PMCID:PMC3621954	CYP2C19	Allele T is not associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele C.	no	= 0.48	225	468	Multiple groups	Toxicity	false	This variant was studied as predictors of cardiac events during clopidogrel therapy initiated after myocardial infarction (MI) or percutaneous coronary intervention (PCI). Cardiovascular events defined as a composite of all-cause mortality, MI, revascularization, and stroke.	clopidogrel
827919665	rs662	PMID:22462746	PON1	Genotype CC is not associated with response to clopidogrel in people with Coronary Artery Disease as compared to genotype TT.	no	= 0.87	86		"Multiple groups, Chinese, Malay, Indian mixed population. "	Efficacy	false	as measured by platelet reactivity index (platelet vasodilator-stimulated phophoprotein test) on blood collected from patients. No significant differences were seen between CC, CT or TT genotypes. [stat_test: kruskal-wallis test, two-sided unpaired wilcoxon test]	clopidogrel
981843691	rs662	PMCID:PMC3621954	PON1	Allele T is not associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele C.	no	= 0.37	225	468	Multiple groups	Toxicity	false	This variant was studied as predictors of cardiac events during clopidogrel therapy initiated after myocardial infarction (MI) or percutaneous coronary intervention (PCI). Cardiovascular events defined as a composite of all-cause mortality, MI, revascularization, and stroke.	clopidogrel
1183699709	rs3745274	PMID:24262617	CYP2B6	Allele T is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	no	= 0.5	1432		Unknown	Other	false	No significant difference in risk of experiencing a major adverse cardiac event (cardiac death, nonfatal myocardial infarction, stent thrombosis during clopidogrel treatment) was seen between the alleles. Patients were assessed over 12 months following drug-eluting stent(s) implantation, and received both clopidogrel and aspirin.	clopidogrel
1444702829	rs4244285	PMID:25860557	CYP2C19	Genotype AA is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	= 0.00078	127		East Asian	Efficacy	false		clopidogrel
1451930360	rs3740066	PMCID:PMC9585281	ABCC2	Genotype TT is not associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotypes CC + CT.	no	= 0.219	213		East Asian	Efficacy	false	"""neither ABCC2 rs2273697 nor ABCC2 rs3740066 polymorphisms affected PAIR% values """	clopidogrel
981802737	rs1045642	PMCID:PMC3467260	ABCB1	Genotype AA is associated with increased risk of early major adverse cardiovascular events (MACE) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	= 0.005			Unknown	Toxicity	false	Meta-analysis included 3 studies that provided data on early MACE (MACE happened in about one month).	clopidogrel
1183699705	rs762551	PMID:24262617	CYP1A2	Allele C is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.	no	= 0.22	1432		Unknown	Other	false	No significant difference in risk of experiencing a major adverse cardiac event (cardiac death, nonfatal myocardial infarction, stent thrombosis during clopidogrel treatment) was seen between the alleles. Patients were assessed over 12 months following drug-eluting stent(s) implantation, and received both clopidogrel and aspirin.	clopidogrel
1183699700	rs1045642	PMID:24262617	ABCB1	Allele A is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	no	= 0.2	1432		Unknown	Other	false	No significant difference in risk of experiencing a major adverse cardiac event (cardiac death, nonfatal myocardial infarction, stent thrombosis during clopidogrel treatment) was seen between the alleles. Patients were assessed over 12 months following drug-eluting stent(s) implantation, and received both clopidogrel and aspirin. Please note alleles have been complemented to the plus chromosomal strand.	clopidogrel
1184348910	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24821368	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	< 0.01	249		East Asian	Efficacy	false	Cohort are coronary artery disease patients with diabetes mellitus carriers: 4612 ± 1354 AU*min, non-carriers: 3871 ± 1699, P < 0.01	clopidogrel
1446908484	CYP2C19*1; CYP2C19*2	PMCID:PMC4413440	CYP2C19	CYP2C19 *2 is associated with increased risk of Stroke when treated with clopidogrel in people with Cerebrovascular Disorders as compared to CYP2C19 *1/*1.	yes	< 0.0001	51		Unknown	Efficacy	false	*2 carriers were more likely to suffer from a recurring ischemic stroke during treatment after Acute Ischemic Cerebrovascular Disease. Patients were monitored for at least 1 year.  *2/*2 (n=2), *1/*2 (n=13), and *1/*1 (n=36), one *2/*2 and two *1/*2 suffered from recurrent stroke and switched to warfarin	clopidogrel
1448604375	rs2046934	PMCID:PMC5316454	P2RY12	Allele G is associated with resistance to clopidogrel in people with Acute coronary syndrome as compared to allele A.	no	= 0.45	77	101	Near Eastern	Efficacy	false	The G allele frequency was higher among resistant than nonresistant patients (30% versus 20.8%, resp.).	clopidogrel
982042121	CYP2C19*1; CYP2C19*2	PMID:23556336	CYP2C19	CYP2C19 *1/*2 is associated with increased ADP-induced maximum platelet aggregation when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.002	183		East Asian	Efficacy	false	in Chinese stroke patients. CYP2C19*2 and *3 are analyzed together.	clopidogrel
1183705612	rs1045642	PMID:24535487	ABCB1	Allele A is not associated with increased risk of on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to allele G.	no	= 0.841	162		East Asian	Efficacy	false		clopidogrel
1450664694	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMCID:PMC3248259	CYP2C19	CYP2C19 *2/*2 + *2/*3 is associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.	not stated		90		East Asian	Metabolism/PK	false	"PMs and IMs had lower con-centrations of active metabolite than did *1/*1 and PMs had lower concentrations than did IMs. CYP2C19 *2/*3 is associated with increased area under the plasma concentration-time curve and Cmax as compared to CYP2C19 *1/*1.
Note: P values were NOT provided in the study. Authors chose to report of confidence interval cut-off of 90%, (not classical cut-off of 95%). Confidence interval of 90% does not cross 1 so that suggesting significance."	clopidogrel
981679617	rs12041331	PMCID:PMC3715320	PEAR1	Genotypes AA + AG are associated with increased cardiovascular events in patients undergoing PCI when treated with aspirin and clopidogrel as compared to genotype GG.	yes	= 0.035	83		African American/Afro-Caribbean	Toxicity	false		aspirin; clopidogrel
1444702878	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:25851472	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of Cardiovascular Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.045	434		East Asian	Toxicity	false	Following percutaneous coronary intervention (PCI) patients were treated with dual antiplatelet therapy (aspirin and clopidogrel).  Multivariate Cox proportional hazards analysis identified both carrier of CYP2C19 no function allele (*2, *3 genotyped) (HR: 1.94; 95% CI: 1.1–3.69; p = 0.045) and low reactive hyperemia-peripheral arterial tonometry index as measure for peripheral endothelial dysfunction (HR: 2.15; 95% CI: 1.22–3.78; p = 0.008) as independent and significant predictors of future cardiovascular events.  Details of the cardiovascular events are as follows: cardiovascular death ( n = 4), nonfatal myocardial infarction ( n = 4), stroke ( n = 6), unstable angina ( n = 11), and coronary revascularization ( n = 30).	clopidogrel
1448624859	rs2254638	PMCID:PMC5485718	N6AMT1	Allele G is associated with decreased metabolism of clopidogrel as compared to genotype AA.	yes	= 0.0166	115		East Asian	Metabolism/PK	false	This variant was associated with decreased active metabolite H4 concentration.	clopidogrel
1183705608	rs662	PMID:24535487	PON1	Allele T is not associated with increased risk of on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to allele C.	no	= 0.841	162		East Asian	Efficacy	false		clopidogrel
981204733	rs1050450	PMID:22890915		Allele A is associated with increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors in men with Coronary Artery Disease as compared to allele G.	yes	= 0.0085	44	57	Unknown	Other	false	Not reported as a pharmacogenetic association - patients were on standard therapy including the above drugs and may also have been taking angiotensin converting enzyme inhibitors and calcium antagonists. The minor allele of this genetic variant (reported as GPx-1 599 T allele) results in decreased GPx-1 activity and increased free-radical processes. This allele was associated with increased risk of in-stent restenosis. In carriers of the T allele, ISR was 1.9x higher - p value given. Odds ratio p value not given.	aspirin; Beta Blocking Agents; clopidogrel; hmg coa reductase inhibitors
981843458	rs12248560	PMID:23364775	CYP2C19	Allele T is associated with decreased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	yes	= 0.045	1034		Multiple groups, mostly White (>90%)	Toxicity	false	Association with reduction of the one-year rate of myocardial infarction (from 11.1% to 7.0%).	clopidogrel
1448604382	rs2046934	PMCID:PMC5316454	P2RY12	Genotype GG is associated with increased likelihood of Acute coronary syndrome when treated with clopidogrel as compared to genotypes AA + AG.	yes	= 0.01	77	101	Near Eastern	Toxicity	false	"""there was a statistically significant association of the recessive and additive transmission models with the ACS development risk (OR [95% CI] = 1.78 [1.58-5.05], P = 0.01 and OR [95% CI] = 1.23 [0.74-2.03], P < 0.001, resp.), increasing thus the association of this polymorphism with the pathology. """	clopidogrel
981843471	rs4244285	PMID:22624833	CYP2C19	Allele A is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	yes	= 2.2E-15	1028		Unknown	Efficacy	false		clopidogrel
1449310952	rs12248560	PMID:29540324	CYP2C19	Allele T is associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele C.	yes	= 0.03	448	440	European	Efficacy,Other	false		clopidogrel
1444936339	CYP2C19*1; CYP2C19*2	PMID:25712182	CYP2C19	CYP2C19 *2/*2 is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1 + *1/*2.	yes	< 0.001	31	456	Unknown	Efficacy	false	Patients had undergone percutaneous coronary intervention. Cases had definite stent thrombosis during the first 5 days after stent implantation. Controls had no stent thrombosis during the first 30 days following stent implantation. The CYP2C19 *2/*2 genotype was associated with increased risk for early stent thrombosis as compared to the *1/*1 and *1/*2 genotypes. This allele was significant in multivariate analysis as well as univariate.	aspirin; clopidogrel
1184987695	CYP2C19*1; CYP2C19*3	PMID:24508947	CYP2C19	CYP2C19 *3 is associated with increased risk of Thrombosis when treated with clopidogrel as compared to CYP2C19 *1.	yes	= 0.028	617		East Asian	Toxicity	false	in patients undergoing percutaneous coronary intervention. The clinical primary end point was the 1-year incidence of definite stent thrombosis (ST).	clopidogrel
1451915780	rs4244285	PMID:36215918	CYP2C19	Genotypes AA + AG is associated with increased likelihood of Recurrence when treated with clopidogrel in people with Stroke as compared to genotype GG.	yes	< 0.05	752		East Asian	Efficacy	false	"""The risk of stroke recurrence in patients with GA/AA genotype at CYP2C19 * 2 locus was significantly higher than that with GG genotype."""	clopidogrel
827919816	rs12248560	PMID:22462746	CYP2C19	Genotype CT is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	yes	= 1.0E-4	89		"Multiple groups, Chinese, Malay, Indian mixed population. "	Efficacy	false	CYP2C19*17 heterozygotes (CT) compared to homozygouse wildtype patients (CC), as measured by platelet reactivity index (platelet vasodilator-stimulated phophoprotein test) on blood collected from patients by two-sided unpaired wilcoxon test (p=0.0001). CYP2C19*17 (genotyped rs12248560 C>T) was not mentioned in the results for the multiple linear regression model, though CYP2C19*17 carrier status was said to be an independent variable for platelet reactivity index in the statistical analysis section (but p value not given).	clopidogrel
1449192178	rs2108622	PMID:28806186	CYP4F2	Genotype CT is not associated with platelet aggregation when treated with clopidogrel in people with Angina Pectoris and Myocardial Infarction as compared to genotype CC.	no	= 0.058	110		European	Other	false		clopidogrel
1451915800	rs4986893	PMID:36215918	CYP2C19	Genotype AG is not associated with increased likelihood of Recurrence when treated with clopidogrel in people with Stroke as compared to genotype GG.	no	> 0.05	653		East Asian	Efficacy	false	"""no significant difference in the risk of stroke recurrence between CYP2C19 * 3 GA and GG genotype patients treated with clopidogrel"". ""Only one case of recurrence with CYP2C19 * 3AA genotype was reported in 5 studies."""	clopidogrel
1448624845	CYP2C19*1; CYP2C19*2	PMCID:PMC5485718	CYP2C19	CYP2C19 *2 is not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*2.	no	= 0.9463	299		East Asian	Efficacy	false	This variant is not associated with the occurrence of MACE.	clopidogrel
827919808	rs4986893	PMID:22462746	CYP2C19	Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.	yes	= 0.001	89		"Multiple groups, Chinese, Malay, Indian mixed population. "	Efficacy	false	as measured by platelet reactivity index (platelet vasodilator-stimulated phophoprotein test) on blood collected from patients. Patients with one (p=0.001) or two (p<0.001) loss-of-function alleles (CYP2C19*2 (genotyped rs4244285 G>A) or CYP2C19*3 (genotyped rs4986893 G>A)) had a significantly increased platelet reactivity index compared to those without loss-of-function alleles. [stat_test: multiple linear regression model]	clopidogrel
1184516611	CYP2C19*1; CYP2C19*11	PMID:25001882	CYP2C19	CYP2C19 *11 is not associated with decreased catalytic activity of CYP2C19 when exposed to clopidogrel in cos-7 cells as compared to CYP2C19 *1.	no	> 0.05			Unknown	Metabolism/PK	false	The association is reported for *1B. No differences in Km and Vmax values were determined compared to *1.	clopidogrel
982042130	CYP2C19*1; CYP2C19*3	PMID:23556336	CYP2C19	CYP2C19 *1/*3 is associated with increased ADP-induced maximum platelet aggregation when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.002	183		East Asian	Efficacy	false	in Chinese stroke patients. CYP2C19*2 and *3 are analyzed together.	clopidogrel
981794335	rs662	PMID:21685174	PON1	Allele T is not associated with increased residual platelet aggregation when treated with clopidogrel in people with elective coronary stent placement as compared to allele C.	no	= 0.728	760		Unknown	Efficacy	false		clopidogrel
1183705616	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24535487	CYP2C19	CYP2C19 *2 + *3 are associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 *1/*1.	yes	= 0.033	22	86	East Asian	Toxicity	false	Patients were treated with aspirin and clopidogrel. CYP2C19 *2 and *3 were genotyped.	clopidogrel
1448624837	rs2254638	PMCID:PMC5485718	N6AMT1	Genotypes AG + GG are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype AA.	no	= 0.0653	299		East Asian	Efficacy	false	This variant is marginally associated with occurrence of MACE.	clopidogrel
1043765908	rs776746	PMID:20650435	CYP3A5	Allele C is not associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to allele T.	no	= 0.018	126		East Asian	Efficacy	false		clopidogrel
1184989701	rs5918	PMCID:PMC3952719	ITGB3	Allele C is not associated with resistance to aspirin or clopidogrel as compared to allele T.	no	= 0.208	2085		Unknown	Efficacy	false	Allele C = PIA2, allele T = PIA1.	aspirin; clopidogrel
1444702906	CYP2C19*1; CYP2C19*2	PMID:25850030	CYP2C19	CYP2C19 *2 is associated with increased platelet reactivity when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	yes	= 0.03	72		Unknown	Efficacy	false	Please note at risk genotype in this study was either CYP2C19*2 carrier or ABCB1B 3435 TT genotype.  Logistic regression analysis results are not independently presented.  Multivariate analyses for predictors of 1-month HPR revealed carrier status for an at-risk genotype to be the strongest independent predictor for HPR.	clopidogrel
1451915820	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:36215918	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3 (assigned as poor metabolizer and intermediate metabolizer genotypes phenotype) is associated with increased likelihood of Recurrence when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 (assigned as normal metabolizer genotype phenotype) .	yes	< 0.05	1250		East Asian	Efficacy	false	"""IM(*1/*2 or *1/*3) and PM(*2/*3, *2/*2, *3/*3)."" ""the risk of stroke recurrence between CYP2C19 IM+PM, IM, PM and EM(P<0.05),while there was no significant difference between PM and IM(P>0.05)"""	clopidogrel
1183689255	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:23001453	CYP2C19	CYP2C19 *2 + *3 is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.	yes	< 0.022	617		East Asian	Efficacy	false	Patients undergoing percutaneous coronary intervention who are treated with clopidogrel and carry at least one copy of either the CYP2C19 *2 or *3 alleles have significantly higher maximum platelet aggregation and are at significantly increased risk of developing stent thrombosis as compared to patients with the wildtype *1/*1 genotype. The OR shown below is for the risk of developing stent thrombosis due to the presence of a variant allele (*2 or *3).	clopidogrel
1184987661	CYP2C19*1; CYP2C19*3	PMID:24508947	CYP2C19	CYP2C19 *3 is associated with decreased response to clopidogrel as compared to CYP2C19 *1.	yes	= 0.001	617		East Asian	Efficacy	false	in percutaneous coronary intervention-treated patients. The response was measured by adenosine diphosphate-induced maximum platelet aggregation (MPA) on day 3 after initiation of daily clopidogrel maintenance doses.	clopidogrel
981794345	rs662	PMID:21685174	PON1	Genotype TT is not associated with increased risk of cardiovascular events when treated with clopidogrel in people with elective coronary stent placement as compared to genotype CC.	no	= 0.39	760		Unknown	Toxicity	false	Cardiovascular events defined as 1-year incidence of death and myocardial infarction.	clopidogrel
1448624885	rs12456693	PMCID:PMC5485718	SLC14A2	Genotype CT is associated with increased metabolism of clopidogrel as compared to genotype CC.	no	= 0.0521	115		East Asian	Metabolism/PK	false	The CT genotype was associated with increased active metabolite H4 concentration. However, it was not statistically significant.	clopidogrel
1451342380	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMID:22228204	CYP2C19	CYP2C19 *2/*17 + *1/*2 + *2/*2 are not associated with risk of bleedings events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	no	= 0.6	820		Unknown	Toxicity	false	As compared with extensive metabolizers, intermediate/ poor metabolizers had no altered risk of major bleedings (hazard ratio 1.3, 95% CI: 0.45–4.0, P = 0.60).	clopidogrel
981843499	rs4244285	PMID:21918510	CYP2C19	Genotype AA is associated with increased risk of major cardiovascular events (MACE) at 1 year when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.	not stated	= 0.003	1538		Unknown	Toxicity	false	The study reports this association with 1 year MACE for carriers of two CYP2C19 loss-of-function alleles vs no variant but does not report the specific alleles such as *2 (rs4244285) or other. The study cohort are clopidogrel-treated acute myocardial infarction patients, including patients undergoing percutaneous coronary intervention.	clopidogrel
1448604391	CYP2C19*1; CYP2C19*2	PMID:26873108	CYP2C19	CYP2C19 *2/*2 is associated with increased resistance to clopidogrel in people with Acute coronary syndrome and Stroke as compared to CYP2C19 *1/*1.	yes	= 0.011	189		European	Efficacy	false		clopidogrel
981802548	rs4244285	PMCID:PMC3304338	CYP2C19	Allele A is associated with decreased platelet inhibition when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	= 0.012	151		Multiple groups, White and African American participants	Efficacy	false		clopidogrel
1449192147	rs4244285	PMID:28806186	CYP2C19	Genotype AG is associated with increased platelet aggregation when treated with clopidogrel in people with Angina Pectoris and Myocardial Infarction as compared to genotype AA.	yes	= 0.009	110		European	Efficacy	false		clopidogrel
1444936362	rs2108622	PMID:25712182	CYP4F2	Genotypes CC + CT is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to genotype TT.	yes	= 0.029	31	456	Unknown	Efficacy	false	Patients had undergone percutaneous coronary intervention. Cases had definite stent thrombosis during the first 5 days after stent implantation. Controls had no stent thrombosis during the first 30 days following stent implantation. Those with the CT or CC genotype had an increased risk for stent thrombosis as compared to those with the TT genotype. However, this was only significant in multivariate analysis; it was not significant in univariate analysis (p=0.055). Please note alleles have been complemented to the plus chromosomal strand.	aspirin; clopidogrel
1449310935	rs1045642	PMID:29540324	ABCB1	Allele G is associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele A.	yes	= 0.03	448	440	European	Efficacy,Other	false		clopidogrel
1043880590	CYP2C19*1; CYP2C19*5	PMID:19106084	CYP2C19	CYP2C19 *5 is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	= 0.01	1477		Multiple groups	Toxicity	false	Death from cardiovascular causes, myocardial infarction, or stroke. Significance measured as per carrying at least one CYP2C19 reduced-function allele. CYP2C19 Genotyping Results in Clopidogrel Allocated Subjects: Intermediate metabolizer (N=357) -*1A/*2A, *1A/*3, *1A/*4, *1A/*8; Poor metabolizer (N=38) *2A/*2A, *2A/*3, *2A/*4, *2A/*5A, *2A/*8. The *2 allele (rs4244285) accounted for 95% of the subjects who were classified as carriers of a reduced-function allele. Carriers of a *2 allele (rs4244285) had a higher rate of the primary efficacy outcome (HR: 1.42; 95% CI, 0.98 to 2.05; P=0.04) and of stent thrombosis (HR: 3.33; 95% CI, 1.28 to 8.62; P=0.004) than did noncarriers.	clopidogrel
981794355	rs662	PMID:21972404	PON1	Allele T is not associated with clopi-H4 formation or antiplatelet response after 300 or 900 mg clopidogrel loading dose when treated with clopidogrel in men with Myocardial Infarction as compared to allele C.	no		106		Unknown	Efficacy	false		clopidogrel
1043880576	CYP2C19*1; CYP2C19*5	PMID:20801498	CYP2C19	CYP2C19 *5 is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	= 0.028	5148		Multiple groups, predominantly white (98%)	Toxicity	false	"The higher rate of ischaemic events was determined during the first 30 days of treatment.The study reports association for CYP2C19 loss-of-function alleles, which includes rs4244285 (CYP2C19*2). Further loss-of-function alleles CYP2C19*3, *4, *5, *6, *7, and *8 were genotyped. In 5148 patients on clopidogrel the CYP2C19 genotypes were following:*1/*1=1862 (36%); *1/*2=898 (17%); *1/*3= 6 (<1%); *1/*4=8 (<1%); *1/*6=2 (<1%); *1/*8=21 (<1%); *2/*2=115 (2%); *2/*4	=3 (<1%); *2/*5=1 (<1%); *2/*8=6 (<1%).
However, when the full follow-up period (1 year) was considered, the difference in outcomes between patients with and without any loss-of-function allele was not significant."	clopidogrel
981794365	rs662	PMID:21972404	PON1	Genotype TT is not associated with increased risk of major cardiovascular events or occurrence of stent thrombosis when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.	no	= 0.89	371		Unknown	Toxicity	false		clopidogrel
1448624865	CYP2C19*1; CYP2C19*2	PMCID:PMC5485718	CYP2C19	CYP2C19 *2 is associated with decreased metabolism of clopidogrel as compared to CYP2C19 *1/*1.	yes	< 0.0001	115		East Asian	Metabolism/PK	false	This variant was associated with decreased active metabolite H4 concentration.	clopidogrel
981802559	rs662	PMID:22368149	PON1	Allele T is not associated with increased risk of cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele C.	no	= 0.23	2549	2510	Multiple groups, Individuals with European and Latin American ancestry	Toxicity	false		clopidogrel
1449732819	rs4244285	PMID:30188374	CYP2C19	Genotypes AA + AG are associated with increased major adverse cardiac events (mace) when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	yes	= 0.018	230		Near Eastern	Efficacy,Toxicity	false	dual treatment with clopidogrel 75 mg/day and aspirin 81 mg/day for at least 12 months following their first acute coronary syndrome (ACS). Genotyping for CES1 (rs3815583) and (rs2244613), P2Y12 (rs2046943), CYP2C19*4 (rs28399504), CYP2C19*2 (rs4244285), CYP2C19*3 (rs4986893), CYP2C19*17 (rs12248560), PEAR-1 (rs12041331) and PON-1 (rs662). CYP2C19*2 represented as C/T variant change in the article, although other CYP2C19 variants are reported on the positive strand in the article.	clopidogrel
1184987674	CYP2C19*1; CYP2C19*2	PMID:24508947	CYP2C19	CYP2C19 *2 is associated with increased risk of Thrombosis when treated with clopidogrel as compared to CYP2C19 *1.	yes	= 0.028	617		East Asian	Toxicity	false	in patients undergoing percutaneous coronary intervention.The clinical primary end point was the 1-year incidence of definite stent thrombosis (ST).	clopidogrel
1449310942	rs4244285	PMID:29540324	CYP2C19	Allele A is associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele G.	yes	= 0.03	448	440	European	Efficacy,Other	false		clopidogrel
981755449	CYP2C19*1; CYP2C19*2	PMID:23429358	CYP2C19	CYP2C19 *2 is associated with decreased clopidogrel response in Chinese patients undergoing percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1.	yes	< 0.001	109		East Asian	Efficacy	false		clopidogrel
981843514	rs4244285	PMID:21918510	CYP2C19	Genotype AA is associated with increased risk of ischemic events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.	not stated	= 0.001	1538		Unknown	Toxicity	false	The study reports this association with in-hospital events for carriers of two CYP2C19 loss-of-function alleles vs no variant but does not report the specific alleles such as *2 (rs4244285) or other. The study cohort are clopidogrel-treated acute myocardial infarction patients, including patients undergoing percutaneous coronary intervention.	clopidogrel
1444936352	CYP2C19*1; CYP2C19*17	PMID:25712182	CYP2C19	CYP2C19 *17 is not associated with response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	no	= 0.2	31	456	Unknown	Efficacy	false	Patients had undergone percutaneous coronary intervention. Cases had definite stent thrombosis during the first 5 days after stent implantation. Controls had no stent thrombosis during the first 30 days following stent implantation. The distribution of CYP2C19*17 genotypes (e.g. *1/*1, *1/*17, *17/*17) was not significantly different between cases and controls.	aspirin; clopidogrel
769245465	rs4244285	PMCID:PMC3061841	CYP2C19	Allele A is associated with decreased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele G.	yes	= 0.015	71		Multiple groups	Efficacy	false	The prevalence of High Platelet Reactivity (HPR) was higher in  (AA + AG) compared to GG, but the template doesn't accommodate this.  *2 SNP.  [stat_test: chi-square]	aspirin; clopidogrel
827919768	rs4244285	PMID:22462746	CYP2C19	Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.	yes	= 0.001	89		"Multiple groups, Chinese, Malay, Indian mixed population. "	Efficacy	false	as measured by platelet reactivity index (platelet vasodilator-stimulated phophoprotein test) on blood collected from patients. Patients with one (p=0.001) or two (p<0.001) loss-of-function alleles (CYP2C19*2 (genotyped rs4244285 G>A) or CYP2C19*3 (genotyped rs4986893 G>A)) had a significantly increased platelet reactivity index compared to those without loss-of-function alleles. [stat_test: multiple linear regression model]	clopidogrel
981755462	CYP2C19*1; CYP2C19*3	PMID:23429358	CYP2C19	CYP2C19 *3 is associated with decreased clopidogrel response in Chinese patients undergoing percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1.	yes	< 0.001	109		East Asian	Efficacy	false		clopidogrel
981843527	rs662	PMID:21918510	PON1	Genotype TT is not associated with increased risk of major cardiovascular events (MACE) at 1 year when treated with clopidogrel in people with Myocardial Infarction as compared to genotype CC.	no	= 0.52	1538		Unknown	Toxicity	false	The study cohort are clopidogrel-treated acute myocardial infarction patients, including patients undergoing percutaneous coronary intervention.	clopidogrel
769245468	rs12248560	PMCID:PMC3061841	CYP2C19	Allele T is associated with increased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele C.	yes	= 0.016	49		Multiple groups		false	For 20 microMolar ADP-induced platelet aggregation, the prevalence of High Platelet Reactivity (HPR) was lower in (TT +TC) vs CC, but the template doesn't accommodate this.  *17 SNP.  For 5 microMolar ADP-induced platelet aggregation, the association was NOT significant ( p = 0.32).  [stat_test: chi-square]	aspirin; clopidogrel
1184987748	CYP2C19*1; CYP2C19*2	PMID:24996381	CYP2C19	CYP2C19 *2 is associated with increased resistance to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.	yes		1066	1265	Multiple groups, Chinese, Korean, French	Other	false	Criteria for inclusion in the meta-analysis: (1) the association of CYP2C19*2 gene polymorphism and clopidogrel resistance was studies (2) studies were prospective cohort studies (3) all patients diagnosed with coronary artery disease, (4) all patients received dual antiplatelet therapy with aspirin and clopidogrel (5) the study had to clearly indicate the number of patients present with and without clopidogrel resistance for each genotype. Clopidogrel resistance was defined as: adenosine diphosphate-inhibited percentage =10 %, adenosine diphosphate-induced maximal platelet aggregation =50 %, and vasodilator phosphoprotein index =50 %.	clopidogrel
981755468	CYP2C19*1; CYP2C19*2	PMID:23429358	CYP2C19	CYP2C19 *1/*2 + *2/*2 is associated with increased risk of recurrent cardiovascular (CV) events 1 year after PCI in Chinese patients when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.038	109		East Asian	Toxicity	false	CYP2C19 loss-of-function alleles ( * 1/ * 2 or * 3, * 2/ * 2 or * 3 ) are analyzed together as compared to *1/*1.	clopidogrel
1184469584	rs12248560	PMID:19496924	CYP2C19	Genotypes CT + TT is associated with increased response to clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	yes	= 0.0005	598		Unknown	Dosage,Efficacy	false	"Patients had non-ST elevation acute coronary syndrome.  Result was reported on CYP2C19 *17, but it appears that only one variant was assayed.  TT < CT< CC for Platelet reactivity index vasodilator stimulated phosphoprotein assay (PRI VASP), which indicates better response for TT>CT>CC.  This comparison between the three genotypes was significant prior to but not after adjustment for factors that influence platelet reactivity; however, CT+TT > CC for response WAS significant.  These subjects were also part of a larger such study ""by the same organization"". Assays were performed for *4,*5,*6 and *17.  Genotype was not significantly associated with ADP-Ag (max intensity of 10 microMolar ADP-induced platelet aggregation)."	clopidogrel
769245456	rs4244285	PMCID:PMC3061841	CYP2C19	Allele A is associated with decreased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele G.	yes	= 0.01	118		Multiple groups, 59 White; 55 African American	Efficacy	false	These patients had coronary arterial stenting.  The comparison was that ADP-induced ex vivo platelet aggregation was higher in (AA + AG) compared to GG, but the template does not accommodate this.  *2 SNP.  [stat_test: chi-square]	aspirin; clopidogrel
769245459	rs12248560	PMCID:PMC3061841	CYP2C19	Allele T is not associated with increased response to aspirin and clopidogrel in people with Coronary Artery Disease.	no	= 0.08	118		Multiple groups, 59 White;  50 African American	Efficacy	false	These patients had coronary arterial stenting. Comparison was T carriers (TT + CT) vs non-carriers (CC) but the template doesn't accommodate this choice.  *17 SNP.  ADP-induced ex vivo platelet aggregation was measured.  [stat_test: chi-square]	aspirin; clopidogrel
1043763965	rs4244285	PMID:20924183	CYP2C19	Allele A is associated with suboptimal reperfusion (post-PCI TIMI flow <3) when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.	yes	= 0.01	276		Unknown	Efficacy	false		clopidogrel
981794377	rs854560	PMID:21972404	PON1	Allele A is not associated with clopi-H4 formation or antiplatelet response after 300 or 900 mg clopidogrel loading dose when treated with clopidogrel in men Myocardial Infarction as compared to allele T.	no		106		Unknown	Efficacy	false		clopidogrel
1183705666	rs3785161	PMID:24535487	CES1P1	Genotypes AC + CC are associated with increased on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to genotype AA.	yes	= 0.014	162		East Asian	Efficacy	false	The article found this association for CES1A2 A(-816)C. Patients were on dual treatment of aspirin and clopidogrel.	clopidogrel
1444702924	rs1045642	PMID:25850030	ABCB1	Genotype AA is associated with increased platelet reactivity when treated with clopidogrel in people with Myocardial Infarction as compared to genotypes AG + GG.	yes	= 0.03	72		Unknown	Efficacy	false	Please note at risk genotype in this study was either CYP2C19*2 carrier or ABCB1B 3435 TT genotype. Results are not independently presented. Multivariate analyses for predictors of 1-month HPR revealed carrier status for an at-risk genotype to be the strongest independent predictor for HPR.	clopidogrel
981755473	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:23429358	CYP2C19	CYP2C19 *1/*3 + *2/*3 is associated with increased risk of recurrent cardiovascular (CV) events 1 year after PCI in Chinese patients when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.038	109		East Asian	Toxicity	false	CYP2C19 loss-of-function alleles ( * 1/ * 2 or * 3, * 2/ * 2 or * 3 ) are analyzed together as compared to *1/*1.	clopidogrel
981794386	rs854560	PMID:21972404	PON1	Genotype AA is not associated with increased risk of major cardiovascular events or occurrence of stent thrombosis when treated with clopidogrel in people with Myocardial Infarction as compared to allele T.	no	= 0.19	371		Unknown	Toxicity	false		clopidogrel
981794397	rs4244285	PMID:21972404	CYP2C19	Allele A is associated with decreased clopi-H4 concentrations after 300 or 900 mg clopidogrel loading dose when treated with clopidogrel in men with Myocardial Infarction as compared to genotype GG.	yes	< 0.01	106		Unknown	Efficacy	false		clopidogrel
981843548	rs1045642	PMID:21918510	ABCB1	Genotypes AA + AG are associated with increased risk of major cardiovascular events (MACE) at 1 year when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.	not stated		2208		Unknown	Toxicity	false	The study cohort are clopidogrel-treated acute myocardial infarction patients, including patients undergoing percutaneous coronary intervention. The study reports an association but no p-value documented.	clopidogrel
1451397720	rs1736557	PMID:33089397	FMO3	Genotype AA is associated with decreased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes AG + GG.	yes	= 0.0052	355	167	East Asian	Efficacy	false		clopidogrel
1448530614	rs4986893	PMID:27450232	CYP2C19	Allele A is associated with increased risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	yes	= 0.007	64	313	East Asian	Efficacy	false		clopidogrel
981843559	rs1045642	PMID:22624833	ABCB1	Allele A is not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	no	= 0.32	1028		Unknown	Efficacy	false		clopidogrel
1451342440	CYP2C19*1; CYP2C19*17	PMCID:PMC6986167	CYP2C19	CYP2C19 *1/*17 + *17/*17 are associated with increased risk of Hemorrhage when treated with clopidogrel and rivaroxaban in people with Acute coronary syndrome and Atrial Fibrillation as compared to CYP2C19 *1/*1.	not stated		103		Unknown	Toxicity	false	Among the allelic variant carriers CYP2C19*17 (CYP2C19*17 CT + CYP2C19*17 TT) patients had a twice more often increased risk of bleeding.	clopidogrel; rivaroxaban
981794408	rs4244285	PMID:21972404	CYP2C19	Allele A is associated with increased risk of major cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.	yes	= 0.03	371		Unknown	Toxicity	false		clopidogrel
1448116927	rs776746	PMID:26526111	CYP3A5	Genotype CC is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to genotypes CT + TT.	no	= 0.432	209		European	Efficacy	false	All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting. Alleles given as A and G.	clopidogrel
981794421	rs662	PMCID:PMC3750958	PON1	Genotype TT is not associated with biologigical response to clopidogrel when treated with clopidogrel as compared to allele C.	no	= 0.22	5302		Unknown	Efficacy	false		clopidogrel
981794431	rs662	PMCID:PMC3750958	PON1	Genotype TT is not associated with increased risk of major cardiovascular events (MACE) when treated with clopidogrel as compared to allele C.	no	= 0.08	8092		Unknown	Toxicity	false		clopidogrel
981755512	rs662	PMCID:PMC3572125	PON1	Genotypes CT + TT are associated with increased risk of cardiovascular events (composite of cardiac death, MI, stent thrombosis) in Korean patients after PCI when treated with clopidogrel as compared to genotype CC.	yes	= 0.017	1336		East Asian	Toxicity	false	The T allele (Q-allele) is also associated with decreased PON1 activity.	clopidogrel
981843579	rs662	PMID:22624833	PON1	Allele T is not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	no	= 0.42	1028		Unknown	Efficacy	false		clopidogrel
1450117776	rs2254638	PMID:30487649	N6AMT1	Allele G is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele A.	yes	= 1.87e-3	115		East Asian	Efficacy	false	This variant is associated with decreased H4 concentration, and decreased antiplatelet effects of clopidogrel with a higher PRU.	clopidogrel
1043766070	rs1045642	PMID:20650435	ABCB1	Allele A is not associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to allele G.	no	= 0.018	126		East Asian	Efficacy	false		clopidogrel
1183681419	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:24019397	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 is not associated with risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3 + *2/*17 + *3/*17.	no	= 0.57	1656		East Asian	Toxicity	false	Major adverse cardiac and cerebrovascular events consisted of death from any cause, non-fatal myocardial infarction or stroke during the 1 year follow-up period for patients on clopidogrel. Patients had previously undergone percutaneous coronary intervention. This was a multivariable analysis. No significant difference in the risk for major adverse cardiac and cerebrovascular events was seen between the two genotype groups. *2/*2, *2/*3 and *3/*3 were analyzed as a group (poor metabolizers) and *1/*1, *1/*17, *1/*2, *1/*3, *2/*17 and *3/*17 were analyzed as a group (intermediate and extensive metabolizers).	clopidogrel
982034306	rs776746	PMID:19576320	CYP3A5	Genotypes CT + TT are not associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to genotype CC.	no	= 0.786	387		East Asian	Efficacy	false	Inclusion criteria: coronary artery disease, myocardial ischemia, angiographic evidence of >50% diameter stenosis, and postprocedure Thrombolysis In Myocardial Infarction flow grade 3.	clopidogrel
1447678787	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMCID:PMC4760893	CYP2C19	CYP2C19 *1/*2 + *2/*3 + *1/*3 + *2/*17 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	yes	= 0.011	190		Near Eastern	Toxicity	false	CYP2C19 loss-of-function (LOF) alleles carriers had increased risk of MACE vs. noncarriers in Egyptian patients with acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI), treated with clopidogrel (75 mg/day) for at least a month.	clopidogrel
981802889	CYP2C19*1; CYP2C19*3	PMID:23470885	CYP2C19	CYP2C19 *3 is associated with more frequent high platelet reactivity in Japanese patients in a steady state receiving dual antiplatelet therapy after coronary stent implantation when treated with clopidogrel as compared to CYP2C19 *1.	yes	< 0.05	155		East Asian	Efficacy	false	The loss of function alleles (*2 and *3) are analyzed together. CYP2C19 loss-of-function genotype alone could explain 12.2%, 14.3%, and 14.7% of the variability in the ADP-LTA, VASP and VerifyNow-P2Y12 assays, respectively.	clopidogrel
1184168856	CYP2C19*1; CYP2C19*3	PMID:23726091	CYP2C19	CYP2C19 *1/*3 + *3/*3 is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	no	= 0.004	500		East Asian	Efficacy	false	No significant difference in risk of high on-treatment platelet reactivity was seen between the genotypes. Reactivity was measured after 5 days maintenance dose of clopidogrel. Note: only one patient had the *3/*3 genotype.	clopidogrel
981239667	rs10306114	PMID:22940005	PTGS1	Genotypes AG + GG are associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to genotype AA.	yes	= 0.001	1327		Unknown	Toxicity	false	Cardiovascular events are primary outcome events (cardiac death and recurrent myocardial infarction)All patients were treated with a primary PCI and received dual antiplatelet therapy with aspirin and clopidogrel. Patients might be additionally treated with Beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and/or statins. Aspirin (100 mg/day) was prescribed indefinitely, and clopidogrel (75 mg/day) for 12 months. At discharge from the hospital admission following the primary intervention, aspirin and clopidogrel were prescribed to 96.0% and 99.7% of the patients respectively. However, all patients received the loading of clopidogrel. Considering CYP2C19*2 (rs4244285) and COX1 (- 846A > G) (rs10306114) together, 779 (59%) patients were homozygote for the wild type alleles of both SNPs, 435 (33%) patients had 1 risk allele, 87 (7%) patients had 2 risk alleles and 8 (1%) patients were carrying 3 risk alleles. Compared to the patients with 0 or 1 risk alleles, the patients who were carrying 2 or 3 risk alleles had an increased risk of the primary endpoint, HR 2.57 (95% CI 1.87 to 3.54), P = 6.9 × 10^ 9.	aspirin; clopidogrel
1449147249	rs146456965	PMCID:PMC5637814	CES1	Allele A is associated with decreased metabolism of when assayed with clopidogrel, enalapril and sacubitril in HEK cells as compared to allele C.	yes	< 0.001			Unknown	Metabolism/PK	false	The SNP abolished CES1 enzyme activity when assayed with enalapril, clopidogrel, sacubitril.	clopidogrel; enalapril; sacubitril
981802899	rs1045642	PMCID:PMC3467260	ABCB1	Genotypes AA + AG are not associated with stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	no	= 0.56			Unknown	Toxicity	false	Association with the cumulative incidence of stent thrombosis. Meta-analysis included 7 studies that reported stent thrombosis data.	clopidogrel
1184168844	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:23726091	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *2/*2 is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	= 0.14	500		East Asian	Efficacy	false	Patients with the *2 or *3 allele had an increased risk of high on-treatment platelet reactivity, as compared to those with the *1/*1 genotype. Reactivity was measured after 5 days maintenance dose of clopidogrel.	clopidogrel
981802910	rs1045642	PMCID:PMC3467260	ABCB1	Genotype AA is associated with decreased bleeding events when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	< 1.0E-5			Unknown	Toxicity	false	Meta-analysis included 3 studies that provided data on bleeding rate.	clopidogrel
982034323	rs2046934	PMID:19576320	P2RY12	Genotypes AG + GG are not associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to genotype AA.	no	= 0.086	387		East Asian	Efficacy	false	Inclusion criteria: coronary artery disease, myocardial ischemia, angiographic evidence of >50% diameter stenosis, and postprocedure Thrombolysis In Myocardial Infarction flow grade 3.	clopidogrel
981204837	rs1799983	PMID:22890915	NOS3	Allele T is associated with increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors in men with Coronary Artery Disease as compared to allele G.	yes	= 0.008	44	57	Unknown	Other	false	Not reported as a pharmacogenetic association - patients were on standard therapy including the above drugs and may also have been taking angiotensin converting enzyme inhibitors and calcium antagonists. The minor allele of this genetic variant (reported as eNOS 298 T allele) was significantly more frequent in patients with in-stent restenosis. In carriers of the T allele, ISR was 1.8x higher compared to patients with GG - p value given. Odds ratio p value not given.	aspirin; Beta Blocking Agents; clopidogrel; hmg coa reductase inhibitors
1448262522	rs1061781	PMCID:PMC4982803	B4GALT2	Genotypes CT + TT is associated with decreased platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	yes	= 0.0001	160		European	Efficacy	false	Carriers of T allele had lower on-treatment P2Y12 reaction units (PRUs) and residual platelet aggregation compared with noncarriers, which remained significant after adjusting for CYP2C19 and other clinical variables in both the discovery and replication.	aspirin; clopidogrel
1448567679	rs701265	PMID:28091702	P2RY1	Genotype AA is not associated with risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to genotypes AG + GG.	no	= 0.74	46	380	East Asian	Toxicity	false	"in Chinese patients with minor ischemic stroke (MIS). The primary clinical endpoint was defined as composite of recurrent ischemic stroke, myocardial infarction and death. ""The estimated risks of adverse events were significantly higher in patients carrying rs16863323TT and rs2317676GG or rs16863323TT and rs2317676GG/AG, compared to those harboring rs16863323CC and rs2317676AA"", suggesting that gene interactions conferred a higher risk for adverse events than did any single variant alone."	clopidogrel
1450664799	CYP2C19*2	PMID:21806387	CYP2C19	CYP2C19 *2/*2 is associated with increased platelet reactivity when treated with clopidogrel in people with Angina Pectoris.	yes	= 0.03	189		European	Efficacy	false		clopidogrel
1183681446	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:24019397	CYP2C19	CYP2C19 *1/*1 + *1/*17 + *2/*17 + *3/*17 is associated with increased response to clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.	yes	< 0.001	491		East Asian	Efficacy	false	Patients with stable angina OR acute myocardial infarction. Patients with the *1/*1, *1/*17, *2/*17 or *3/*17 genotype had the more potent antiplatelet effect, as compared to those with the *1/*2, *1/*3, *2/*2, *2/*3 or *3/*3 genotype. Antiplatelet effect was measured by P2Y12 inhibition percentage. Patients had undergone percutaneous coronary intervention, and percentage inhibition of platelet reactivity was measured on day of discharge. *1/*2, *1/*3, *2/*2, *2/*3 and *3/*3 were analyzed as a group (intermediate and poor metabolizers) and *1/*1, *1/*17, *2/*17 and *3/*17 were analyzed as a group (extensive metabolizers).	clopidogrel
981802921	rs1045642	PMID:23364775	ABCB1	Allele A is not associated with increased risk of myocardial infarction (MI) or composite outcome of non-fatal MI, all cause death and stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	no	= 0.127	1034		Multiple groups, mostly White (>90%)	Efficacy,Toxicity	false	Cardiovascular events defined as myocardial infarction (MI) or composite outcome of non-fatal MI, all cause death and stent thrombosis.The study observed that event rates for both MI and composite outcome of non-fatal MI, all cause death and stent thrombosis at one year were numerically higher for patients with the ABCB1 3435 C allele compared with patients with the T allele (10.3% vs. 8.3% for MI and 13.6% vs. 11.5% for composite outcome). A significant risk was found in association with the combined CYP2C19*2 (rs4244285) and ABCB1 3435 CC (rs1045642) genotype for both MI (p=0.026; HR=1.25) and the composite outcome (p=0.034; HR=1.21) occurring between 6 and 12 month.	clopidogrel
1184469934	CYP2C19*1; CYP2C19*2; CYP2C19*8; CYP2C19*17	PMCID:PMC2709885	CYP2C19	CYP2C19 *1/*2 + *1/*8 + *2/*2 (assigned as poor metabolizer genotype phenotype) is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer genotype phenotype) .	yes	< 0.05	46		European	Efficacy,Metabolism/PK	false	VASP platelet reactivity index and VerifyNow(TM) P2Y12 reaction unit values were significantly higher in PM than in EM.  Patients were also treated with aspirin.   There were 37 EM (by genotype) and 9 PM (by genotype).  Dosage was 600 mg loading/75 mg maintenance.	clopidogrel
1184168867	rs1045642	PMID:23726091	ABCB1	Genotypes AA + AG is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.	no	= 0.45	500		East Asian	Efficacy	false	No significant difference in risk of high on-treatment platelet reactivity was seen between the genotypes. Reactivity was measured after 5 days maintenance dose of clopidogrel. Please note alleles have been complemented to the plus chromosomal strand.	clopidogrel
1184168878	CYP2C19*1; CYP2C19*17	PMID:23726091	CYP2C19	CYP2C19 *1/*17 is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	no	= 0.15	500		East Asian	Efficacy	false	No significant difference in platelet aggregation was seen between the genotypes. Reactivity was measured after 5 days maintenance dose of clopidogrel.	clopidogrel
1449147227	rs151291296	PMCID:PMC5637814	CES1	Allele C is associated with decreased enzyme activity of when assayed with clopidogrel, enalapril and sacubitril in HEK cells as compared to allele A.	yes	< 0.001			Unknown	Metabolism/PK	false	The SNP abolished CES1 enzyme activity when assayed with enalapril, clopidogrel, sacubitril.	clopidogrel; enalapril; sacubitril
982009780	CYP2C19*1; CYP2C19*2	PMID:22374717	CYP2C19	CYP2C19 *1/*2 is associated with decreased antiplatelet response and reduced clopidogrel active metabolite formation when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.	yes	= 0.02	21		Unknown	Efficacy	false	Reduced function alleles (*1/*2, *2/*2 or *1/*3) are grouped together  for analysis vs. the extensive metabolizer alleles (*1/*1, *1/*17).	clopidogrel
981802939	rs4244285	PMID:23364775	CYP2C19	Genotype AA is associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	yes	= 0.018	1034		Multiple groups, mostly White (>90%)	Toxicity	false	"The increase in risk was predominantly seen between 6 and 12 months following
discharge (HR=2.9). The one-year event rates were 8.4% for patients with the GG genotype, 10.9% for patients with the GA genotype and 44.4% for
patients with the AA genotype."	clopidogrel
1184168874	rs662	PMID:23726091	PON1	Genotypes CC + CT is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype TT.	no	= 0.33	500		East Asian	Efficacy	false	No significant difference in risk of high on-treatment platelet reactivity was seen between the genotypes. Reactivity was measured after 5 days maintenance dose of clopidogrel. Please note alleles have been complemented to the plus chromosomal strand.	clopidogrel
1446896509	rs6809699	PMID:26362473	P2RY12	Genotype AA is not associated with decreased response to clopidogrel as compared to genotype CC.	no	= 0.009	276		Latino	Efficacy	false	in a Mexican population undergoing percutaneous coronary intervention.	clopidogrel
981239613	rs4244285	PMID:22940005	CYP2C19	Genotype AA is associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to genotypes AG + GG.	yes	= 2.1E-5	1327		Unknown	Toxicity	false	Cardiovascular events are primary outcome events (cardiac death and recurrent myocardial infarction). All patients were treated with a primary PCI and received dual antiplatelet therapy with aspirin and clopidogrel. Patients might be additionally  treated with Beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and/or statins. Aspirin (100 mg/day) was prescribed indefinitely, and clopidogrel (75 mg/day) for 12 months. At discharge from the hospital admission following the primary intervention, aspirin and clopidogrel were prescribed to 96.0% and 99.7% of the patients respectively. However, all patients received the loading of clopidogrel. Considering CYP2C19*2 (rs4244285) and COX1 (- 846A > G) (rs10306114) together, 779 (59%) patients were homozygote for the wild type alleles of both SNPs, 435 (33%) patients had 1 risk allele, 87 (7%) patients had 2 risk alleles and 8 (1%) patients were carrying 3 risk alleles. Compared to the patients with 0 or 1 risk alleles, the patients who were carrying 2 or 3 risk alleles had an increased risk of the primary endpoint, HR 2.57 (95% CI 1.87 to 3.54), P = 6.9 × 10^ 9.	aspirin; clopidogrel
1451633600	rs4244285	PMID:34954768	CYP2C19	Allele A is associated with increased platelet reactivity when treated with aspirin and clopidogrel in people with Ischemic Attack, Transient or Stroke as compared to allele G.	yes	= 0.037	106	202	East Asian	Efficacy	false	"CYP2C19*2 (rs4244285) A allele was significantly higher in HPR (high platelet reactivity group) vs NPR (normal platelet reactivity). ""Patients with , inhibition of platelet aggregation IPA <30%
were considered as clopidogrel high on-treatment platelet reactivity (HPR) group"""	aspirin; clopidogrel
1446896503	rs16846673	PMID:26362473	P2RY12	Genotype TT is not associated with decreased response to clopidogrel as compared to genotype CC.	no	= 0.009	276		Latino	Efficacy	false	in a Mexican population undergoing percutaneous coronary intervention.	clopidogrel
1184349146	CYP3A5*1; CYP3A5*3	PMID:24763934	CYP3A5	CYP3A5 *3/*3 is associated with increased Platelet reactivity after 9month of treatment when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP3A5 *1/*1 + *1/*3.	yes	= 0.048	25		East Asian	Efficacy	false	Association only found in CYP2C19 poor metabolizers assigned as carriers of two loss-of-function alleles; genotyped for *2 and *3. Dual treatment aspirin and clopidogrel.	clopidogrel
981802954	rs4244285	PMID:23364775	CYP2C19	Genotype AA is associated with increased risk of composite outcome of non-fatal MI, all cause death and stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	yes	= 0.02	1034		Multiple groups, mostly White (>90%)	Toxicity	false	The increase in risk was predominantly seen between 6 and 12 months following discharge (HR=2.06). The one-year event rates were 11.4% for patients with the GG genotype, 14.1% for patients with the GA genotype and 44.4% for patients with the AA genotype.	clopidogrel
1446896493	CYP2C19*1; CYP2C19*3	PMID:26362473	CYP2C19	CYP2C19 *3 is not associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.009	276		Latino	Efficacy	false	in a Mexican population undergoing percutaneous coronary intervention.	clopidogrel
1450664741	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMCID:PMC3248259	CYP2C19	CYP2C19 *2/*2 + *2/*3 are associated with increased high on-treatment platelet reactivity when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.	not stated		90		Unknown	Efficacy	false	"CYP2C19-predicted phenotype group was consistently associated with a dampened PD effect for IMs and for PMs. CYP2C19 *2/*3 and *2/*2 is associated with severity of inhibition of platelet response (IPA) when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.
Note: P values were NOT provided in the study. NM (*1/*1) have about 60% more IPA values than poor metabolizers  and this is considered significant by authors"	clopidogrel
981848029	rs6809699	PMID:18485500	P2RY12	Genotype AA is associated with stronger aggreagtion when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes AC + CC.	yes	= 0.0212	557		Unknown	Efficacy	false		clopidogrel
1448624896	rs2487032	PMCID:PMC5485718	ABCA1	Allele A is associated with increased metabolism of clopidogrel as compared to genotype GG.	yes	= 0.0441	115		East Asian	Metabolism/PK	false	This variant was associated increased the concentration of plasma clopidogrel’s active metabolite H4 and increased inhibition of platelet function. However, it was not associated with clinical outcome of clopidogrel.	clopidogrel
1446896483	CYP2C19*1; CYP2C19*2	PMID:26362473	CYP2C19	CYP2C19 *2 is not associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.009	276		Latino	Efficacy	false	in a Mexican population undergoing percutaneous coronary intervention.	clopidogrel
1446896476	rs1045642	PMID:26362473	ABCB1	Genotype AA is associated with decreased response to clopidogrel as compared to genotypes AG + GG.	yes	= 0.009	276		Latino	Efficacy	false	in a Mexican population undergoing percutaneous coronary intervention.	clopidogrel
1184470013	rs12248560	PMID:18781853	CYP2C19	Genotypes CT + TT is not associated with response to clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	no	= 0.14	237		European	Efficacy	false	These were patients undergoing percutaneous coronary intervention.  Carriers of the T allele at rs12248560(determining *17) did not show significantly different residual platelet aggregation after a 600 mg loading dose of clopidogrel when compared to non-carriers(*1/*1 after typing for the main variants determining *2,*3,and *17).   Patients also were dosed with 500 mg aspirin and 70 u/kg body weight unfractionated heparin prior to PCI.  Patients were classified as having low or high residual platelet aggregation and the comparison was between those with low and high RPA.	clopidogrel
1184470005	rs4244285	PMID:18781853	CYP2C19	Genotypes AA + AG is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	< 0.0001	237		European	Efficacy	false	These were patients undergoing percutaneous coronary intervention.  Carriers of the A allele at rs4244285(determining *2) showed significantly increased residual platelet aggregation after a 600 mg loading dose of clopidogrel when compared to non-carriers.  Patients were also typed for the main variants which determine *3 and *17.  Patients also were dosed with 500 mg aspirin and 70 u/kg body weight unfractionated heparin prior to PCI.  Patients were classified as having low or high residual platelet aggregation and the comparison was between those with low and high RPA.	clopidogrel
981848040	rs6809699	PMID:18485500	P2RY12	Genotype AA is associated with increased risk of non-response when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes AC + CC.	yes	= 0.004	557		Unknown	Efficacy	false		clopidogrel
1451633640	rs168753	PMID:34954768	F2R	Allele T is associated with decreased platelet reactivity when treated with aspirin and clopidogrel in people with Ischemic Attack, Transient or Stroke as compared to allele A.	yes	= 0.015	106	202	East Asian	Efficacy	false	"""minor allele T of SNP rs168753 in F2R (P = 0.017) was significantly
associated with normal platelet reactivity from clopidogrel-aspirin therapy"" higher in NPR (normal platelet reactivity) vs HPR (high platelet reactivity group). ""Patients with inhibition of platelet aggregation IPA <30%
were considered as clopidogrel high on-treatment platelet reactivity (HPR) group"""	aspirin; clopidogrel
1448731446	CYP2C9*1; CYP2C9*2	PMID:28745576	CYP2C9	CYP2C9 *2 is not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C9 *1.	no	= 0.142	274		Multiple groups, 45% Chinese, 22% Malay, 23% Iban, 10% others	Efficacy	false	in patients undergoing elective percutaneous coronary intervention. Patients with higher on treatment platelet reactivity had higher risk of MACE but this was not significant for CYP2C9*2 (*2/*2 + *1/*2 MACE rate 7.8 versus 3.8% for *1/*1).	clopidogrel
1184349157	CYP3A5*1; CYP3A5*3	PMID:24763934	CYP3A5	CYP3A5 *3/*3 is not associated with increased platelet reactivity after 9month of treatment when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP3A5 *1/*1 + *1/*3.	no	= 0.51	30		East Asian	Efficacy	false	In CYP2C19 intermediate metabolizers assigned as carriers of one loss-of-function alleles; genotyped for *2 and *3 and extensive metabolizers assigned as *1/*1. Dual treatment aspirin and clopidogrel.	clopidogrel
981848051	rs6809699	PMID:18485500	P2RY12	Genotype AA is associated with increased risk of clopidogrel resistance when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes AC + CC.	yes	= 0.01	557		Unknown	Efficacy	false		clopidogrel
1183863790	CYP2C19*1; CYP2C19*2	PMCID:PMC3946470	CYP2C19	CYP2C19 *2 is not associated with recurrence of acute coronary events when treated with clopidogrel as compared to CYP2C19 *1.	no	= 0.692	15	12	Unknown	Efficacy	false		clopidogrel
1183699725	rs4986910	PMID:24262617	CYP3A4	Allele G is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.	no	= 0.4	1432		Unknown	Other	false	No significant difference in risk of experiencing a major adverse cardiac event (cardiac death, nonfatal myocardial infarction, stent thrombosis during clopidogrel treatment) was seen between the alleles. Patients were assessed over 12 months following drug-eluting stent(s) implantation, and received both clopidogrel and aspirin. Please note alleles have been complemented to the plus chromosomal strand.	clopidogrel
981798663	rs662	PMID:22374717	PON1	Allele T is not associated with clopidogrel active metabolite formation and antiplatelet response after a single dose when treated with clopidogrel in healthy individuals as compared to allele C.	no	= 0.55	21		Unknown	Efficacy	false		clopidogrel
1184348948	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24821368	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	< 0.001	270		East Asian	Toxicity	false	Cohort are coronary artery disease patients without diabetes mellitus carriers. While there were no significant differences in platelet reactivity in patients having cardiovascular events between carrier and non-carrier in the non-DM group (Carriers (n = 32), 5047 ± 1522 AU*min; non-Carriers (n = 2), 5282 ± 546 AU*min; P = 0.59) (Table 2). The following clinical events were registered in the non-DM group: 2 versus 0 in cardiovascular death, 3 versus 0 in nonfatal MI, 4 versus 0 in stroke, 18 versus 2 in urgent revascularization, and 5 versus 0 in IPTE in Carriers versus non-Carriers in the non-DM group, respectively.	clopidogrel
981802753	rs1045642	PMCID:PMC3467260	ABCB1	Genotypes AA + AG are not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	no	= 0.99			Unknown	Efficacy	false	Meta-analysis included 4 studies that provided data on the association of high platelet activity with the ABCB1 C3435T variation.	clopidogrel
1183699721	rs2242480	PMID:24262617	CYP3A4	Allele T is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	no	= 0.26	1432		Unknown	Other	false	No significant difference in risk of experiencing a major adverse cardiac event (cardiac death, nonfatal myocardial infarction, stent thrombosis during clopidogrel treatment) was seen between the alleles. Patients were assessed over 12 months following drug-eluting stent(s) implantation, and received both clopidogrel and aspirin. Please note alleles have been complemented to the plus chromosomal strand.	clopidogrel
1447521217	rs71647871	PMCID:PMC4915569	CES1	Allele T is not associated with decreased risk of composite endpoints (transient ischemic attack (tia), stroke, myocardial infarction, or death) when treated with aspirin and clopidogrel as compared to allele C.	no	= 0.12	188		Multiple groups	Toxicity	false	within 12 months in patients with symptomatic intracranial atherosclerotic disease.	aspirin; clopidogrel
1448530896	rs1062535	PMID:27450232	PEAR1	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.900	64	313	East Asian	Efficacy	false		clopidogrel
1183699717	rs1799853	PMID:24262617	CYP2C9	Allele T is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	no	= 0.38	1432		Unknown	Other	false	No significant difference in risk of experiencing a major adverse cardiac event (cardiac death, nonfatal myocardial infarction, stent thrombosis during clopidogrel treatment) was seen between the alleles. Patients were assessed over 12 months following drug-eluting stent(s) implantation, and received both clopidogrel and aspirin.	clopidogrel
1451031540	rs6787801	PMID:20031628	P2RY12	Allele G is associated with decreased residual on-clopidogrel platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.	yes	< 0.05	1031		Multiple groups, 95% of the study population was of Caucasian origin	Efficacy	false	"as part of haplotype F (CcCAGT) vs reference haplotype A (tTCgGT). Haplotype rs6798347, rs6787801, rs9859552, rs6801273, rs9848789, and rs2046934, respectively, with the minor alleles in lower case. Alleles in sentence complemented to plus chromosomal strand. 
Maintenance therapy of 75 mg daily for >5 days together with a loading dose of 300 mg of clopidogrel at least 24 hours before PCI  or a loading dose of 600 mg of clopidogrel at least 6 hours before PCI. Ninety percent of the patients were on aspirin (80 to 100 mg daily) and 10% were on coumadins."	clopidogrel
1184467728	CYP2C9*1; CYP2C9*3	PMID:20833683	CYP2C9	CYP2C9 *1/*3 + *3/*3 is associated with increased risk of stent thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary interventions as compared to CYP2C9 *1/*1.	yes	= 0.043	176	420	Multiple groups, 3 high volume centers in the Netherlands (> 85% Caucasian)	Efficacy	false	Controls were consecutive patients who underwent PCI with stent implantation at one of the participating centers and who did not experience any adverse cardiovascular events within one year after stenting.  There was a stronger association when compared using subacute stent thrombosis.	aspirin; clopidogrel
982034178	rs5918	PMID:15166949	ITGB3	Genotype CT is associated with decreased antiplatelet effect to a 300 mg clopidogrel loading-dose up to 24 h following intervention when treated with clopidogrel in patients undergoing coronary stent implantation as compared to genotype TT.	yes	< 0.05	38		Unknown	Efficacy	false	All patients were on chronic treatment with aspirin (100 - 250 mg/day) and received a 300 mg clopidogrel loading-dose at intervention time.	clopidogrel
1183699713	rs10509681	PMID:24262617	CYP2C8	Allele T is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	no	= 0.8	1432		Unknown	Other	false	No significant difference in risk of experiencing a major adverse cardiac event (cardiac death, nonfatal myocardial infarction, stent thrombosis during clopidogrel treatment) was seen between the alleles. Patients were assessed over 12 months following drug-eluting stent(s) implantation, and received both clopidogrel and aspirin. Please note alleles have been complemented to the plus chromosomal strand.	clopidogrel
1183681283	CYP2C19*1; CYP2C19*2	PMID:24019397	CYP2C19	CYP2C19 *2/*2 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	yes	= 0.027	532		East Asian	Toxicity	false	Major adverse cardiac and cerebrovascular events consisted of death from any cause, non-fatal myocardial infarction or stroke during the 1 year follow-up period for patients on clopidogrel. Patients had previously undergone percutaneous coronary intervention.	clopidogrel
1448530904	rs1062535	PMID:27450232	PEAR1	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele del.	no	= 0.900	64	313	East Asian	Efficacy	false		clopidogrel
1184348932	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24821368	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	< 0.01	270		East Asian	Efficacy	false	Cohort are coronary artery disease patients without diabetes mellitus carriers: 4501 ± 1668 AU*min, non-carriers: 3639 ± 1714, P < 0.01	clopidogrel
1183699737	rs854560	PMID:24262617	PON1	Allele A is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele T.	no	= 0.46	1432		Unknown	Other	false	No significant difference in risk of experiencing a major adverse cardiac event (cardiac death, nonfatal myocardial infarction, stent thrombosis during clopidogrel treatment) was seen between the alleles. Patients were assessed over 12 months following drug-eluting stent(s) implantation, and received both clopidogrel and aspirin.	clopidogrel
981352424	CYP2C19*1; CYP2C19*5	PMID:19106083	CYP2C19	CYP2C19 *5 is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	yes	= 0.003	2208		European	Toxicity	false	Patients carrying any two CYP2C19 loss-of-function alleles (*2,*3,*4,*5) had a higher event(all cause death,nonfatal stroke, myocardial infarction) rate than patients with none. Patients with one loss-of-function allele had a slightly lower risk in the overall population compared to those with none. Stats given are for any two loe alleles vs. none.	clopidogrel
1448530880	rs4244285	PMID:27450232	CYP2C19	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.742	64	313	East Asian	Efficacy	false		clopidogrel
1183681306	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24019397	CYP2C19	CYP2C19 *2/*3 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	yes	= 0.043	532		East Asian	Toxicity	false	Major adverse cardiac and cerebrovascular events consisted of death from any cause, non-fatal myocardial infarction or stroke during the 1 year follow-up period for patients on clopidogrel. Patients had previously undergone percutaneous coronary intervention.	clopidogrel
1183699733	rs2046934	PMID:24262617	P2RY12	Allele G is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.	no	= 0.3	1432		Unknown	Other	false	No significant difference in risk of experiencing a major adverse cardiac event (cardiac death, nonfatal myocardial infarction, stent thrombosis during clopidogrel treatment) was seen between the alleles. Patients were assessed over 12 months following drug-eluting stent(s) implantation, and received both clopidogrel and aspirin. Please note alleles have been complemented to the plus chromosomal strand.	clopidogrel
1183699729	rs776746	PMID:24262617	CYP3A5	Allele C is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele T.	no	= 0.06	1432		Unknown	Other	false	No significant difference in risk of experiencing a major adverse cardiac event (cardiac death, nonfatal myocardial infarction, stent thrombosis during clopidogrel treatment) was seen between the alleles. Patients were assessed over 12 months following drug-eluting stent(s) implantation, and received both clopidogrel and aspirin. Please note alleles have been complemented to the plus chromosomal strand.	clopidogrel
981352416	rs28399504	PMID:19106083	CYP2C19	Allele G is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype AA.	yes	= 0.003	2208		European	Efficacy,Toxicity	false	Patients carrying any two CYP2C19 loss-of-function alleles (*2,*3,*4,*5) had a higher event(all cause death,nonfatal stroke, myocardial infarction) rate than patients with none. Patients with one loss-of-function allele had a slightly lower risk in the overall population compared to those with none. Stats given are for any two loe alleles vs. none.	clopidogrel
1448530888	rs762551	PMID:27450232	CYP1A2	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele C.	no	= 0.793	64	313	East Asian	Efficacy	false		clopidogrel
1184469816	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:21075428	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 is associated with decreased response to clopidogrel in people with percutaneous coronary intervention as compared to CYP2C19 *1/*1.	yes	= 0.001	190		East Asian	Efficacy,Toxicity	false	Statistics below are for the risk of High Platelet Reactivity.	clopidogrel
699638805	rs2046934	PMID:16181985	P2RY12	Genotypes AG + GG are not associated with response to clopidogrel as compared to genotype AA.	not stated		119		Unknown	Efficacy	false	This is one of four SNPs that comprise H1/H2 haplotypes. The four SNPs (C139T, T744C, ins801A, G52T(=G50T) are in perfect LD, and T744C is frequently used as the tagging SNP. H1 is 139C/744T/no ins at 801A/52G.	clopidogrel
1448119286	CYP2B6*1; CYP2B6*9	PMID:27380588	CYP2B6	CYP2B6 *9 is not associated with platelet reactivity when treated with clopidogrel as compared to CYP2B6 *1/*1.	no	= 0.03	69		East Asian	Efficacy	false	"uniformlly in Korean patients. CYP2B6 genotype only significantly influenced
the platelet response after PCI, and exclusively in a 300-mg loading group."	clopidogrel
1448530928	rs1799983	PMID:27450232	NOS3	Allele G is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	no	= 0.414	64	313	East Asian	Efficacy	false		clopidogrel
981802786	rs1045642	PMCID:PMC3467260	ABCB1	Genotypes AA + AG are not associated with increased risk of major adverse cardiovascular events (MACE) (more than one year) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	no	= 0.62			Unknown	Toxicity	false	Meta-analysis included 7 studies that provided data on long-term MACE (more than one year).	clopidogrel
1184471856	CYP2C19 poor metabolizer genotype	PMCID:PMC3048820	CYP2C19	CYP2C19 poor metabolizer genotype is associated with increased risk of Thrombosis when treated with clopidogrel in people with percutaneous coronary intervention (most of the patients) as compared to CYP2C19 normal metabolizer genotype.	yes	= 0.001	5894		Multiple groups, Most of patients were White, but race information was not captured uniformly between the studies.	Efficacy	false	This result is for stent thrombosis in carriers of two reduced function alleles compared to no reduced function alleles. Six studies were included in this meta-analysis. Out of a larger group of nine studies, seven studies assayed for only *2(rs4244285); one study assayed for *2,*3(rs4986893), *4(rs28399504) and *5(rs56337013); one study assayed for *2,*3,*4,*5 and *8(rs41291556).	clopidogrel
1448530941	rs16863356	PMID:27450232	MED12L	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.771	64	313	East Asian	Efficacy	false		clopidogrel
1449147340	rs202001817	PMCID:PMC5637814	CES1	Allele A is associated with decreased enzyme activity of when assayed with clopidogrel in HEK cells as compared to allele G.	yes	< 0.05			Unknown	Metabolism/PK	false	The SNP abolished CES1 enzyme activity when assayed with clopidogrel.	clopidogrel
699638814	rs2046934	PMID:15795539	P2RY12	Allele G is not associated with response to clopidogrel in people with Angina Pectoris as compared to allele A.	not stated		416		Unknown	Efficacy	false		clopidogrel
1183699744	rs662	PMID:24262617	PON1	Allele T is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.	no	= 0.6	1432		Unknown	Other	false	No significant difference in risk of experiencing a major adverse cardiac event (cardiac death, nonfatal myocardial infarction, stent thrombosis during clopidogrel treatment) was seen between the alleles. Patients were assessed over 12 months following drug-eluting stent(s) implantation, and received both clopidogrel and aspirin. Please note alleles have been complemented to the plus chromosomal strand.	clopidogrel
1183681314	CYP2C19*1; CYP2C19*2	PMID:24019397	CYP2C19	CYP2C19 *1/*2 is not associated with risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.	no	= 0.170	532		East Asian	Toxicity	false	Major adverse cardiac and cerebrovascular events consisted of death from any cause, non-fatal myocardial infarction or stroke during the 1 year follow-up period for patients on clopidogrel. Patients had previously undergone percutaneous coronary intervention. No significant difference in the risk for major adverse cardiac and cerebrovascular events was seen between the two genotype groups.	clopidogrel
1184471848	CYP2C19 poor metabolizer genotype	PMCID:PMC3048820	CYP2C19	CYP2C19 poor metabolizer genotype is associated with increased risk of cardiovascular death,myocardial infarction or stroke when treated with clopidogrel in people with percutaneous coronary intervention (most of the patients) as compared to CYP2C19 normal metabolizer genotype.	yes	= 0.002	9685		Multiple groups, Most of patients were White, but race information was not captured uniformly between the studies.	Efficacy	false	This result is for carriers of two reduced function alleles compared to no reduced function alleles.  Out of nine studies included in this meta-analysis, seven studies assayed for only *2(rs4244285); one study assayed for *2,*3(rs4986893), *4(rs28399504) and *5(rs56337013); one study assayed for *2,*3,*4,*5 and *8(rs41291556).  71.5% of the patients were non-carriers, 26.3% carried one reduced-function allele and 2.2% had two reduced-function alleles.	clopidogrel
1184348964	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24821368	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are not associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	no	= 0.538	249		East Asian	Toxicity	false	Cohort are coronary artery disease patients with diabetes mellitus carriers. there were no significant differences in platelet reactivity in patients having cardiovascular events between carrier and non-carrier in the DM group (Carriers (n = 34), 4288 ± 1435 AU*min; non-Carriers (n = 14), 4089 ± 1408 AU*min; P = 0.68) (Table 2). The following clinical events were noted in the DM: 4 versus 3 in cardiovascular death, 4 versus 4 in nonfatal MI, 2 versus 1 in stroke, 16 versus 6 in urgent revascularization, and 8 versus 0 in IPTE in Carriers versus non-Carriers in the DM group, respectively.	clopidogrel
981352394	rs4986893	PMID:19106083	CYP2C19	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.	yes	= 0.003	2208		European	Efficacy,Toxicity	false	Patients carrying any two CYP2C19 loss-of-function alleles (*2,*3,*4,*5) had a higher event(all cause death,nonfatal stroke, myocardial infarction) rate than patients with none.  Patients with one loss-of-function allele had a slightly lower risk in the overall population compared to those with none.  Stats given are for any two loe alleles vs. none.	clopidogrel
1446896521	rs6785930	PMID:26362473	P2RY12	Genotype AA is not associated with decreased response to clopidogrel as compared to genotype GG.	no	= 0.009	276		Latino	Efficacy	false	in a Mexican population undergoing percutaneous coronary intervention.	clopidogrel
1184471852	CYP2C19 intermediate metabolizer genotype	PMCID:PMC3048820	CYP2C19	CYP2C19 intermediate metabolizer genotype is associated with increased risk of Thrombosis when treated with clopidogrel in people with percutaneous coronary intervention (most of the patients) as compared to CYP2C19 normal metabolizer genotype.	yes	< 0.0001	5894		Multiple groups, Most of patients were White, but race information was not captured uniformly between the studies.	Efficacy	false	This result is for stent thrombosis in carriers of one reduced function allele compared to no reduced function alleles.  Six studies were included in this meta-analysis. Out of a larger group of nine studies, seven studies assayed for only *2(rs4244285); one study assayed for *2,*3(rs4986893), *4(rs28399504) and *5(rs56337013); one study assayed for *2,*3,*4,*5 and *8(rs41291556).	clopidogrel
1448530912	rs12041331	PMID:27450232	PEAR1	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.924	64	313	East Asian	Efficacy	false		clopidogrel
1183681338	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:24019397	CYP2C19	CYP2C19 *1/*17 + *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is not associated with risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1.	no	= 0.195	1656		East Asian	Toxicity	false	Major adverse cardiac and cerebrovascular events consisted of death from any cause, non-fatal myocardial infarction or stroke during the 1 year follow-up period for patients on clopidogrel. Patients had previously undergone percutaneous coronary intervention. No significant difference in the risk for major adverse cardiac and cerebrovascular events was seen between those with the *1/*1 genotype and any of the following genotypes: *1/*17, *1/*2, *1/*3, *2/*2, *2/*3 or *3/*3.	clopidogrel
982034226	rs4986893	PMID:19576320	CYP2C19	Allele A is associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to allele G.	yes	= 0.001	387		East Asian	Efficacy	false	Inclusion criteria: coronary artery disease, myocardial ischemia, angiographic evidence of >50% diameter stenosis, and postprocedure Thrombolysis In Myocardial Infarction flow grade 3.	clopidogrel
1184471843	CYP2C19 intermediate metabolizer genotype	PMCID:PMC3048820	CYP2C19	CYP2C19 intermediate metabolizer genotype is associated with increased risk of cardiovascular death,myocardial infarction or stroke when treated with clopidogrel in people with percutaneous coronary intervention (most of the patients) as compared to CYP2C19 normal metabolizer genotype.	yes	= 0.01	9685		Multiple groups, Most of patients were White, but race information was not captured uniformly between the studies.	Efficacy	false	This result is for carriers of one reduced function allele compared to having no reduced function alleles.  Out of nine studies included in this meta-analysis, seven studies assayed for only *2(rs4244285); one study assayed for *2,*3(rs4986893), *4(rs28399504) and *5(rs56337013); one study assayed for *2,*3,*4,*5 and *8(rs41291556).  71.5% of the patients were non-carriers, 26.3% carried one reduced-function allele and 2.2% had two reduced-function alleles.	clopidogrel
981802814	rs662	PMID:23346768	PON1	Allele C is not associated with maximum platelet aggregation (MPA) or the anti-platelet effect of clopidogrel in Chinese stroke patients when treated with clopidogrel in people with Stroke as compared to allele T.	no	= 0.91	170		East Asian	Efficacy	false		clopidogrel
1184469799	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:21075428	CYP2C19	CYP2C19 *1/*2 is not associated with response to aspirin and clopidogrel as compared to CYP2C19 *1/*3.	no		71	18	East Asian	Efficacy,Toxicity	false	There were 71 *1/*2 and 18 *1/*3.  Patients received a 300-mg loading dose of clopidogrel and aspirin at least 12 hours prior to percutaneous coronary intervention, and then 200 mg/day aspirin and 75 mg/day clopidogrel after that.  The comparison was based on the rate of HPR.  Determination of *2 was based upon genotype at rs4244285, and determination of *3 on genotype at rs4986893.	aspirin; clopidogrel
1448530920	rs1126643	PMID:27450232	ITGA2	Allele C is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	no	= 0.930	64	313	East Asian	Efficacy	false		clopidogrel
981802821	rs1045642	PMCID:PMC3467260	ABCB1	Genotypes AA + AG are associated with increased risk of major adverse cardiovascular events (MACE) (more than one year) when receiving a loading dose of 300 mg when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	= 0.01			Unknown	Toxicity	false	Meta-analysis included 10 studies that provided data on long-term MACE (more than one year). 2 studies provided data on a clopidogrel loading dose of 300mg.	clopidogrel
1184471896	rs4244285	PMID:20620727	CYP2C19	Genotypes AA + AG is associated with increased risk of Thrombosis when treated with clopidogrel as compared to genotype GG.	yes	< 0.001	4905		Multiple groups	Efficacy	false	In this 10 study meta-analysis, CYP2C19 *2 carriers had a 2.9% risk of stent thrombosis as compared to 0.9% risk for non-carriers.	clopidogrel
982034249	rs4244285	PMID:19576320	CYP2C19	Allele A is not associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to allele G.	no	= 0.227	387		East Asian	Efficacy	false	Inclusion criteria: coronary artery disease, myocardial ischemia, angiographic evidence of >50% diameter stenosis, and postprocedure Thrombolysis In Myocardial Infarction flow grade 3.	clopidogrel
1027543294	rs4244285	PMID:19108880	CYP2C19	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.	yes	= 6.0E-4	259		European	Efficacy,Toxicity	false	cardiovascular events defined as death, myocardial infarction, and urgent coronary revascularisation occurring during exposure to clopidogrel.	clopidogrel
1184990053	rs662	PMCID:PMC4199712	PON1	Allele T is not associated with response to clopidogrel in people with Coronary Artery Disease as compared to allele C.	no	= 0.622	211		East Asian	Efficacy	false		clopidogrel
1184349010	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMID:24782221	CYP2C19	CYP2C19 *1/*2 + *2/*17 (assigned as intermediate metabolizers phenotype) is associated with decreased mean peak plasma concentration of H4 when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 *1/*17 + *17/*17.	no	= 0.055	44		European	Metabolism/PK	false	after 75mg of Clopidogrel	clopidogrel
1184467794	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*4; CYP2C19*17	PMID:20965456	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *1/*4 + *2/*2 + *2/*3 is not associated with increased reduction in OTR when treated with aspirin and clopidogrel in people with coronary artery disease who had high on-therapy-reactivity after percutaneous intervention as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	no	= 0.4	40		Unknown	Efficacy	false	Genotyping was done for *2,*3,*4,*5,*6,*7,*8 and *17 alleles.  20 of the 41 patients were carriers of at least one Loss-of-function allele (*2,*3,*4).  One patient was  *2/*17 and was prospectively excluded from analysis.  There was a trend toward lesser reduction corresponding to carriage of loss-of-function alleles, and the patients who were homozygous for loss-of-function alleles had the least reduction in OTR, but this was not significant.	aspirin; clopidogrel
1184471892	rs4244285	PMID:20620727	CYP2C19	Genotypes AA + AG is associated with increased risk of Death when treated with clopidogrel as compared to genotype GG.	yes	< 0.019	6225		Multiple groups	Efficacy	false	In this 10 study meta-analysis, CYP2C19 *2 carriers had a 1.8% risk of death as compared to 1.0% risk for non-carriers.	clopidogrel
1184467784	rs1057910	PMID:20833683	CYP2C9	Genotypes AC + CC is associated with increased risk of stent thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary interventions as compared to genotype AA.	yes	= 0.043	176	420	Multiple groups, 3 high volume centers in the Netherlands (> 85% Caucasian)	Efficacy	false	Controls were consecutive patients who underwent PCI with stent implantation at one of the participating centers and who did not experience any adverse cardiovascular events within one year after stenting.  There was a stronger association when compared using subacute stent thrombosis.	aspirin; clopidogrel
1184348998	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMID:24782221	CYP2C19	CYP2C19 *1/*2 + *2/*17 (assigned as intermediate metabolizers phenotype) is associated with decreased mean peak plasma concentration of H4 when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 *1/*1.	yes	= 0.026	44		European	Metabolism/PK	false	after 75mg of Clopidogrel	clopidogrel
981239727	rs11188072	PMID:22940005		Allele T is not associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to allele C.	no	= 0.93	1327		Unknown	Toxicity	false	Cardiovascular events are primary outcome events (cardiac death and recurrent myocardial infarction).	aspirin; clopidogrel
1449147316	rs202121317	PMCID:PMC5637814	CES1	Allele C is not associated with enzyme activity of when assayed with clopidogrel and sacubitril in HEK cells as compared to allele A.	no	> 0.05			Unknown	Metabolism/PK	false	The SNP has no effect CES1 enzyme activity when assayed with clopidogrel, sacubitril.	clopidogrel; sacubitril
1184469836	CYP2C19*2; CYP2C19*3	PMID:21075428	CYP2C19	CYP2C19 *2/*2 is not associated with response to aspirin and clopidogrel as compared to CYP2C19 *2/*3.	no		18	8	East Asian	Efficacy,Toxicity	false	There were 18 *2/*2 and 8 *2/*3.  Patients received a 300-mg loading dose of clopidogrel and aspirin at least 12 hours prior to percutaneous coronary intervention, and then 200 mg/day aspirin and 75 mg/day clopidogrel after that.  The comparison was based on the rate of HPR.  Determination of *2 was based upon genotype at rs4244285, and determination of *3 on genotype at rs4986893.	aspirin; clopidogrel
981239721	rs1065776	PMID:22940005	P2RY1	Allele T is not associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to allele C.	no	= 0.71	1327		Unknown	Toxicity	false	Cardiovascular events are primary outcome events (cardiac death and recurrent myocardial infarction) during follow-up.	aspirin; clopidogrel
1447521170	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*8	PMCID:PMC4915569	CYP2C19	CYP2C19 *2 + *3 + *8 are associated with decreased risk of composite endpoints (transient ischemic attack (tia), stroke, myocardial infarction, or death) when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.0101	188		Multiple groups	Toxicity	false	within 12 months in patients with symptomatic intracranial atherosclerotic disease.	aspirin; clopidogrel
981802835	rs1045642	PMCID:PMC3467260	ABCB1	Genotypes AA + AG are not associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	no	= 0.84	3923		Unknown	Toxicity	false	Meta-analysis included 5 studies that provided data on myocardial infarction.	clopidogrel
1184471887	rs4244285	PMID:20620727	CYP2C19	Genotypes AA + AG is associated with increased risk of major adverse cardiovascular events when treated with clopidogrel as compared to genotype GG.	yes	< 0.001	11959		Multiple groups	Efficacy	false	In this 10 study meta-analysis, CYP2C19 *2 carriers had a 9.7% risk of major adverse cardiovascular events as compared to 7.8% risk for non-carriers.	clopidogrel
981802847	rs1045642	PMCID:PMC3467260	ABCB1	Genotypes AA + AG are not associated with increased risk of ischemic stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	no	= 0.93			Unknown	Toxicity	false	Meta-analysis included 5 studies that provided data on ischemic stroke.	clopidogrel
981239713	rs1126643	PMID:22940005	ITGA2	Allele T is not associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to allele C.	no	= 0.38	1327		Unknown	Toxicity	false	Cardiovascular events are primary outcome events (cardiac death and recurrent myocardial infarction) during follow-up.	aspirin; clopidogrel
1184467780	rs4244285	PMID:20833683	CYP2C19	Genotypes AA + AG is associated with increased risk of stent thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary interventions as compared to genotype GG.	yes	= 0.018	176	420	Multiple groups, 3 high volume centers in the Netherlands (> 85% Caucasian)	Efficacy	false	Controls were consecutive patients who underwent PCI with stent implantation at one of the participating centers and who did not experience any adverse cardiovascular events within one year after stenting.  40% of the cases had at least one *2 allele (AA or AG), compared with 29.5% of the controls (p = 0.013).  There was a stronger association when compared using subacute stent thrombosis.	aspirin; clopidogrel
982034280	rs2470890	PMID:19576320	CYP1A2	Allele T is not associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to allele C.	no	= 0.298	387		East Asian	Efficacy	false	Inclusion criteria: coronary artery disease, myocardial ischemia, angiographic evidence of >50% diameter stenosis, and postprocedure Thrombolysis In Myocardial Infarction flow grade 3.	clopidogrel
1447521191	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*8	PMCID:PMC4915569	CYP2C19	CYP2C19 *2 + *3 + *8 are associated with decreased risk of secondary composite endpoints (transient ischemic attack (tia), stroke, or death) when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.078	188		Multiple groups	Toxicity	false	in patients with symptomatic intracranial atherosclerotic disease.	aspirin; clopidogrel
1183681384	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:24019397	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3 + *2/*17 + *3/*17.	yes	= 0.009	532		East Asian	Toxicity	false	Major adverse cardiac and cerebrovascular events consisted of death from any cause, non-fatal myocardial infarction or stroke during the 1 year follow-up period for patients on clopidogrel. Patients had previously undergone percutaneous coronary intervention. This was a multivariable analysis. *2/*2, *2/*3 and *3/*3 were analyzed as a group (poor metabolizers) and *1/*1, *1/*17, *1/*2, *1/*3, *2/*17 and *3/*17 were analyzed as a group (intermediate and extensive metabolizers).	clopidogrel
1448119221	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:27380588	CYP2C19	CYP2C19 *2 + *3 are associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	< 0.001	136		East Asian	Efficacy	false	in Korean patients both prior and after percutaneous coronary interventions (PCI).	clopidogrel
982034287	rs2246709	PMID:19576320	CYP3A4	Genotypes AG + GG are not associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to genotype AA.	no	= 0.885	387		East Asian	Efficacy	false	Inclusion criteria: coronary artery disease, myocardial ischemia, angiographic evidence of >50% diameter stenosis, and postprocedure Thrombolysis In Myocardial Infarction flow grade 3.	clopidogrel
981239700	rs8069732	PMID:22940005		Allele C is not associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to allele T.	no	= 0.51	1327		Unknown	Toxicity	false	Cardiovascular events are primary outcome events (cardiac death and recurrent myocardial infarction).	aspirin; clopidogrel
1449147272	rs201065375	PMCID:PMC5637814	CES1	Allele A is associated with decreased metabolism of clopidogrel, enalapril and sacubitril in HEK cells as compared to allele G.	yes	< 0.001			Unknown	Metabolism/PK	false	The SNP abolished CES1 enzyme activity when assayed with enalapril, clopidogrel, sacubitril.	clopidogrel; enalapril; sacubitril
1184168830	CYP2C19*1; CYP2C19*2	PMID:23726091	CYP2C19	CYP2C19 *1/*2 + *2/*2 is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	= 0.004	500		East Asian	Efficacy	false	Patients with the *2 allele had an increased risk of high on-treatment platelet reactivity, as compared to those with the *1/*1 genotype. Reactivity was measured after 5 days maintenance dose of clopidogrel.	clopidogrel
982034276	rs1048943	PMID:19576320	CYP1A1	Allele C is not associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to allele T.	no	= 0.114	387		East Asian	Efficacy	false	Inclusion criteria: coronary artery disease, myocardial ischemia, angiographic evidence of >50% diameter stenosis, and postprocedure Thrombolysis In Myocardial Infarction flow grade 3.	clopidogrel
827714744	rs662	PMID:21918510	PON1	Genotype TT is not associated with increased risk of ischemic events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype CC.	no	= 0.58	1538		Unknown	Toxicity	false	The study cohort are clopidogrel-treated acute myocardial infarction patients, including patients undergoing percutaneous coronary intervention. events were in-hospital ischemic events.	clopidogrel
1448530872	rs1045642	PMID:27450232	ABCB1	Allele A is not associated with risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele G.	no	= 0.214	64	313	East Asian	Efficacy	false		clopidogrel
981802858	rs1045642	PMCID:PMC3467260	ABCB1	Genotypes AA + AG are not associated with all-cause mortality when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	no	= 0.62	3387		Unknown	Toxicity	false	Meta-analysis included 4 studies that provided data on all-cause mortality.	clopidogrel
1184990030	CYP2C19*1; CYP2C19*2	PMCID:PMC4199712	CYP2C19	CYP2C19 *2 is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.	yes	< 0.001	211		East Asian	Efficacy	false		clopidogrel
1448530854	rs8192950	PMID:27450232	CES1	Allele G is associated with decreased risk of Ischemic Attack, Transient and Stroke when treated with clopidogrel in people with Constriction, Pathologic as compared to allele T.	yes	= 0.029	64	313	East Asian	Efficacy	false		clopidogrel
981802868	CYP2C19*1; CYP2C19*2	PMID:23470885	CYP2C19	CYP2C19 *2 is associated with more frequent high platelet reactivity in Japanese patients in a steady state receiving dual antiplatelet therapy after coronary stent implantation when treated with clopidogrel as compared to CYP2C19 *1.	yes	< 0.05	155		East Asian	Efficacy	false	The loss of function alleles (*2 and *3) are analyzed together. CYP2C19 loss-of-function genotype alone could explain 12.2%, 14.3%, and 14.7% of the variability in the ADP-LTA, VASP and VerifyNow-P2Y12 assays, respectively.	clopidogrel
982034297	rs2242480	PMID:19576320	CYP3A4	Genotypes CT + TT are not associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to genotype CC.	no	= 0.512	387		East Asian	Efficacy	false	Inclusion criteria: coronary artery disease, myocardial ischemia, angiographic evidence of >50% diameter stenosis, and postprocedure Thrombolysis In Myocardial Infarction flow grade 3.	clopidogrel
1447521206	CYP2C19*1; CYP2C19*17	PMCID:PMC4915569	CYP2C19	CYP2C19 *17 is not associated with decreased risk of composite endpoints (transient ischemic attack (tia), stroke, myocardial infarction, or death) when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.89	188		Multiple groups	Toxicity	false	within 12 months in patients with symptomatic intracranial atherosclerotic disease.	aspirin; clopidogrel
981239689	rs1045642	PMID:22940005	ABCB1	Allele A is not associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to allele G.	no	= 0.91	1327		Unknown	Toxicity	false	Cardiovascular events are primary outcome events (cardiac death and recurrent myocardial infarction) during follow-up.	aspirin; clopidogrel
1184349025	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24781308	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are not associated with increased risk of elective PCI-related peri-procedural myocardial damage when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	no	> 0.05	91		East Asian	Toxicity	false	Multiple logistic regression analysis identified old age, high hemoglobin A1c level, and long stent, but not CYP2C19 reduced-function allele or high on-clopidogrel PA, as independent predictors of elective PCI-related MD.	clopidogrel
1184469857	CYP2C19*1; CYP2C19*2; CYP2C19*8; CYP2C19*17	PMCID:PMC2709885	CYP2C19	CYP2C19 *1/*2 + *1/*8 + *2/*2 (assigned as poor metabolizer genotype phenotype) is associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer genotype phenotype) .	yes	= 0.0015	46		European	Efficacy,Metabolism/PK	false	Active metabolite exposure was significantly lower with PM than with EM.  Patients were also treated with aspirin.   There were 37 EM (by genotype) and 9 PM (by genotype).  Dosage was 600 mg loading/75 mg maintenance.	clopidogrel
1449147288	rs143718310	PMCID:PMC5637814	CES1	Allele G is associated with decreased metabolism of when assayed with clopidogrel, enalapril and sacubitril in HEK cells as compared to allele T.	yes	< 0.05			Unknown	Metabolism/PK	false	The SNP caused a 50% in CES1 enzyme activity when assayed with enalapril, clopidogrel, sacubitril.	clopidogrel; enalapril; sacubitril
1184990042	CYP2C19*1; CYP2C19*3	PMCID:PMC4199712	CYP2C19	CYP2C19 *3 is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.	yes	= 0.002	211		East Asian	Efficacy	false		clopidogrel
981239680	rs662	PMID:22940005	PON1	Allele C is not associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to allele T.	no	= 0.23	1327		Unknown	Toxicity	false	Cardiovascular events are primary outcome events (cardiac death and recurrent myocardial infarction) during follow-up.	aspirin; clopidogrel
1449147295	rs200707504	PMCID:PMC5637814	CES1	Allele C is associated with decreased enzyme activity of when assayed with clopidogrel, enalapril and sacubitril in HEK cells as compared to allele T.	yes	< 0.001			Unknown	Metabolism/PK	false	The SNP caused a decrease in CES1 enzyme activity when assayed with enalapril (- 78.8%), clopidogrel (-82.3%), sacubitril (-80.3%).	clopidogrel; enalapril; sacubitril
655386898	rs4244285	PMCID:PMC3036672	CYP2C19	Allele A is associated with increased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	yes	= 0.0155	1454		European	Efficacy	false	(significance stated as per loss-of function CYP2C19 alleles)	clopidogrel
1451737220	rs3749187	PMCID:PMC8602039	ZDHHC3	Allele A is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele G.	yes	= 5.19E-6	1871		East Asian	Efficacy	false	Patients carrying the A allele were more likely to experience MACE in 18 months of follow-up.	aspirin; clopidogrel
655386901	rs4986893	PMCID:PMC3036672	CYP2C19	Allele A is associated with increased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	yes	= 0.0155	1454		European	Efficacy	false	(significance as per loss-of-function CYP2C19 allele)	clopidogrel
1447954507	rs1896832	PMCID:PMC4804508		Allele T is not associated with platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.16	674		East Asian	Efficacy	false		aspirin; clopidogrel
982037646	CYP2B6*5	PMID:21831410	CYP2B6	CYP2B6 *5 is associated with high on-treatment platelet reactivity in CYP2C19*1/*1 carriers when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to CYP2B6 *1.	yes	= 0.04	146		European	Efficacy	false	Patient were on dual treatment with aspirin. Platelet reactivity was assessed by the Verify Now P2Y12 point-of-care assay.	clopidogrel
982037635	rs4244285	PMID:21831410	CYP2C19	Allele A is associated with high on-treatment platelet reactivity when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to allele G.	yes	= 0.023	146		European	Efficacy	false	Patient were on dual treatment with aspirin. Platelet reactivity was assessed by the Verify Now P2Y12 point-of-care assay.	clopidogrel
1447954498	rs1801278	PMCID:PMC4804508	IRS1	Allele G is not associated with platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.59	674		East Asian	Efficacy	false		aspirin; clopidogrel
1450932340	rs2046934	PMID:31124414	P2RY12	Genotype AG is associated with increased likelihood of Death and Drug Resistance when treated with clopidogrel or prasugrel.	no		1		African American/Afro-Caribbean	Efficacy	false	in a single case study. Patient also was carrier of CYP2B6*6 and P2RY12 rs6787801 A/G	clopidogrel; prasugrel
1447954516	rs956115	PMCID:PMC4804508		Allele G is not associated with platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.15	674		East Asian	Efficacy	false		aspirin; clopidogrel
1450932320	rs6787801	PMID:31124414	P2RY12	Genotype AG is associated with increased likelihood of Death and Drug Resistance when treated with clopidogrel or prasugrel.	no		1		African American/Afro-Caribbean	Efficacy	false	in a single case study. Patient also was carrier of CYP2B6*6 and P2RY12 rs2046934 A/G	clopidogrel; prasugrel
1448601675	rs3732759	PMID:27566695	P2RY12	Genotype GG is associated with decreased response to clopidogrel in people with Coronary Disease as compared to genotypes AA + AG.	yes	< 0.05	24	154	East Asian	Efficacy	false		clopidogrel
655386894	rs1045642	PMCID:PMC3036672	ABCB1	Genotype AA is associated with increased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AG + GG.	yes	= 0.002	1454		European	Efficacy	false		clopidogrel
982033598	rs4986893	PMID:18346178	CYP2C19	Allele A is associated with decreased clopidogrel inhibition of ADP-induced platelet aggregation when treated with clopidogrel in healthy individuals as compared to genotype GG.	yes	< 0.05	18		East Asian	Efficacy	false	Study compared subjects homozygous for loss-of-function alleles (*2, *3) vs wild type *1/*1. The change in platelet aggregation was seen in response to 5 mmol/L ADP.  The change in ADP-induced platelet aggregation did not differ significantly when 2 mmol/L ADP was used (P > 0.05).	clopidogrel
827787114	rs4244285	PMID:22088980	CYP2C19	Genotype AG is associated with increased risk of significantly higher on-treatment platelet reactivity with a maintenance dose of 75 mg daily when treated with clopidogrel in people with Cardiovascular Diseases as compared to genotype GG.	yes	< 0.001	333		Unknown	Efficacy	false	"Among CYP2C19*2 heterozygotes (AG), higher clopidogrel maintenance doses (up to 300 mg) produced significant reductions in platelet reactivity (P < .001 for trend). The risk ratios for nonresponder status (defined as on-treatment platelet reactivity more or equal 230 PRU) were 0.51 (95% CI, 0.37-0.69), 0.21 (95% CI, 0.11-0.39), and 0.20 (95% CI, 0.11-0.38) with 150, 225, and 300 mg daily of clopidogrel, respectively. 
For CYP2C19*2 homozygotes (AA), even 300 mg daily of clopidogrel did not result in platelet reactivity levels similar to standard clopidogrel dosing in noncarriers."	clopidogrel
1448601704	rs659366	PMID:23621569	UCP2	Allele T is not associated with risk of when treated with clopidogrel in people with Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.57	405		East Asian	Toxicity	false		clopidogrel
1447954445	rs13431554	PMCID:PMC4804508	IRS1	Genotypes AG + GG are associated with increased platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to genotype AA.	yes	< 0.001	674		East Asian	Efficacy	false	The  G  allele  frequency  of  rs13431554  was  significantly  higher  in  the  high platelet reactivity (HPR) group  compared  with  the  non-HPR  group  (27.7  vs  18.6  %  in coronary artery disease (CAD) patients with type 2 diabetes mellitus (T2DM).	aspirin; clopidogrel
982033614	rs4986893	PMID:18323861	CYP2C19	Genotypes AA + AG are associated with decreased antiplatelet effect when treated with clopidogrel in healthy individuals as compared to genotype GG.	yes	= 0.001	24		East Asian	Efficacy	false	Study compared subjects carrying any loss-of-function alleles (*2, *3) vs wild type *1/*1.	clopidogrel
1451737280	rs140410716	PMCID:PMC8602039	ECHS1	Allele T is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele C.	yes	= 6.88E-6	1871		East Asian	Efficacy	false	Patients carrying the T allele were more likely to experience MACE in 18 months of follow-up.	aspirin; clopidogrel
1444706389	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:25891840	CYP2C19	CYP2C19 *2 + *3 is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 *1/*1.	yes	< 0.001	238		East Asian	Efficacy	false	Patients received 100 mg/day aspirin and 75 mg/day clopidogrel as a maintenance dose, after a loading dose of clopidogrel at 300 mg, in this prospective single-center study with a 3-month follow-up. The patients were prospectively assigned to intensification of treatment with esomeprazole (10–20 mg/day, n = 50) or conventional treatment with regular gastric medicine (teprenone at 150 mg/day, or histamine H2-receptor antagonist: famotidine at 10–20 mg/day, n = 311) at the day of the clopidogrel loading dose. The cohort was *2 and * 3 were genotyped. There were no differences in platelet reactivity between esomeprazole and non-esomeprazole groups according to CYP2C19 genotype.	clopidogrel
981478604	CYP2C19*1; CYP2C19*2	PMID:23150151	CYP2C19	CYP2C19 *2 is associated with decreased efficacy when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.	yes	= 0.005	670		East Asian	Efficacy	false	(Loss of function alleles *2 and *3 are grouped together for analysis).	clopidogrel
1448116253	rs662	PMID:26526111	PON1	Genotype CC is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to genotypes CT + TT.	no	= 0.326	209		European	Efficacy	false	All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting. Alleles given as G and A.	clopidogrel
1184747730	CYP2C19*2; CYP2C19*3	PMID:24504666	CYP2C19	CYP2C19 *2 + *3 is not associated with response to clopidogrel in people with Cardiovascular Diseases.	no	> 0.05	263		Unknown	Efficacy	false	Individuals that presented with a coronary event. Patients were classified as intermediate or poor metabolizers (IM, PM) depending on whether they carried one or two of these loss-of-function alleles (one = IM; two = PM). Neither IMs nor PMs showed an association with non-response to treatment. Patients who were re-hospitalized due to relapse of an acute coronary event within a one-year treatment period were defined as the non-responders (n=20). CYP2C19*2 LOF haplotypes (*2A, B, C and D) were detected by variation at rs4244285, showing similar allelic distributions within both groups, in the expected frequencies: 0.154 for the A allele, and 0.855 for the G allele. The CYP2C19*3 haplotypes (A and B) were defined by variation at rs4986893, and carried by 6 heterozygotes.	clopidogrel
981478609	CYP2C19*1; CYP2C19*3	PMID:23150151	CYP2C19	CYP2C19 *3 is associated with decreased efficacy when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.	yes	= 0.005	670		East Asian	Efficacy	false	(Loss of function alleles *2 and *3 are grouped together for analysis).	clopidogrel
1184747724	rs662	PMID:24504666	PON1	Genotype TT is not associated with response to clopidogrel in people with Cardiovascular Diseases as compared to genotypes CC + CT.	no	> 0.05	263		European	Efficacy	false	Individuals that presented with a coronary event. No association was seen between genotype and non-response to treatment. Patients who were re-hospitalized due to relapse of an acute coronary event within a one-year treatment period were defined as the non-responders (n=20). Please note alleles have been complemented to the plus chromosomal strand.	clopidogrel
981478613	CYP2C19*1; CYP2C19*2	PMID:23150151	CYP2C19	CYP2C19 *2 is associated with increased risk of composite ischemic events when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.	yes	= 0.056	670		East Asian	Toxicity	false	(Loss of function (LOF) alleles *2 and *3 are grouped together for analysis. p=0.056 for 1 LOF allele, P=0.007 for two LOF alleles.)	clopidogrel
982033630	rs4244285	PMID:18394438	CYP2C19	Allele A is associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	yes	= 0.03	603		Unknown	Efficacy	false		clopidogrel
981478617	CYP2C19*1; CYP2C19*3	PMID:23150151	CYP2C19	CYP2C19 *3 is associated with increased risk of composite ischemic events when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.	yes	= 0.056	670		East Asian	Toxicity	false	(Loss of function (LOF) alleles *2 and *3 are grouped together for analysis. p=0.056 for 1 LOF allele, P=0.007 for two LOF alleles.)	clopidogrel
1447954455	rs2251692	PMCID:PMC4804508		Allele G is not associated with platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.58	674		East Asian	Efficacy	false		aspirin; clopidogrel
981478621	rs1045642	PMID:23150151	ABCB1	Allele A is not associated with the antiplatelet effect or clinical outcomes of clopidogrel when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to allele G.	no	= 0.223	670		East Asian	Efficacy,Toxicity	false		clopidogrel
982033641	rs776746	PMID:18394438	CYP3A5	Allele C is not associated with differences in ADP-induced platelet aggregation, vasodilator-stimulated phosphoprotein phosphorylation index, and ADP-induced P-selectin expression when treated with clopidogrel in people with Acute coronary syndrome as compared to allele T.	no	= 0.67	603		Unknown	Efficacy	false	ADP-induced platelet aggregation (p=0.94), vasodilator-stimulated phosphoprotein phosphorylation index(p=0.81), and ADP-induced P-selectin expression (p=0.67)	clopidogrel
981478631	rs662	PMID:23150151	PON1	Allele T is not associated with the antiplatelet effect or clinical outcomes of clopidogrel when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to allele C.	no	= 0.963	670		East Asian	Efficacy,Toxicity	false		clopidogrel
1448601648	rs7428575	PMID:27566695	P2RY12	Allele G is not associated with response to clopidogrel in people with Coronary Disease as compared to allele T.	no	> 0.05	24	154	East Asian	Efficacy	false		clopidogrel
1447954471	rs10205923	PMCID:PMC4804508	IRS1	Allele G is not associated with platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.09	674		East Asian	Efficacy	false		aspirin; clopidogrel
1451342060	CYP2C19*1; CYP2C19*17	PMCID:PMC4104276	CYP2C19	CYP2C19 *17 is not associated with risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1.	no		1205		European	Toxicity	false	The study didnt explicitly reported a no association of *17 with bleeding risk for white TRIUMPH patients . However it stated that bleeding events were significantly more common among black carriers of CYP2C19*17.	clopidogrel
1448601657	rs2046934	PMID:27566695	P2RY12	Genotype AA is associated with increased response to clopidogrel in people with Coronary Disease as compared to genotypes AG + GG.	yes	< 0.05	24	154	East Asian	Efficacy	false		clopidogrel
1448417338	CYP2C19*1; CYP2C19*2	PMID:27767438	CYP2C19	CYP2C19 *1/*1 is associated with decreased likelihood of Recurrence when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*2 + *2/*2.	not stated		200		European	Efficacy	false	A reinfarction event occurred in 2.3% of the CYP2C19*1/*1 patients, as compared with 11.2% in the CYP2C19*1/*2 and CYP2C19*2/*2 patients arm. The average number of hospitalization days for the CYP2C19*1/*1 patients was estimated at 10.1 ± 6.5 days, compared with 11.0 ± 6.9 days in the CYP2C19*1/*2 and CYP2C19*2/*2 patients arm. Statistics were not shown, paper focused on cost/benefits of testing guided therapy options.	clopidogrel
1451737320	rs201441480	PMCID:PMC8602039	KRTAP10-4; TSPEAR	Allele A is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele C.	yes	= 7.26E-6	1871		East Asian	Efficacy	false	Patients carrying the A allele were more likely to experience MACE in 18 months of follow-up.	aspirin; clopidogrel
982033659	rs2740574	PMID:18394438	CYP3A4	Allele C is not associated with differences in ADP-induced platelet aggregation, vasodilator-stimulated phosphoprotein phosphorylation index, and ADP-induced P-selectin expression when treated with clopidogrel in people with Acute coronary syndrome as compared to allele T.	no	= 0.58	603		Unknown	Efficacy	false	ADP-induced platelet aggregation (p=0.94), vasodilator-stimulated phosphoprotein phosphorylation index(p=0.56), and ADP-induced P-selectin expression (p=0.58)	clopidogrel
1447954489	rs2288586	PMCID:PMC4804508	IRS1	Allele G is not associated with platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to allele C.	no	= 0.11	674		East Asian	Efficacy	false		aspirin; clopidogrel
1450127378	rs2487032	PMID:30487649		Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.	yes	= 3.46e-3	115		East Asian	Efficacy	false	This variant is associated with decreased Cmax, decreased AUC of clopidogrel, decreased H4 concentration, and decreased antiplatelet effects of clopidogrel with a higher PRU.	clopidogrel
1447954480	rs1078533	PMCID:PMC4804508	IRS1	Allele C is not associated with platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to allele A.	no	= 0.48	674		East Asian	Efficacy	false		aspirin; clopidogrel
982035468	rs1126643	PMID:16214444	ITGA2	Genotypes CT + TT are associated with increased platelet aggregation after stimuli with adenosine diphosphate, collagen, and epinephrine when treated with aspirin and clopidogrel in people with Coronary Disease as compared to genotype CC.	yes	< 0.05	82		Unknown	Efficacy	false	Patients had been on aspirin (100 mg/day) and clopidogrel (75 mg/day) therapy for ¿1 month. Platelet aggregation was assessed using light transmittance aggregometry after stimuli with adenosine diphosphate (20 micromol/L), collagen (6 microg/ml), and epinephrine (20 micromol/L).	aspirin; clopidogrel
1444706449	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:25897911	CYP2C19	CYP2C19 *2 + *3 is not associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	no	= 0.35	269		East Asian	Efficacy	false	The association was only found in patients younger 75 years. Patients older than or 75 years shown no association of CYP2C19 genotype with platelet reactivity differences. Dual treatment with aspirin and clopidogrel. *2 and *3 were genotyped.	clopidogrel
1444706434	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:25897911	CYP2C19	CYP2C19 *2 + *3 is associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	< 0.001	1135		East Asian	Efficacy	false	The association was only found in patients younger 75 years. Patients older than 75 years shown no association of CYP2C19 genotype with platelet reactivity differences. Dual treatment with aspirin and clopidogrel. *2 and *3 were genotyped.	clopidogrel
982033431	rs4244285	PMID:16772608	CYP2C19	Genotype AG is associated with decreased platelet responsiveness to clopidogrel when treated with clopidogrel in healthy individuals as compared to genotype GG.	yes	< 0.02	28		European	Efficacy	false	Platelet aggregation in the presence of 10 microM ADP decreased gradually during treatment with clopidogrel 75 mg once daily in GG (*1/*1) subjects but not in AG (*1/*2) subjects.	clopidogrel
1184473150	rs662	PMID:23993903	PON1	Genotypes CT + TT is associated with decreased relative inhibition of ADP-induced platelet aggregation when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to genotype CC.	yes	= 0.01	180		East Asian	Efficacy	false		aspirin; clopidogrel
1043765400	rs4244285	PMID:20650435	CYP2C19	Genotypes AA + AG are associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to genotype GG.	yes	= 0.018	126		East Asian	Efficacy	false		clopidogrel
982033467	rs4244285	PMID:17697139	CYP2C19	Genotype AG is associated with decreased platelet responsiveness to clopidogrel when treated with clopidogrel in healthy individuals as compared to genotype GG.	yes	= 0.02	28		European	Efficacy	false		clopidogrel
1451737140	rs74569896	PMCID:PMC8602039	NECAB1	Allele G is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele A.	yes	= 1.31E-6	1871		East Asian	Efficacy	false	Patients carrying the G allele were more likely to experience MACE in 18 months of follow-up.	aspirin; clopidogrel
982033457	rs2242480	PMID:17697139	CYP3A4	Allele C is not associated with clopidogrel responsiveness when treated with clopidogrel in healthy individuals as compared to allele T.	no	= 0.23	28		European	Efficacy	false		clopidogrel
1451737148	rs4736529	PMCID:PMC8602039	EFR3A	Allele G is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele C.	yes	= 2.52E-6	1871		East Asian	Efficacy	false	Patients carrying the C allele were more likely to experience MACE in 18 months of follow-up.	aspirin; clopidogrel
1444706464	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:25897911	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of Cardiovascular Diseases when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	= 0.01	1135		East Asian	Toxicity	false	Composite cardiovascular events, including cardiovascular death, acute or sub-acute stent thrombosis, recurrent ACS and ischemic stroke are summarizes as Cardiovascular Diseases. Dual treatment with aspirin and clopidogrel. *2 and *3 were genotyped.	clopidogrel
1184473178	CYP2C19*1; CYP2C19*2	PMID:23993903	CYP2C19	CYP2C19 *2/*2 is associated with decreased relative inhibition of ADP-induced platelet aggregation when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1.	yes	= 0.02	180		East Asian	Efficacy	false		aspirin; clopidogrel
982033484	rs4244285	PMID:18323861	CYP2C19	Genotypes AA + AG are associated with decreased antiplatelet effect when treated with clopidogrel in healthy individuals as compared to genotype GG.	yes	= 0.001	24		East Asian	Efficacy	false	Study compared subjects carrying any loss-of-function alleles (*2, *3) vs wild type *1/*1.	clopidogrel
1446906094	CYP3A5*1; CYP3A5*3	PMCID:PMC4833149	CYP3A5	CYP3A5 *1/*3 (assigned as intermediate metabolizer phenotype) is not associated with metabolism of clopidogrel in healthy individuals as compared to CYP3A5 *3/*3 (assigned as poor metabolizer phenotype) .	no	= 0.328	27		East Asian	Metabolism/PK	false	either when clopidogrel is administered alone or in combination with cilostazole. The authors observed no differences in AUC (ng*hr/ml) or Cmax (ng/ml) values of clopidogrel thiol metabolite when comparing between  CYP3A5 genotype groups. The differences in concentrations of clopidogrel thiol metabolite AUC, or Cmax between the CYP3A5 *1/*3 and CYP3A5 *3/*3 was not significant either when clopidogrel was administered alone or in combiation with cilostazole.	clopidogrel
1452023900	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMCID:PMC9931738	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 is associated with increased resistance to clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.	yes	< 0.001	93	119	East Asian	Efficacy	false	this was greater for the *2/*2+*2/*3 than *1/*2+*1/*3. Two patients with *17 (one was *2/*17 and other was *3/*17) were excluded from analysis.	clopidogrel
1444706496	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:25897911	CYP2C19	CYP2C19 *2 + *3 is associated with increased risk of Cardiovascular Diseases when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	= 0.04	269		East Asian	Toxicity	false	Composite cardiovascular events, including cardiovascular death, acute or sub-acute stent thrombosis, recurrent ACS and ischemic stroke are summarizes as Cardiovascular Diseases. Dual treatment with aspirin and clopidogrel. *2 and *3 were genotyped.	clopidogrel
1446906082	CYP3A5*1; CYP3A5*3	PMCID:PMC4833149	CYP3A5	CYP3A5 *1/*3 (assigned as intermediate metabolizer phenotype) is associated with metabolism of clopidogrel in healthy individuals.	yes	= 0.020	27		East Asian	Metabolism/PK	false	when clopidogrel is administered in combination with cilostazole. The authors observed no differences in AUC (ng*hr/ml) or Cmax (ng/ml) values of clopidogrel thiol metabolite when comparing between *1/*3 and *3/*3 diplotypes within the same treatment group. Differences in clopidogrel thiol metabolite concentrations were observed when comparing between treatment groups. When clopidogrel and cilostazole were co-administered, this caused a decrease in Cmax (ng/ml) and AUC (ng*hr/ml) within the CYP3A5 *1/*3 group as compared to when clopidogrel was administered alone.	clopidogrel
1444704450	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:25877345	CYP2C19	CYP2C19 *2 + *3 are associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	< 0.001			Unknown	Toxicity	false	"Twenty-two studies involving a total of 25564 CAD patients treated with clopidogrel contributed to this analysis. But the analysis was further stratified the studies by race. The number of patients per race was not reported. The outcome analyzed is recurrence of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction and non-fatal
ischemic stroke."	clopidogrel
1444696319	rs71647871	PMID:25704243	CES1	Genotypes CT + TT are associated with increased response to clopidogrel in healthy individuals as compared to genotype CC.	yes	= 0.036	22		European	Efficacy	false	The average inhibition of P2Y12 -mediated platelet aggregation 0-12 h after clopidogrel intake was 19% higher in the c.428G/A carriers than in noncarriers (P=0.036) suggesting the antiplatelet effect of clopidogrel was enhanced in subjects with the CES1 c.428G/A genotype.	clopidogrel
1184473201	rs662	PMID:23993903	PON1	Genotypes CT + TT is associated with increased non-responsiveness when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to genotype CC.	yes	= 0.02	180		East Asian	Efficacy	false		aspirin; clopidogrel
1444696308	rs71647871	PMID:25704243	CES1	Genotypes CT + TT are associated with increased exposure to clopidogrel in healthy individuals as compared to genotype CC.	yes	= 0.009	22		European	Metabolism/PK	false	The AUC of clopidogrel and Cmax of its active metabolite were 67% (P=0.009) and 63% (P=0.017) higher in subjects with the CES1 c.428G/A genotype than in those with the c.428G/G genotype, suggesting reduced  clopidogrel hydrolysis to inactive metabolites and increased antiplatelet effects.	clopidogrel
1184473205	CYP2C19*1; CYP2C19*2	PMID:23993903	CYP2C19	CYP2C19 *1/*2 + *2/*2 is associated with increased non-responsiveness when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1.	yes	= 0.04	180		East Asian	Efficacy	false		aspirin; clopidogrel
1444704497	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:25877345	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers phenotype) are associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	yes	< 0.001			Multiple groups	Toxicity	false	"Twelve studies reported PMs vs. EMs, PMs vs. IMs, and 14 studies reported IMs vs. EMs. The analysis was further stratified the studies by race. The number of patients per race or CYP2C19 metabolizer group was not reported. The outcome analyzed is recurrence of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction and non-fatal
ischemic stroke."	clopidogrel
1449140365	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	PMCID:PMC5775044	CYP2C19	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel.	yes	= 0.016	226	346	Multiple groups, 1416 patients in the cohort were white, 285 were black and 114 were classed as 'other'	Toxicity	false	Poor metabolizer and intermediate metabolizer genotypes are combined into a 'loss of function' (LOF) allele group. This was a multicenter study where all seven centers genotyped for the *2, *3 and *17 alleles and some of the centers carried out additional testing for some of the *4, *4B, *5, *6, *8, *9, *10, *12, *13 or *14 alleles. See Online Table 1 in the paper for further details.	clopidogrel
1448640683	rs2307240	PMCID:PMC5543069	CES1	Genotypes CT + TT are associated with increased response to clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	yes	< 0.001	845		East Asian	Efficacy	false	The authors investigated the association between genotypes and several clinical outcomes in patients with acute coronary syndrome who were also taking clopidogrel	clopidogrel
1451737200	rs75750968	PMCID:PMC8602039	AGAP3	Allele A is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele T.	yes	= 4.85E-6	1871		East Asian	Efficacy	false	Patients carrying the A allele were more likely to experience MACE in 18 months of follow-up.	aspirin; clopidogrel
982037616	rs1057910	PMID:21831410	CYP2C9	Allele C is not associated with differences in platelet reactivity and high on-treatment platelet reactivity when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to allele A.	no	= 0.3	146		European	Efficacy	false	Patient were on dual treatment with aspirin. Platelet reactivity was assessed by the Verify Now P2Y12 point-of-care assay.	clopidogrel
1184473186	rs662	PMID:23993903	PON1	Genotypes CT + TT is not associated with ADP-induced on treatment platelet aggregation (OTPR) when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to genotype CC.	no	= 0.41	180		East Asian	Efficacy	false		aspirin; clopidogrel
982033525	rs4244285	PMID:18346178	CYP2C19	Allele A is associated with decreased clopidogrel inhibition of ADP-induced platelet aggregation when treated with clopidogrel in healthy individuals as compared to genotype GG.	yes	< 0.05	18		East Asian	Efficacy	false	Study compared subjects homozygous for loss-of-function alleles (*2, *3) vs wild type *1/*1. The change in platelet aggregation was seen in response to 5 mmol/L ADP.  The change in ADP-induced platelet aggregation did not differ significantly when 2 mmol/L ADP was used (P > 0.05).	clopidogrel
1448634534	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMID:28589365	CYP2C19	CYP2C19 *1 + *17 are associated with decreased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *2.	yes	= 0.01	211		Unknown	Efficacy	false	In patients with stable coronary artery disease (SCAD) and elective percutaneous coronary intervention (PCI) multivariate analysis showed that *17 and *1 were associated with low on treatment platelet response (LTPR) versus  *2.	clopidogrel
1184473190	CYP2C19*1; CYP2C19*2	PMID:23993903	CYP2C19	CYP2C19 *2/*2 + *1/*2 is associated with increased ADP-induced on treatment platelet aggregation (OTPR) when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1.	yes	= 0.009	180		East Asian	Efficacy	false		aspirin; clopidogrel
1451090300	rs5853517	PMID:21349573	MED12L; P2RY12	Genotype TT is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel.	not stated		1		Unknown	Efficacy	false	Case study. Patient was homozygous for H2 haplotype (rs10935838AA, rs2046934GG, rs5853517TT, rs6809699AA). The high on-clopidogrel platelet reactivity was determine for the patient during long-term treatment with 75 mg/day clopidogrel and 75 mg/day aspirin after patient re-admitted for silent myocardial ischaemia. Patient  has the CYP2C19*1/*1 genotype.	clopidogrel
1449718123	CYP2C19*1; CYP2C19*17	PMID:29723426	CYP2C19	CYP2C19 *17 is not associated with response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	no	= 0.194	368		Unknown	Efficacy	false	Presence of the *3 allele was not associated with likelihood of readmission to hospital for an adverse cardiovascular event within the first year of antiplatelet therapy. *17 allele was determined by genotyping for the variant rs12248560.	aspirin; clopidogrel
1452024202	rs4244285	PMCID:PMC9951409	CYP2C19	Allele A is not associated with increased likelihood of Hemorrhage when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	no	= 0.901	37	526	East Asian	Toxicity	false	"""We defined the bleeding events based on the criteria of the Bleeding Academic Research Consortium (BARC)""""Bleeding was observed in 37 patients (6.6%): 21 (56.8%) had BARC type 2 and 16 (43.2%) had BARC type 3.""""The majority of bleeding events included epistaxis (15.4%), gingival hemorrhage (30.8%), subcutaneous hemorrhage (25.6%), and gastrointestinal hemorrhage (28.2%)."""	clopidogrel
1444704529	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:25877345	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers phenotype) are not associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	no	=  0.089			Unknown	Toxicity	false	"Compared to the Asian studies were all subjects underwent PCI, the studies in the Western population had a lower number of patients undergoing PCI. The exclusion of of Pare et al, the analysis showed significantly higher risk for MACE in Western subgroup, with RR being 1.57, 95% CI: 1.11–2.11, P=0.01. Twelve studies reported PMs vs. EMs, PMs vs. IMs, and 14 studies reported IMs vs. EMs. The analysis was further stratified the studies by race. The number of patients per race or CYP2C19 metabolizer group was not reported. The outcome analyzed is recurrence of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction and non-fatal
ischemic stroke."	clopidogrel
1451342220	CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:22552318	CYP2C19	CYP2C19 *17 is not associated with risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *2 + *3.	no	= 0.79	3851		Multiple groups	Toxicity	false	UM individuals did not have a higher risk of bleeding compared to PM/IM individuals RR 1.05 [95% confidence interval (CI): 0.72–1.53]. UM: carriers of no LoF alleles and one or more GoF allele, IM: carriers of one wild type and one LoF allele, PM: carriers of 2 LoF alleles	clopidogrel
1183697283	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:24214141	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with significantly delayed time to inhibition of platelet aggregation (IPA) when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .	yes	< 0.05	92		East Asian	Efficacy	false	"Time to inhibit IPA for PM vs IM vs. EM is : 12 vs. 9 vs. 2h as median Tmax. Delayed time to reach maximal IPA as well as decreased IPA may influence the increased risk of the acute cardiac events in CYP2C19 PM and IM. CYP2C19 extensive metabolizer (EM)  includes: CYP2C19EM; CYP2C19*1/*1
and heterozygous for CYP2C19*17 allele; CYP2C19
intermediate metabolizer (IM) includes: CYP2C19*1/*2 and CYP2C19*1/*3; CYP2C19 poor metabolizer (PM) includes: CYP2C19*2/*2, CYP2C19*2/*3
and CYP2C19*3/*3."	clopidogrel
1452024220	rs4986893	PMCID:PMC9951409	CYP2C19	Allele A is not associated with increased likelihood of Hemorrhage when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.	no	= 0.368	37	526	East Asian	Toxicity	false	"""We defined the bleeding events based on the criteria of the Bleeding Academic Research Consortium (BARC)""""Bleeding was observed in 37 patients (6.6%): 21 (56.8%) had BARC type 2 and 16 (43.2%) had BARC type 3.""""The majority of bleeding events included epistaxis (15.4%), gingival hemorrhage (30.8%), subcutaneous hemorrhage (25.6%), and gastrointestinal hemorrhage (28.2%)."""	clopidogrel
1451342224	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:22552318	CYP2C19	CYP2C19 *2 + *3 are not associated with risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.08	2515		Multiple groups	Toxicity	false	non-significant trend towards increased risk of bleeding for the PM/IM group compared to the EM group (RR 1.18 [95% CI: 0.98–1.42].  NM: carriers of 2 wild type alleles, IM: carriers of one wild type and one LoF allele, PM: carriers of 2 LoF alleles	clopidogrel
1451090280	rs2046934	PMID:21349573	MED12L; P2RY12	Genotype GG is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel.	not stated		1		Unknown	Efficacy	false	Case study. Patient was homozygous for H2 haplotype (rs10935838AA, rs2046934GG, rs5853517TT, rs6809699AA). The high on-clopidogrel platelet reactivity was determine for the patient during long-term treatment with 75 mg/day clopidogrel and 75 mg/day aspirin after patient re-admitted for silent myocardial ischaemia. Patient  has the CYP2C19*1/*1 genotype.	clopidogrel
1449187703	CYP2C19*1; CYP2C19*3	PMID:29397568	CYP2C19	CYP2C19 *3 is associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	= 0.046	168		East Asian	Toxicity	false	in patients with coronary heart disease who underwent PCI operation. The endpoint measured was cardiovascular ischemic events (cardiac death, recurrent thrombosis in stent confirmed by coronary angiography, recurrent unstable angina, and recurrent acute myocardial infarction).	clopidogrel
1446900004	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMCID:PMC4599525	CYP2C19	CYP2C19 *2 is not associated with likelihood of Hemorrhage when exposed to aspirin and clopidogrel in people with Stroke as compared to CYP2C19 *1 + *17.	not stated		493		Multiple groups	Efficacy,Other	false	The authors grouped patients with the *1/*1, *1/*17, and *17/*17 diplotypes and compared them to patients with the *1/*2, *2/*2 genotypes as extensive, ultra rapid metabolizers, intermediate metabolizers, and poor metabolizers, respectively. Primary safety outcome was major bleeding (serious or life threatening bleeding requiring transfusion of blood or surgery). Results are for patients randomized to receive aspirin and clopidogrel (dual anti platelet therapy). The results were not significant for the any group and there were no events in the African-American group.	aspirin; clopidogrel
1449296254	CYP2C19*2	PMCID:PMC5903579	CYP2C19	CYP2C19 *2 is associated with decreased response to clopidogrel.	yes	= 5.1E-40	5328		European	Efficacy	false	Validation of ICPC central database. CYP2C19*2 was associated with increased on-treatment platelet reactivity.	clopidogrel
1183697317	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:24214141	CYP2C19	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) is associated with significantly delayed time to inhibition of platelet aggregation (IPA) when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .	yes	< 0.05	92		East Asian	Efficacy	false	"Time to inhibit IPA for PM vs IM vs. EM is : 12 vs. 9 vs. 2h as median Tmax. Delayed time to reach maximal IPA as well as decreased IPA may influence the increased risk of the acute cardiac events in CYP2C19 PM and IM. CYP2C19 extensive metabolizer (EM)  includes: CYP2C19EM; CYP2C19*1/*1
and heterozygous for CYP2C19*17 allele; CYP2C19
intermediate metabolizer (IM) includes: CYP2C19*1/*2 and CYP2C19*1/*3; CYP2C19 poor metabolizer (PM) includes: CYP2C19*2/*2, CYP2C19*2/*3
and CYP2C19*3/*3."	clopidogrel
1445296396	CYP2C19*1; CYP2C19*17	PMID:25115434	CYP2C19	CYP2C19 *17/*17 + *1/*17 are associated with increased platelet aggregation inhibition when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.	yes	= 0.014	29		Unknown	Efficacy	false	Individuals with CYP2C19*17/*17 and CYP2C19*1/*17 genotype had significantly higher percentage inhibition of platelet aggregation compared with the CYP2C19*1/*1 subjects (geometric mean percentage inhibition of 84%, 73% and 63%, respectively; P = 0.014). However, this variant do not have significantly lower absolute P2Y12 receptor-activated platelet aggregation or higher exposure to the active metabolite after a single oral administration of 600 mg clopidogrel.	clopidogrel
1451090262	rs6809699	PMID:21349573	MED12L; P2RY12	Genotype AA is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel.	not stated		1		Unknown	Efficacy	false	Case study. Patient was homozygous for H2 haplotype (rs10935838AA, rs2046934GG, rs5853517TT, rs6809699AA). The high on-clopidogrel platelet reactivity was determine for the patient during long-term treatment with 75 mg/day clopidogrel and 75 mg/day aspirin after patient re-admitted for silent myocardial ischaemia. Patient  has the CYP2C19*1/*1 genotype.	clopidogrel
1446899985	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMCID:PMC4599525	CYP2C19	CYP2C19 *2 is associated with increased likelihood of Stroke when exposed to aspirin and clopidogrel in people with Stroke as compared to CYP2C19 *1 + *17.	not stated		493		Multiple groups	Efficacy,Other	false	The authors grouped patients with the *1/*1, *1/*17, and *17/*17 diplotypes and compared them to patients with the *1/*2, *2/*2 genotypes as extensive, ultra rapid metabolizers, intermediate metabolizers, and poor metabolizers, respectively. Primary outcome was time to recurrent stroke (ischemic or hemorrhagic).  Results are for patients randomized to receive aspirin and clopidogrel (dual anti platelet therapy). The results were not significant for the whole group but were significant for the White sub-group analysis. There were no events in the Hispanic group.	aspirin; clopidogrel
1449718085	CYP2C19*1; CYP2C19*3	PMID:29723426	CYP2C19	CYP2C19 *3 is not associated with response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	no	= 0.348	368		Unknown	Efficacy	false	Presence of the *3 allele was not associated with likelihood of readmission to hospital for an adverse cardiovascular event within the first year of antiplatelet therapy. *3 allele was determined by genotyping for the variant rs4986893.	aspirin; clopidogrel
1184000445	rs5985	PMCID:PMC4295494	F13A1	Genotype AA is associated with decreased fibrin clot formation time when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	yes	= 0.011	211		Multiple groups, 72% White;27% Black; 2% other	Efficacy	false	TEG K ( a measurement of clot formation) : 1.27 +/- 0.3 vs. 1.68 +/- 1.1 min for AA vs. CC.  The value for AC was intermediate.	aspirin; clopidogrel
1444704559	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMID:24402637	CYP2C19	CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	yes	< 0.001	74		European	Metabolism/PK	false	The *1/*1 (n=38) + *1/*17 + *17/*17 (*17 carrier n=21) group had significantly higher exposure to the clopidogrel active metabolite compared with the *1/*2 (n=14) + *2/*2 (n=1) group, as reflected in AUC(0-tlast) values (LSmeans 12.6 ng*h/ml vs 7.7 ng*h/ml, respectively; p<0.001). No patients had decreased/no function variants other than *2 (also genotyped for *3-*10 and *13).	clopidogrel
1183697338	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:24214141	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with decreased Cmax and AUC of thiol metabolite when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .	yes	< 0.01	92		East Asian	Metabolism/PK	false	"CYP2C19 extensive metabolizer (EM)  includes: CYP2C19EM; CYP2C19*1/*1
and heterozygous for CYP2C19*17 allele; CYP2C19
intermediate metabolizer (IM) includes: CYP2C19*1/*2 and CYP2C19*1/*3; CYP2C19 poor metabolizer (PM) includes: CYP2C19*2/*2, CYP2C19*2/*3
and CYP2C19*3/*3."	clopidogrel
1183631797	CYP2C19*1; CYP2C19*2	PMID:24088578	CYP2C19	CYP2C19 *2 is associated with increased On-clopidogrel platelet aggregation (PA) and higher platelet reactivity index (PRI) in patients undergoing elective percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.05	104		East Asian	Efficacy	false	The reduced function alleles CYP2C19*2 and *3 are pooled together in the analysis.	clopidogrel
1450824004	rs2242480	PMCID:PMC5306247	CYP3A4	Genotype C/T is not associated with metabolism of clopidogrel in people with Coronary Artery Disease as compared to genotype C/C.	no	> 0.293	82		European	Efficacy	false	No significant difference in concentrations of clopidogrel or its metabolites between genotype groups. The publication reports the finding for CYP3A4*1G. PharmVar re-assigned CYP3A4*1G to CYP3A4*36. Previously, this annotation used CYP3A4*36 which has been retired by PharmVar. All references to *36 have been replaced by rs2242480 alleles.	clopidogrel
827815445	rs12248560	PMID:22228204	CYP2C19	Genotypes CT + TT are associated with decreased magnitude of platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	yes	= 0.002	820		Unknown	Efficacy	false		clopidogrel
982042060	CYP2C19*2	PMCID:PMC3773276	CYP2C19	CYP2C19 *2 is associated with decreased clopidogrel active metabolite level when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1.	yes	= 3.3E-14	621		European	Metabolism/PK	false	CYP2C19*2 was strongly associated with decreased levels of clopidogrel active metabolite in both single SNP and multi-SNP association analysis (beta=-5.36, P=3.3x10-14 for single SNP; beta=-5.24, P=3.0x10-9 for multiple SNP analysis, respectively). Multiple-SNP analysis model includes both CYP2C19*2 and CYP2C19*17 in the model.	clopidogrel
1183631816	CYP2C19*1; CYP2C19*2	PMID:24088578	CYP2C19	CYP2C19 *2 is not associated with the levels of the coagulation or inflammatory biomarkers or serum cardiac biomarker hs-TnT when treated with clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.05	104		East Asian	Other	false	The reduced function alleles CYP2C19*2 and *3 are pooled together in the analysis.	clopidogrel
1450823997	rs2242480	PMCID:PMC5306247	CYP3A4	Genotype C/T is not associated with response to clopidogrel in people with Coronary Artery Disease as compared to genotype C/C.	no	= 0.484	82		European	Efficacy	false	No significant difference in platelet aggregation between genotype groups. The publication reports the finding for CYP3A4*1G. PharmVar re-assigned CYP3A4*1G to CYP3A4*36. Previously, this annotation used CYP3A4*36 which has been retired by PharmVar. All references to *36 have been replaced by rs2242480 alleles.	clopidogrel
1448995092	rs1128503	PMCID:PMC5373545	ABCB1	Genotypes AA + AG is associated with increased resistance to clopidogrel as compared to genotype GG.	yes	= 0.021	81	99	East Asian	Efficacy	false	Patients with genotype GG showed decreased platelet inhibtion compared to genotypes AA+AG. The authors than link increased platelet inhibition to increased resistance to clopidogrel.	clopidogrel
827815453	rs12248560	PMID:22228204	CYP2C19	Genotypes CT + TT are associated with increased risk of bleeding events when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	yes	= 0.039	820		Unknown	Toxicity	false	Patients with the ultrarapid metabolizer genotype (*1/*17 + *17/*17) exhibited a more than two-fold increased risk of major bleedings as compared with extensive metabolizers (hazard ratio 2.6, 95% CI: 1.0–6.4, P=0.046), which remained significant after adjustment for potential confounders [adjusted hazard ratio (HRadj) 2.7, 95% CI: 1.1–7.0, P = 0.039	clopidogrel
1183631808	CYP2C19*1; CYP2C19*3	PMID:24088578	CYP2C19	CYP2C19 *3 is associated with increased on-clopidogrel platelet aggregation (PA) and higher platelet reactivity index (PRI) in patients undergoing elective percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.05	104		East Asian	Efficacy	false	The reduced function alleles CYP2C19*2 and *3 are pooled together in the analysis.	clopidogrel
1448603929	CYP2C19*1; CYP2C19*2	PMCID:PMC4997918	CYP2C19	CYP2C19 *2/*2 is not associated with increased inhibition of CYP2C19 when treated with clopidogrel as compared to CYP2C19 *1/*1.	no	> 0.05	90		Near Eastern	Efficacy	false	The VerifyNow® (Accumetrics, Sandigo, CA) assay was used to detect PRU values to determine the level of inhibition.  There was no significant change detected at the assay time point, which was two to three days following admission.	clopidogrel
1184516565	CYP2C19*1; CYP2C19*10; CYP2C19*13; CYP2C19*14; CYP2C19*15; CYP2C19*18; CYP2C19*19; CYP2C19*23; CYP2C19*25; CYP2C19*26	PMID:25001882	CYP2C19	CYP2C19 *10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26 are associated with decreased catalytic activity of CYP2C19 when exposed to clopidogrel in cos-7 cells as compared to CYP2C19 *1.	yes	< 0.005			Unknown	Metabolism/PK	false	The Km, Vmax and CLint values for clopidogrel 2-oxidation were measured and compared to *1B. Although differences in Vmax compared to *1B are found for *1A, *10, *13, *14, *15, *18, *19, *23, *25, *26, the Km value only differed for *19 and *26. The clearance was affected for *10, *14, *19, *23, *25, *26. Please note the article separated *1A and *1B.	clopidogrel
1184000450	rs5985	PMCID:PMC4295494	F13A1	Genotypes AA + AC is associated with increased risk of Myocardial Infarction when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	yes	= 0.008	211		Multiple groups, 72% White;27% Black; 2% Other	Efficacy	false	The highest event rate was in subjects with genotype AA.	aspirin; clopidogrel
769182345	rs28399504	PMCID:PMC3310336	CYP2C19	Allele G is associated with decreased metabolism of clopidogrel in people with CYP2C19*17 (rs12248560 T) as compared to allele A.	no		250		European	Other	false	This SNP modifies the UM phenotype of CYP2C19*17 to the PM allele CYP2C19*4B.	clopidogrel
1451090220	rs10935838	PMID:21349573	MED12L; P2RY12	Genotype AA is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel.	not stated		1		Unknown	Efficacy	false	Case study. Patient was homozygous for H2 haplotype (rs10935838AA, rs2046934GG, rs5853517TT, rs6809699AA). The high on-clopidogrel platelet reactivity was determine for the patient during long-term treatment with 75 mg/day clopidogrel and 75 mg/day aspirin after patient re-admitted for silent myocardial ischaemia. Patient  has the CYP2C19*1/*1 genotype.	clopidogrel
1183848900	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMID:24576527	CYP2C19	CYP2C19 *1/*17 + *1/*2 + *17/*17 + *2/*17 are not associated with platelet aggregation activity as measured by the VerifyNow P2Y12 test when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	no	= 0.77	50		American	Efficacy	false	There was no significant effect of CYP2C19 genotype on platelet aggregation as measured by the VerifyNow P2Y12 test (P = .77). The allele frequencies for CYP2C19*2 and CYP2C19*17 in the population group were 11% (95% CI 7%-16%) and 9% (95% CI 5%-13%), respectively.	aspirin; clopidogrel
1184000455	rs5985	PMCID:PMC4295494	F13A1	Genotypes AA + AC is associated with increased risk of Death when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to genotype CC.	yes	= 0.006	211		Multiple groups, 72% White;27% Black; 2% Other	Efficacy	false	This result is for increased occurence of Myocardial Infarction and Cardiovascular Death.  The highest event rate was in subjects with genotype AA.	aspirin; clopidogrel
982023647	CYP2C19*2	PMID:23692149	CYP2C19	CYP2C19 *2 is associated with ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing pe rcutaneous coronary intervention when treated with clopidogrel as compared to CYP2C19 *1.	yes	= 0.001	617		East Asian	Efficacy	false	CYP2C19*2 and *3 are analyzed together.	clopidogrel
1183703514	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:22974728	CYP2C19	CYP2C19 *2 + *3 is associated with increased on-clopidogrel platelet reactivity (HPR) when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	< 0.001	424		East Asian	Efficacy	false		clopidogrel
1183703509	rs662	PMID:22974728	PON1	Genotypes CT + TT is associated with increased ADP-induced platelet aggregation when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	yes	= 0.027	424		East Asian	Efficacy	false	PON1 QQ/QR192 patients (T allele carriers) were also more likely to be classified as high on-clopidogrel platelet reactivity (HPR) than PON1 RR192 patients (CC genotype).	clopidogrel
1184987641	CYP2C19*1; CYP2C19*2	PMID:24508947	CYP2C19	CYP2C19 *2 is associated with decreased response to clopidogrel as compared to CYP2C19 *1.	yes	= 0.001	617		East Asian	Efficacy	false	in percutaneous coronary intervention-treated patients. The response was measured by adenosine diphosphate-induced maximum platelet aggregation (MPA) on day 3 after initiation of daily clopidogrel maintenance doses.	clopidogrel
1183631824	CYP2C19*1; CYP2C19*3	PMID:24088578	CYP2C19	CYP2C19 *3 is not associated with the levels of the coagulation or inflammatory biomarkers or serum cardiac biomarker hs-TnT in patients undergoing elective percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.05	104		East Asian	Other	false	The reduced function alleles CYP2C19*2 and *3 are pooled together in the analysis.	clopidogrel
827815433	rs4244285	PMID:22228204	CYP2C19	Genotypes AA + AG are associated with increased risk of on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	< 1.0E-4	820		Unknown	Efficacy	false	The diplotypes *2/*17, *1/*2, and *2/*2 are associated with increased on-treatment platelet reactivity; however, this is not translated into a lower risk of bleeding events.	clopidogrel
982023639	rs4793665	PMID:23692149	ABCC3	Genotypes CC + CT are not associated with ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing percutaneous coronary intervention when treated with clopidogrel as compared to genotype TT.	no	= 0.539	249		East Asian	Efficacy	false	The study was conducted in a cohort of 249 Chinese patients not carrying the CYP2C19*2, *3, or *17 variant.	clopidogrel
1184516601	CYP2C19*1; CYP2C19*28	PMID:25001882	CYP2C19	CYP2C19 *28 is associated with increased catalytic activity of CYP2C19 when exposed to clopidogrel in cos-7 cells as compared to CYP2C19 *1.	yes	< 0.005			Unknown	Metabolism/PK	false	association compared to *1B. Please note the article separated between *1A and *1B. While the Vmax was increased compared to *1B the Vmax for *1A was decreased compared to *1B. For both * alleles no-significant difference was shown for Km values.	clopidogrel
982023661	rs4793665	PMID:23692149	ABCC3	Genotypes CC + CT are not associated with risk of stent thrombosis (ST) when treated with clopidogrel as compared to genotype TT.	no	= 0.76	249		East Asian	Toxicity	false	The study was conducted in a cohort of 249 Chinese patients not carrying the CYP2C19*2, *3, or *17 variant.	clopidogrel
982042094	CYP2C19*2	PMCID:PMC3773276	CYP2C19	CYP2C19 *2 is associated with increased post-treatment ADP-stimulated platelet aggregation when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1.	yes	= 2.9E-16	621		European	Efficacy	false	CYP2C19*2 was strongly associated with increased post-treatment ADP-stimulated platelet aggregation in both single SNP and multi-SNP association analysis (beta=7.55, P=2.9x10-16 and beta=7.51, P=7.0x10-15, respectively). Multiple-SNP analysis model includes both CYP2C19*2 and CYP2C19*17 in the model.	clopidogrel
1183703525	rs662	PMID:22974728	PON1	Genotypes CT + TT is associated with increased on-clopidogrel platelet reactivity (HPR) when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype CC.	yes	< 0.014	424		East Asian	Efficacy	false		clopidogrel
982023653	CYP2C19*3	PMID:23692149	CYP2C19	CYP2C19 *3 is associated with ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing pe rcutaneous coronary intervention when treated with clopidogrel as compared to CYP2C19 *1.	yes	= 0.001	617		East Asian	Efficacy	false	CYP2C19*2 and *3 are analyzed together.	clopidogrel
982042087	CYP2C19*17	PMCID:PMC3773276	CYP2C19	CYP2C19 *17 is not associated with clopidogrel active metabolite level when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1.	no	= 0.04	621		European	Metabolism/PK	false	"independently from CYP2C19*2.
CYP2C19*17 was only marginally associated with levels of clopidogrel active metabolite in single SNP (beta=1.57, P=0.04) analysis, but not in multi-SNP association analysis (beta=0.40, P=0.59) after adjustment for the CYP2C19*2 variant. Multiple-SNP analysis model includes both CYP2C19*2 and CYP2C19*17 in the model."	clopidogrel
1449718023	CYP3A5*1; CYP3A5*3	PMID:29723426	CYP3A5	CYP3A5 *3 is not associated with response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP3A5 *1.	no	= 0.506	368		Unknown	Efficacy	false	Presence of the *3 allele was not associated with likelihood of readmission to hospital for an adverse cardiovascular event within the first year of antiplatelet therapy. *3 allele was determined by genotyping for the variant rs776746.	aspirin; clopidogrel
982023672	CYP2C19*1; CYP2C19*3	PMID:23692149	CYP2C19	CYP2C19 *3 is associated with increased risk of stent thrombosis when treated with clopidogrel as compared to CYP2C19 *1.	yes	= 0.019	617		East Asian	Toxicity	false	after 1 year. CYP2C19*2 and *3 are analyzed together.	clopidogrel
1183705597	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24535487	CYP2C19	CYP2C19 *2 + *3 are associated with increased risk of on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 *1/*1.	yes	= 0.004	162		East Asian	Efficacy	false	"Patients were treated with aspirin and clopidogrel. CYP2C19 *2 and *3 were genotyped. The PRI increased 
according to the CYP2C19 genotype (43.81±18.17,
51.10±18.59, and 58.29±17.91% in the EM, IM, and
PM individuals, respectively, P=0.004)"	clopidogrel
1449718041	CYP2C19*1; CYP2C19*2	PMID:29723426	CYP2C19	CYP2C19 *2 is not associated with response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.	no	= 0.219	368		Unknown	Efficacy	false	The presence of the *2 allele was not associated with likelihood of readmission to hospital for an adverse cardiovascular event within the first year of antiplatelet therapy. *2 allele was defined by genotyping for the variant rs4244285.	aspirin; clopidogrel
981679601	rs12041331	PMCID:PMC3715320	PEAR1	Allele A is associated with decreased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration when treated with aspirin and clopidogrel as compared to allele G.	yes	= 7.66E-9	565		European	Efficacy	false	In PAPI participants with 0, 1, and 2 copies of the rs12041331 minor allele (A), collagen stimulated platelet aggregation was reduced to 25.0%, 14.6%, and 7.0% of baseline in response to DAPT, respectively.	aspirin; clopidogrel
1445296466	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:25175362	CYP2C19	CYP2C19 *1/*1 is associated with decreased platelet reactivity when treated with clopidogrel in people with as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.	yes	< 0.0001	114		East Asian	Efficacy	false	Platelet reactivity measured using VerifyNow-P2Y12. The first channel of the device shows P2Y12 Reaction Units (PRU), the second channel shows BASE (estimate of patient's baseline platelet function independent of P2Y12 receptor inhibiton), and %Inihibition calculated as ([BASE-PRU]/BASE) x 100 and indicates the difference between pre- and post-clopidogrel treatment platelet reactivities. Significant results were seen for PRU and %Inhibition, but not BASE. PRU: *1/*1 < *1/*2 + *1/*3 < *2/*2 + *2/*3 + *3/*3; %Inhibition: *1/*1 > *1/*2 + *1/*3 > *2/*2 + *2/*3 + *3/*3.	clopidogrel
981679610	rs12041331	PMCID:PMC3715320	PEAR1	Genotypes AA + AG are associated with increased cardiovascular events in patients undergoing PCI when treated with aspirin and clopidogrel as compared to genotype GG.	yes	= 0.059	144		European	Toxicity	false		aspirin; clopidogrel
982023666	CYP2C19*1; CYP2C19*2	PMID:23692149	CYP2C19	CYP2C19 *2 is associated with increased risk of stent thrombosis (ST) after 1 year when treated with clopidogrel as compared to CYP2C19 *1.	yes	= 0.019	617		East Asian	Toxicity	false	CYP2C19*2 and *3 are analyzed together.	clopidogrel
1444704608	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMID:24402637	CYP2C19	CYP2C19 *1/*2 + *2/*2 are associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.	yes	< 0.05	74		European	Efficacy	false	"PRU values were significantly lower in EMs compared to IMs +PM (LS means
158 vs 212; p=0.003) determined with the VerifyNow assay. Likewise, during clopidogrel (75 mg/day) administration, VASP PRI values were lower in EMs than in IMs +PM determined with the VASP assay.
(LS means: 48% vs 63%; p=0.01)"	clopidogrel
982042102	CYP2C19*17	PMCID:PMC3773276	CYP2C19	CYP2C19 *17 is not associated with post-treatment ADP-stimulated platelet aggregation when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1.	no	= 0.01	621		European	Efficacy	false	"independently from CYP2C19*2.
CYP2C19*17 was only marginally associated with post-treatment ADP-stimulated platelet aggregation in single SNP (beta=-1.98, P=0.01) analysis, but not in multi-SNP association analysis (beta=-0.13, P=0.69) after adjustment for the CYP2C19*2 variant. Multiple-SNP analysis model includes both CYP2C19*2 and CYP2C19*17 in the model."	clopidogrel
1449165280	rs12248560	PMID:29260275	CYP2C19	Allele T is not associated with risk of Hemorrhage when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.	no	= 0.107	53	55	European	Other,Toxicity	false		clopidogrel
1444667802	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24440142	CYP2C19	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are associated with increased risk of Cardiovascular Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	yes	= 0.029	174		East Asian	Toxicity	false	Cardiovascular events include cardiovascular death, nonfatal myocardial infarction, unstable angina, ischemic stroke, or coronary revascularization to new lesions. Event rate is 12.7% for IM and 1.6% for EM.	clopidogrel
982033674	rs4244285	PMID:18482659	CYP2C19	Genotypes AA + AG are associated with increased risk of high-on clopidogrel platelet reactivity when treated with clopidogrel in patients undergoing elective coronary stent placement as compared to genotype GG.	yes	< 0.001	797		Unknown	Efficacy	false	Residual platelet aggregation >14% at pre-discharge incurred a 3.0-fold increase (95% confidence interval 1.4 to 6.8; p = 0.004) in the 1-year incidence of death and myocardial infarction.	clopidogrel
1449165287	rs11568732	PMID:29260275	CYP2C19	Allele G is associated with increased risk of Hemorrhage when treated with clopidogrel in people with Myocardial Infarction as compared to allele T.	no	= 0.025	53	55	European	Other,Toxicity	false	Association of the variant with higher risk of bleeding remained significant after adjustment for presence of the CYP2C19*2 allele (OR 3.52; 95% CI, 1.05–11.89; p = 0.042).	clopidogrel
982035715	rs5918	PMID:16458133	ITGB3	Genotype CT is not associated with differences in platelet inhibition when exposed to clopidogrel in people with Coronary Artery Disease as compared to genotype TT.	no		20		Unknown	Efficacy	false		clopidogrel
981351920	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMCID:PMC3376439	CYP2C19	CYP2C19 *2/*3 is associated with increased high on-treatment platelet reactivity when treated with aspirin, cilostazol and clopidogrel in high risk patients (acute myocaridal infarction, diabetes e.g.) as compared to CYP2C19 *1/*1.	yes	< 0.028	127		East Asian	Metabolism/PK	false		aspirin; cilostazol; clopidogrel
981351915	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMCID:PMC3376439	CYP2C19	CYP2C19 *2/*3 is associated with increased maximal platelet aggregation when treated with aspirin, cilostazol and clopidogrel in high risk patients (acute myocaridal infarction, diabetes e.g.) as compared to CYP2C19 *1/*1.	yes	< 0.007	127		East Asian	Metabolism/PK	false		aspirin; cilostazol; clopidogrel
1451737380	rs4244285	PMCID:PMC8602039	CYP2C19	Allele A is not associated with risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele G.	no	= 0.044	168		East Asian	Efficacy	false	No significant association between this variant and risk of MACE over an 18 month follow-up period. This is the defining variant of the CYP2C19*2 allele.	aspirin; clopidogrel
1444704692	CYP2C19*1; CYP2C19*2	PMID:24856643	CYP2C19	CYP2C19 *2 is associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.	yes	= 0.045	137		European	Efficacy	false	multivariate linear regression analysis for high on-treatment platelet reactivity was preformed. We included diabetes type II, smoking status, comedication with proton pump inhibitors, use of acetylic salicylic acid and P2Y 12 receptor blocker pre-treatment and type of loading, CYP2C19*2 allele carrier status as fixed factors and age, GFR, platelet count and pre-treatment platelet reactivity as covariates with on-treatment platelet reactivity as dependent variable. In this model, the CYP2C19*2 allele carrier status, loading with different types of P2Y 12 receptor blockers and platelet count were significant predictors of on-treatment platelet reactivity.	clopidogrel
982033700	rs6785930	PMID:15933261	P2RY12	Allele A is associated with increased risk of neurological events when treated with clopidogrel in people with Peripheral Vascular Diseases as compared to genotype GG.	yes	= 0.038	137		Unknown	Efficacy	false	Neurological events defined as stroke, carotid stenting, carotid endarterectomy.	clopidogrel
1444667831	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24440142	CYP2C19	CYP2C19 *2/*2 + *3/*3 + *2/*3 (assigned as poor metabolizers phenotype) are associated with increased risk of Cardiovascular Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	yes	= 0.04	174		East Asian	Toxicity	false	Cardiovascular events include cardiovascular death, nonfatal myocardial infarction, unstable angina, ischemic stroke, or coronary revascularization to new lesions. Event rate is 12.5% for PM and 1.6% for EM.	clopidogrel
1450928591	rs12041331	PMID:28820077	PEAR1	Genotypes AA + AG are associated with increased response to aspirin, clopidogrel or prasugrel as compared to genotype GG.	yes	< 0.00001	5466		Multiple groups, European, African American and East Asian ancestries	Efficacy	false	The AA genotype was associated with lower platelet aggregation compared to the AG or GG genotypes, while the AG genotype was associated with lower platelet aggregation compared to the GG genotype.	aspirin; clopidogrel; prasugrel
982029617	rs2046934	PMID:23751603	P2RY12	Genotypes AG + GG are associated with increased platelet activation response to ADP when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype AA.	yes	< 0.001	40	40	Unknown	Efficacy	false	This study showed that there is statistically significant difference between responders vs. non-responders with  higher expression of the G allele (GG or AG genotype) among non-responders than responders (p<0.001).	clopidogrel
1451737402	rs4986893	PMCID:PMC8602039	CYP2C19	Allele A is not associated with risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele G.	no	= 0.176	168		East Asian	Efficacy	false	No significant association between this variant and risk of MACE over an 18 month follow-up period. This is the defining variant of the CYP2C19*3 allele.	aspirin; clopidogrel
1451737411	rs1057910	PMCID:PMC8602039	CYP2C9	Allele C is not associated with risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele A.	no	= 0.686	1703		East Asian	Efficacy	false	No significant association between this variant and risk of MACE over an 18 month follow-up period. This is the defining variant of the CYP2C9*3 allele.	aspirin; clopidogrel
1451116983	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	PMCID:PMC6946839	CYP2C19	CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with percutaneous coronary intervention.	yes	< 0.001	1493		Multiple groups, 20.1% African American	Toxicity	false	As compared to IM or PM patients treated with prasugel or ticagrelor.	clopidogrel
1184467283	CYP2C19*1; CYP2C19*2	PMID:23402725	CYP2C19	CYP2C19 *2/*2 + *1/*2 is associated with increased likelihood of major adverse cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	= 0.05	289		Unknown	Toxicity	false	The association is marginal (p=0.05). The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke or hospitalization for cardiovascular causes including stroke, severe recurrent cardiac ischemia, recurrent cardiac ischemia, transient ischemic attack, or other arterial thrombotic event during follow up.	clopidogrel
1449187754	CYP2C19*1; CYP2C19*2	PMID:29397568	CYP2C19	CYP2C19 *2 is not associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	no	= 0.116	168		East Asian	Efficacy	false	in patients with coronary heart disease who underwent PCI operation.	clopidogrel
1451737420	rs1045642	PMCID:PMC8602039	ABCB1	Allele A is not associated with risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele G.	no	= 0.321	1703		East Asian	Efficacy	false	No significant association between this variant and risk of MACE over an 18 month follow-up period. Please note that alleles have been complemented to the positive strand.	aspirin; clopidogrel
1450129827	rs4244285	PMID:30487649	CYP2C19	Genotypes AA + AG is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotype GG.	yes	= 1.66e-5	115		East Asian	Efficacy	false	This variant is associated with decreased H4 concentration, and decreased antiplatelet effects of clopidogrel with a higher PRU.	clopidogrel
982037849	rs1045642	PMID:21831410	ABCB1	Allele A is not associated with differences in platelet reactivity and high on-treatment platelet reactivity when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to allele G.	no	= 0.7	146		European	Efficacy	false	Patient were on dual treatment with aspirin. Platelet reactivity was assessed by the Verify Now P2Y12 point-of-care assay.	clopidogrel
1451737429	rs662	PMCID:PMC8602039	PON1	Allele T is not associated with risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele C.	no	= 0.0036	1871		East Asian	Efficacy	false	No significant association between this variant and risk of MACE over an 18 month follow-up period. Please note that alleles have been complemented to the positive strand.	aspirin; clopidogrel
1444667855	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24440142	CYP2C19	CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizers phenotype) are associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	yes	= 0.0037	174		East Asian	Efficacy	false	On-treatment platelet reactivity was  3560 ± 1404 in EM and 4203 ± 1302 in IM.	clopidogrel
1449187765	rs1045642	PMID:29397568	ABCB1	Allele A is not associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	no	= 0.188	168		East Asian	Efficacy	false	in patients with coronary heart disease who underwent PCI operation.	clopidogrel
982037840	rs6787801	PMID:21831410	P2RY12	Genotypes AG + GG are associated with high on-treatment platelet reactivity in CYP2C19*1/*1 carriers when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to genotype AA.	yes	= 0.04	146		European	Efficacy	false	Patient were on dual treatment with aspirin. Platelet reactivity was assessed by the Verify Now P2Y12 point-of-care assay.	clopidogrel
1444704705	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:25529343	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizers phenotype) is associated with decreased response to clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.	yes	< 0.001	76		East Asian	Efficacy	false	Response as defined by increase in early ischemic lesion recurrence detected on diffusion-weighted imaging. Early ischemic lesion recurrence were observed more frequently in IMs (*1/*2 and *1/*3) than in EMs although not significantly ( P = .053)	clopidogrel
1448634758	CYP2C19*1; CYP2C19*2	PMCID:PMC5813097	CYP2C19	CYP2C19 *2 is associated with increased risk of Arterial Occlusive Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1.	yes	= 0.015	94		European	Toxicity	false	The primary endpoint is recurrent arterial thrombo-occlusive event (ATO) or death.	clopidogrel
1184467270	CYP2C19*1; CYP2C19*2	PMID:23402725	CYP2C19	CYP2C19 *2/*2 is associated with increased PRU when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*2.	yes	= 0.045	353		Unknown	Efficacy	false	(287 ± 54 vs. 199 ± 86). Patients presenting with values exceeding 230 PRU (P2Y12 reaction units) are categorized as non responders to clopidogrel accompanied with high on treatment platelet reactivity.	clopidogrel
1451342180	CYP2C19*1; CYP2C19*17	PMID:22552318	CYP2C19	CYP2C19 *17 is not associated with risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.	no	= 0.16	4144		Multiple groups	Toxicity	false	UM group had a non-significant trend towards increased bleeding rates compared to the EM group (RR 1.26 [95% CI: 0.92 – 1.72]. UM: carriers of no LoF alleles and one or more GoF allele, NM: carriers of 2 wild type alleles	clopidogrel
1449187720	CYP2C19*1; CYP2C19*2	PMID:29397568	CYP2C19	CYP2C19 *2 is not associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	no	= 0.798	168		East Asian	Toxicity	false	in patients with coronary heart disease who underwent PCI operation. The endpoint measured was cardiovascular ischemic events (cardiac death, recurrent thrombosis in stent confirmed by coronary angiography, recurrent unstable angina, and recurrent acute myocardial infarction).	clopidogrel
1184516457	CYP2C19*1; CYP2C19*10; CYP2C19*14; CYP2C19*19; CYP2C19*23; CYP2C19*25; CYP2C19*26	PMID:25001882	CYP2C19	CYP2C19 *10 + *14 + *19 + *23 + *25 + *26 are associated with decreased clearance of clopidogrel in cos-7 cell as compared to CYP2C19 *1.	yes	< 0.005			Unknown	Metabolism/PK	false	Please note the article separated *1A and *1B. All parameters were compared to CYP2C19*1B. The clearance of *1A was 115% compared to *1B.	clopidogrel
1449187731	rs1045642	PMID:29397568	ABCB1	Allele A is not associated with risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.	no	= 0.087	168		East Asian	Toxicity	false	in patients with coronary heart disease who underwent PCI operation. The endpoint measured was cardiovascular ischemic events (cardiac death, recurrent thrombosis in stent confirmed by coronary angiography, recurrent unstable angina, and recurrent acute myocardial infarction).	clopidogrel
1444667887	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:24440142	CYP2C19	CYP2C19 *2/*2 + *3/*3 + *2/*3 (assigned as poor metabolizers phenotype) are associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .	yes	< 0.0001	174		East Asian	Efficacy	false	On-treatment platelet reactivity was  3560 ± 1404 in EM and 5084 ± 1007 in PM.	clopidogrel
1448116648	rs2242480	PMID:26526111	CYP3A4	Genotype CC is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to genotypes CT + TT.	no	= 0.532	209		European	Efficacy	false	All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting. Alleles given as A and G.	clopidogrel
1452024180	rs1463411	PMCID:PMC9951409	MIR6076	Genotypes GG + GT is associated with increased likelihood of Hemorrhage when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype TT.	yes	< 0.001	37	526	East Asian	Toxicity	false	"""We defined the bleeding events based on the criteria of the Bleeding Academic Research Consortium (BARC)""""Bleeding was observed in 37 patients (6.6%): 21 (56.8%) had BARC type 2 and 16 (43.2%) had BARC type 3.""""The majority of bleeding events included epistaxis (15.4%), gingival hemorrhage (30.8%), subcutaneous hemorrhage (25.6%), and gastrointestinal hemorrhage (28.2%)."""	clopidogrel
1449187738	CYP2C19*1; CYP2C19*3	PMID:29397568	CYP2C19	CYP2C19 *3 is associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.	yes	< 0.001	168		East Asian	Efficacy	false	in patients with coronary heart disease who underwent PCI operation.	clopidogrel